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Abstract 
Parkinson’s disease (PD) is one of the most prevalent movement disorders in the 
world. A clinical hallmark of PD is the appearance of proteinaceous Lewy Bodies 
throughout the brain that are predominantly formed from aggregation of the 
presynaptic protein alpha-Synuclein (αSyn). Increasing evidence, however, suggests 
that the soluble annular αSyn oligomers, formed during early stages of aggregation, 
are more toxic and pathologically relevant than the larger fibrils which form at later 
stages of aggregation. The underlying mechanism(s) through which αSyn oligomers 
exert their toxicity is still largely unknown. 
This thesis investigates how the toxic nature of αSyn oligomers may affect the 
electrophysiological properties of neurons. A population of soluble oligomers, termed 
mOligomers, were isolated from the early stages of in vitro aggregation. In addition, a 
separate oligomeric species was recovered from the fragmentation of large fibrils; 
termed fOligomers. Structural characterisation of these two species revealed them to 
be similar in size and ring-like in shape but showed subtle differences in their 
secondary structure. 
Purified, oligomeric αSyn was injected directly into the somata of thick-tufted layer 5 
pyramidal neurons in mouse neocortical brain slices during whole-cell patch clamp 
recording and compared to the effects of equivalent concentrations of αSyn monomer. 
Using a combined experimental and modelling approach, a wide range of neuronal 
parameters were extracted and demonstrated oligomer-specific changes in neuronal 
electrophysiology that were time dependent. Perfusion with αSyn oligomers markedly 
reduced input resistance, enhanced the current required to trigger an action potential 
and reduced the firing rate illustrating a reduction in excitability that has the potential 
to impact both neural circuitry and cognitive output. 
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1 Introduction 
Parkinson’s disease is one of the most prevalent movement disorders in the world and 
is clinically characterised by the appearance of Lewy Bodies made predominantly 
from the protein alpha-Synuclein. However, increasing evidence produced within the 
last few decades strongly suggests that soluble, oligomeric species are more 
neurotoxic than the large fibrillar aggregates that form later. The exact mechanism 
through which oligomers exert their toxicity is still unknown. The aims of this thesis 
are twofold: to provide in-depth structural characterisation of alpha-Synuclein 
oligomers and to investigate their impact on the electrophysiological properties of 
neurons. Such goals will help to develop our understanding of the cellular mechanisms 
through which oligomers exert their toxicity. 
This introduction reviews the aspects of structural biology and neurobiology relevant 
to this body of work. Firstly, I provide an overview on the origin, clinical staging and 
pathology of Parkinson’s disease and related neurodegenerative disorders. In addition 
to motor dysfunction, I draw attention to the wide range of non-motor symptoms that 
are prevalent throughout the disease and describe the microcircuitry of pyramidal 
neurons in the neocortex; a region severely affected in late stages of the disease. The 
second half of this introduction is dedicated to the structure and function of both native 
and pathological alpha-Synuclein. Discussed here are the speculated physiological 
roles ascribed to this protein, the evidence for its association with Parkinson’s disease, 
the variety of oligomeric intermediates formed during aggregation, and the leading 
theories on the mechanism of toxicity. Lastly, this introduction shall conclude with a 
brief outline of the research carried out in this thesis. 
1.1 History of Parkinson’s disease 
Parkinson’s disease (PD) was first characterised in 1817 by James Parkinson, who 
analysed the collective symptoms of six case studies (two of whom he met in the street 
and one he observed from a distance) in which the patients suffered from a vague 
motor disorder. He describes: 
‘Involuntary tremulous motion, with lessened muscular power, in parts not in action 
and even when supported; with a propensity to bend the trunk forward, and to pass 
from a walking to a running pace: the senses and intellects being uninjured.’ 
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This constituded the first clinical description of a motor disorder refered to then as 
paralysis agitans or ‘shaking palsy’ (Parkinson, 1817) but was later renamed in 1877 
by Jean-Martin Charcot (Charcot, 1877; Lees, 2007) in honour of the original 
discoverer. Charcot helped to refine and expand upon the description of PD; 
particularly in defining bradykinesia as a fundimental symptom (Charcot, 1877). 
Around the same time, Armand Trousseau described muscle rigidity and a displaced 
centre of gravity in patients with PD (Trousseau, 1867; Pearce, 1989). Although these 
pioneers are accredited as the first to medically examine the disease, several early 
sources, including 1200 B.C. Egyptain papyrus, Hindu texts and Bible passages give 
accounts of people suffering from PD-like symptoms (Ruiz, 2004). 
The end of the 19th century marked the first anatomical insight into PD and other 
movement disorders. The general role of the basal ganglia in the brain at effecting 
motility had already been proposed in relation to Wilson’s disease (Gowers, 1888). 
However, it was Edouard Brissaud that proposed a connection between motor 
dysfunction and the specific substantia nigra region within the basal ganglia 
(Brissaud, 1899). This was proven in 1919 by Tretiakoff who noted a reduction in the 
number of pigmented cells in the substantia nigra in PD patients (Trétiakoff, 1919). A 
few years earlier, a key pathological finding was made by Frederic Lewy who 
discovered large concentric inclusion bodies, that he named Lewy bodies, in the brains 
of Alzheimer’s patients (Lewy, 1912). The detection of Lewy bodies throughout the 
brain is still regarded as a clinical hallmark of PD (Braak et al., 2003b). These 
aggregates were also found by Tretiakoff in the cytoplasm of neurons in the substantia 
nigra pars compacta (Trétiakoff, 1919). However, the loss of neurons in this region of 
the brain was not generally accepted as a critical pathological lesion in PD until the 
much later neuropathological studies carried out by Hassler (1938) and then 
Greenfield and Bosanquet (1953) which led to an almost universal acceptance (Lees, 
2007).  
During the 1950s, Arvid Carlsson showed that dopamine functioned as a 
neurotransmitter in the brain and was not simply the precursor to noradrenalin, as was 
the dominant opinion at the time (Bertler and Rosengren, 1959; Carlsson, 1959). In 
1957, he revealed that depleting the otherwise abundant supply of dopamine in the 
basal ganglia, using the drug reserpine, resulted in a loss of movement control 
reflecting the symptoms of PD (Carlsson et al., 1957). It was soon after establised that 
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the motor dysfunction observed in PD did indeed stem from a loss of dopaminergic 
innervation within the basal ganglia (Ehringer and Hornykiewicz, 1960; 
Hornykiewicz, 1963). Importantly, the administration of levodopa (L-dopa) reversed 
the immobilising effects of reserpine in animals (Carlsson et al., 1958) and was even 
able to successfully, albeit temporarily, aleviate the symptoms of PD patients (Cotzias 
et al., 1967; Cotzias et al., 1969; Yahr et al., 1969). For this work, Carlsson was 
awarded the 2000 Nobel prize in medicine and has since been considered one of the 
poineers of L-dopa treatment (Lees et al., 2015). 
1.2 Pathology of Parkinson’s disease 
1.2.1 Clinical stages 
The pathological development of PD is a slow process that can take several years 
before accumulative damage in the brain produces symptoms. In the course of the 
disorder, specific regions of the brain become increasingly affected in a predictable, 
ascending pathology. As such, neuron degeneration commonly occurs in areas of the 
brainstem prior to the onset of classical PD motor dysfunction; this is known as the 
presymptomatic phase. The spread of pathology to the substantia nigra pars compacta 
(SNc) region of the basal ganglia marks the beginning of the symptomatic phase of 
PD as loss of these predisposed neurons is exclusively responsible for loss of motor 
control. The later stages of PD are fraught with secondary, non-motor symptoms as 
pathology reaches the higher centres of the brain includng the hippocampus and 
neocortex. This pathological topology is closely complemented by the prevalence of 
Lewy bodies in the same neuronal regions during presymptomatic and symptomatic 
phases of PD (figure 1.1) (Braak et al., 2002). This finding, by Braak and colleagues, 
now defines the six clinical stages of PD progression (Braak et al., 2002; Braak et al., 
2003b).  
1.2.2 Stages 1 and 2: the presymptomatic phase 
The earliest appearances of inclusion bodies in the brainstem denote the first stages of 
PD and precede the onset of motor symptoms. In stage 1, Lewy bodies appear in the 
dorsal motor nucleus of the vagus nerve and surrounding areas of the medulla and 
pons (figure 1.1a) (Del Tredici et al., 2002). Curiously, Lewy bodies also appear at 
this stage in the olfactory bulb and related portions of the anterior olfactory nucleus 
(Barz et al., 1997; Braak et al., 2002). However, since the pathology does not advance 
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out from the olfactory bulb into the neocortex or subcortical structures, it is the dorsal 
nucleus that is considered the main starting point for disease ascention (Del Tredici et 
al., 2002; Braak et al., 2003b). 
In stage 2, Lewy bodies are still confined to the medulla and pons however the lesions 
within the dorsal vagal region become increasingly severe, and portions of the caudal 
raphe nuclei and locus coeruleus become involved (figure 1.1a) (Braak et al., 2002). 
Diagnosis of PD during these two early stages, which collectively comprise the 
presymptomatic phase, is difficult and non – definitive. Olfactory loss occurs in up to 
90 % of patients with PD and has thus become a reliable indicator in the 
presymptomatic phase (Sommer et al., 2004; Haehner et al., 2007; Ross et al., 2008a; 
Silveira-Moriyama et al., 2009). A variety of other non-motor symptoms are often 
seen in patients with early untreated PD including rapid eye movement (REM) sleep 
behavioural disorder, constipation, autonomic dysfunction, and mood/behavioural 
disorders (Wu et al., 2011). Such non-motor symptoms are less universal during the 
early stages but become increasingly dominant in cases of advanced PD (Chaudhuri 
et al., 2006). 
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1.2.3 Stages 3 and 4: the symptomatic phase 
Stages 3 and 4 are the most well established in PD pathology as Lewy bodies spread 
to the basal ganglia and are detected specifically in the dopaminergic neurons of the 
SNc (figure 1.1b). It is during these stages that we enter the symptomatic phase and 
the main clinical characteristics of PD including muscle rigidity, bradykinesia, and 
tremours at rest begin to appear (Eriksen et al., 2009). Although destruction in the 
subsequent stages is assured, the SNc in stage 3 appears macroscopically intact with 
no detectable reduction in neuromelanin within the dopamine-containing neurons 
(Braak et al., 2003b). Lewy bodies, however, typically develop close to the 
neuromelanin accumulations in the SNc neurons. Importantly, non-dopaminergic 
neurons from the nigral subnuclei (particularly the substantia nigra pars reticulata) 
refrain from developing Lewy bodies or lesions (Braak et al., 2003b). Other areas in 
stage 3 that begin to accumulate Lewy bodies include the magnocellular nuclei of the 
basal forebrain, which is involved in sleep/wake regulation and projects throughout 
the neocortex (Divac, 1975; Szymusiak, 1995), and the CA2/3 region of the 
hippocampus (Dickson et al., 1991). 
In stage 4, the SNc becomes strikingly impaired; showing a significant decrease in the 
number of dopamine-containing neurons (Braak et al., 2003b). Disease severity is also 
elevated in the basal forebrain which spreads Lewy bodies up through the mesocortex 
(figure 1.1b). Stage 4 Lewy bodies and lesions in the mesocortex become less dense 
following the cortex either medially to the entorhinal region or laterally to the high 
order sensory areas of the neocortex (Braak et al., 2003b). 
1.2.4 The underlying mechanism of motor dysfunction: basal ganglia circuitry 
The basal ganglia represents a collection of subcortical nuclei that are involved in the 
regulation of movement. Within the basal ganglia lies the neostriatum (caudate 
nucleus and putamen), the external and internal segments of the globus palidus (GPe 
and GPi), the subthalamic nucleus (STN), and the substantia nigra pars reticulata (SNr) 
and pars compacta (SNc) (figure 2.1a). Other projections in basal ganglia reach the 
centromedian (CM) thalamic nucleus and lower brainstem regions including the 
pedunculopontine nucleus (PPN) involved in the reticular activating system. When 
preparing to carry out a desired movement, the striatum and STN receive 
glutamatergic transmission from specific motor areas of the neocortex (M1, PMA and 
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SMA) and also from the thalamus. Information is transferred from the striatum to the 
basal ganglia output nuclei, GPi and SNr, through two separate pathways; a ‘direct’ 
(monosynaptic) connection, and an ‘indirect’ projection via the GPe and STN. The 
inhibitory γ-aminobutyric acid (GABA) output from GPi/SNr is received by the 
ventral anterior and ventrolateral nuclei of the thalamus (VA/VL), which, in turn, 
project back to the cerebral cortex. 
As such a ‘striatal’ loop exists; travelling from the neocortex to the basal ganglia and 
back again, that ensures fine tuning of neurons to carry out the intended movement 
(figure 1.2b). Thus, the key motor function of the basal ganglia is the selection and 
implimentation of willed movements.  
Importantly, the striatum receives vital dopaminergic input from the SNc; forming the 
nigrostriatal pathway. The SNc neurons form synapses with striatal medium spiny 
output neurons (MSNs) which are also the recipients of corticostriatal projections 
carrying the raw motor planning signal (Nicola et al., 2000; Wang et al., 2006; 
Surmeier et al., 2007). This anatomical arrangement places the dopaminergic inputs 
in a position to regulate corticostriatal transmission (figure 1.2b). MSNs in the ‘direct’ 
and ‘indirect’ pathways carry different dopamine receptors that produce opposing 
effects on the basal ganglia output nuclei (Gerfen et al., 1990). Activation of the 
‘direct’ pathway by dopamine D1-receptors inhibits the GPi/SNr, thereby disinhibiting 
thalamocortical interactions, while reduction of the ‘indirect’ pathway by D2-
receptors creates the opposite effect (figure 1.2) (DeLong and Wichmann, 2007; 
Galvan and Wichmann, 2008; Keeler et al., 2014). 
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Figure 1.2 Schematic diagram of the direct and indirect pathways of the basal ganglia motor circuits in 
normal and PD states. (a) Anatomic layout of the areas affected in Parkinson’s disease. In addition to the areas 
that comprise the basal ganglia, the brain stem, thalamus and cortex are shown. (b) Red arrows indicate inhibitory 
projections and blue arrows indicate excitatory projections. Changes in arrow thickness between normal and PD 
states denotes an increase (larger arrow) or decrease (thinner arrow) in the firing activity of specific projections. 
The dashed arrow in the PD state illustrates the lesioning of dopaminergic neurons that make up the nigrostriatal 
pathway. CM, centromedian nucleus; CMA, cingulate motor area; GPe, globus pallidus, external segment; GPi, 
globus pallidus, internal segment; M1, primary motor cortex; PMC, pre-motor cortex; PPN, pedunculopontine 
nucleus; SMA, supplementary motor area; SNc, substantia nigra pars compacta; SNr, substantia nigra pars 
reticulata; STN, subthalamic nucleus; VA/VL, ventral anterior/ventral lateral nucleus (Smith et al., 2012). 
a 
b 
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Overall, the net action of the SNc is to reduce GPi/SNr activity which in turn 
upregulates glutamatergic output from the thalamus back to the neocortex. In 
Parkinson’s disease, the eventual loss of SNc neurons and their dopaminergic 
innervation of the striatum results in unregulated GPi/SNr inhibition of the thalamus, 
a subsequent loss of excitation to the neocortex (figure 1.2b) and impaired motor 
control. 
1.2.5 Stages 5 and 6: non-motor symptoms 
The later stages of PD mark the most severe and wide spread pathology in the brain. 
In addition to the areas affected in the earlier stages, the hippocampus and neocortex 
become increasingly damaged (figure 1.1c). In stage 5, Lewy bodies extend from the 
mesocortex into adjoining prefrontal and sensory areas of the neocotrex. Of the layers 
of pyramidal neurons that make up the neocortex structure, layers 5 and 6 in particular 
develop Lewy bodies and a thick band of neuritic filaments appear in layers 2/3 (Braak 
et al., 2000; Braak et al., 2002). Within the hippocampus, Lewy bodies are detected 
in all CA sections with increasing prevalence. Stage 6 signifies the most advanced 
topography for the distribution of Lewy bodies and neuron degeneration, with the 
entirity of the neocortex becoming affected (figure 1.1c). 
Secondary, non-motor  symptoms of PD correlate with advancing age and disease 
progression into stages 5 and 6 (Braak et al., 2005). As described above some non-
motor symptoms can appear in the early stages of PD (Wu et al., 2011), however in 
the later stages these become more prevalent. A wide variety of non-motor symptoms 
have been described in patients with PD including; dementia, cognitive impairments 
such as apathy, depression, anxiety and hallucinations, as well as sleep disorders, 
sexual dysfunction, gastrointestinal problems and many more that are listed in table 
1.1 (Chaudhuri et al., 2006). In a 15 year follow up study of non-levodopa responsive 
patients, non-motor symptoms were noted as the most debilitating feature of the 
disease (Hely et al., 2005). Other surveys have similarly found that sleep distubances, 
episodic confusion/memory loss, and dribbling of saliva were rated by PD patients to 
be the most disabling features (Gulati et al., 2004). Many non-motor symptoms, 
including dementia and hallucinations, are now recognised as leading causes of patient 
morbidity and institutionalisation (Goetz and Stebbins, 1993; Guttman et al., 2003), 
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and can effectively quadruple the cost of care (Findley et al., 2003; Chaudhuri et al., 
2005). 
Table 1.1 The range of non-motor symptoms reported in patients with Parkinson’s disease. * indicates 
symptoms that may be drug induced (Chaudhuri et al., 2006). 
1.3 The microcircuitry of the neocortex 
While denervation of the dopaminergic nigrostriatal pathway is the cause of traditional 
motor symptoms, many of these non-motor symptoms are the result of dysruption to 
cholinergic systems in higher functioning centres of the brain (Bohnen and Albin, 
2011). Loss of cholinergic input to the cerebral cortex from the basal forebrain, along 
with the presence of cortical Lewy bodies, is recognised as a key pathological cause 
of dementia in both Alzheimer’s and Parkinson’s disease (Müller and Bohnen, 2013). 
The neocortex is the most evolutionarily recent part of the brain and is vital for higher 
cognitive functions including perception, motor command, semantic memory, 
language, social interactions and emotional processing. Developmental abnormalities 
within the neocortex form the basis for several neurophysiological disorders; such as 
schizophrenia, autism and epilepsy, while pathological damage results in cognitive 
The non – motor symptom complex of Parkinson’s disease 
Neuropsychiatric 
symptoms 
Seelp 
disorders 
Autonomic 
symptoms 
Gastrointestinal 
symptoms 
Sensory 
symptoms 
Other symptoms 
Depression, 
apathy, anxiety 
 
Anhedonia 
 
Attention deficit 
 
Hallucinations, 
illusion, delusions 
 
Dementia 
 
Obsessional 
behaviour*, 
repetitive 
behaviour 
 
Confusion 
 
Delirium* 
 
Panic attacks 
Restless legs 
and periodic 
limb 
movements 
 
Rapid eye 
movement 
(REM) sleep 
behaviour 
disorder 
 
Non – REM – 
sleep related 
disorders 
 
Excessive 
daytime 
somnolence 
 
Insomnia 
 
Sleep 
disordered 
breathing 
Bladder 
disturbances 
(urgency, 
nocturia, 
frequency) 
 
Sweating 
 
Orthostatic 
hypotension (falls, 
coat – hanger 
pain) 
 
Sexual dysfunction 
(hypersexuality*, 
erectile 
impotence) 
 
Dry eyes 
(xerostomia) 
Dribbling of 
saliva 
 
Ageusia 
 
Dysphagia and 
choking 
 
Reflux, nausea 
and vomiting 
 
Constipation 
 
Faecal 
incontinence 
Pain 
 
Paraesthesia 
 
Oflactory 
distrubance 
Fatigue 
 
Diplopia 
 
Seborrhoea 
 
Weight loss 
 
Weight gain* 
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dysfunction witnessed in many neurodegenerative diseases including Alzheimer’s 
disease (AD), PD, dementia with Lewy bodies (DLB) and multiple system atrophy 
(MSA) (Sugiyama et al., 1994; Bierer et al., 1995; Armstrong et al., 2005).  
The neocortex is generally divided into six layers (figure 1.3) although the distinction 
between individual layers is dependent on the cortical region of interest. Despite their 
functional diversity, different regions of the neocortex all share a distinctly 
standardised neuronal morphology, columnar organisation and interlayer connectivity 
(Kozloski et al., 2001; Silberberg et al., 2002). The preservation of certain patterns of 
connectivity between layers throughout the neocortex has led to the development of a 
canonical microcircuit (figure 1.3) that is now a well established concept for 
experimental and theoretical neuroscientists alike (Thomson and Lamy, 2007).  
The topmost layer of the neocortex, layer 1, is primarily composed of dendritic tufts 
from pyramidal neurons in the lower layers that are synapsed by a sparse population 
of GABAergic neuronal somata (Cauller and Connors, 1994). Layer 1 is believed to 
provide top-down ‘contextual’ information from cortical areas to bottom-up sensory 
signals arriving via the thalamus and other subcortical regions (Cauller, 1995; 
Petreanu et al., 2012). 
With the exception of the primary visual cortex, layers 2 and 3 are generally 
considered to be a single layer (Gur and Snodderly, 2008). Layer 2/3 receives strong 
feed-forward excitation from layer 4 that converges with input from other layers to 
provide an integrated signal that is relayed to layer 5; the crucial output layer that 
projects to the thalamus and other subcortical regions (Feldmeyer et al., 2002; Kampa 
et al., 2006). 
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Although all layers of the neocortical sensory areas receive thalamic inputs, the 
strongest is in layer 4. One of the principle cells (PCs) in layer 4, in addition to 
pyramidal neurons, are spiny stellate neurons. Spiny stellate neurons are the main 
excitatory neurons that target the pyramidal neurons in layer 2/3 (Feldmeyer et al., 
2002). Layer 4 is absent from the motor cortex, however the organisation of this area 
remains poorly understood (Shepherd, 2009; Hooks et al., 2011). 
Layer 5 pyramidal neurons are subdivided into two classes of excitatory cells. Slender-
tufted pyramidal cells, also referred to as intratelencephalic neurons (ITNs), are 
situated higher in the layer, have a regular spiking pattern and project to intra-cortical 
targets. Thick-tufted pyramidal cells, also referred to as subcerebral projection neurons 
(SPNs), are located deeper in the layer (layer 5b) and represent the major output to 
subcortical targets, often firing bursts of action potentials.  
The deepest layer of the neocortex, layer 6, is possibly the least well understood 
although it has been shown to offer gain control to layers 5a and 4 (Kim et al., 2014). 
Layer 6 contains a more heterogenous neuronal population relative to the others (Chen 
Figure 1.3 Simplified diagram of the canonical microcircuit of the neocortex. The locations and connectivity 
of excitatory cells are illustrated (Harris and Mrsic-Flogel, 2013). 
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et al., 2009; Thomson, 2010). Corticocortical (CC) cells have a uniquely inverted soma 
morphology and form long-range horizontal connections with other cortical areas 
(Thomson, 2010). Corticothalamic (CT) cells send signals along slow conducting 
fibers (Swadlow, 1989) to reticular and primary sensory thalamic nuclei (Sherman, 
2012). CT cells also inhibit the principle cells of layer 4 by strongly innervating fast-
spiking interneurons (Watakabe et al., 2012).  
Since the canonical microcircuit utilises all layers in some manner, especially layers 
2/3, 4 and 5, it is possible that neuron degeneration in any of the layers will have 
pathological consequences. However, as they present the main subcortical output 
projections of the neocortex, my investigations in this thesis will focus on the thick-
tufted pyramidal neurons of layer 5b. 
1.4 Electrophysiological modelling of neurons 
The electrophysiological properties of a neuron can be captured and recreated through 
mathematical modelling; an important tool for investigating neuron signalling at the 
single cell and network levels. In mathematical models, neurons are represented as 
electrical circuits that vary in complexity from single variable differential equations 
that can predict the firing times of action potentials, to multi-variable equations that 
attempt to illustrate the complete spatial arrangement of the neuron membrane. 
Complex models are often difficult to accurately fit to experimental data but have been 
used to examine spike-threshold variability (Shu et al., 2007), the effects of 
temperature on action potential efficiency (Yu et al., 2012) and the influence of 
dendritic morphology on cell output (Hay et al., 2011; Hay et al., 2013). Simple 
models, on the other hand, have less biophysical representation in the cell circuit but 
can reliably fit experimental recordings and are more easily included in network 
models. The simplest neuron model describes an RC circuit (figure 1.4a) in which the 
capacitor represents the charge storing ability of the phospholipid bilayer, resistors 
represent ion channels and batteries represent the ionic reversal potentials. The 
collective action of all ion channels can be represented by a single resistor or multiple 
resistors can be added in parallel to show different ion channels, each with their own 
reversal potential (figure 1.4b). The potential difference across the membrane, V(t), is 
governed by 
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𝐶
𝑑𝑉
𝑑𝑡
+ 𝐼𝑖𝑜𝑛 =  𝐼𝑖𝑛    (1.1) 
where C is the membrane capacitance and Iin is the input current, either from synapses 
or injected experimentally. Iion is the ionic current and gives the current passing 
through the resistor in the RC circuit, which is equivalent to the sum of currents from 
all ion channels in the model. 
In continuous models, designed to capture both subthreshold and action potential 
behaviour (Hines and Carnevale, 1997), the ionic current is described as a time-
dependent conductance in the general form 
𝐼𝑖𝑜𝑛(𝑡, 𝑉(𝑡)) = ∑ 𝑔𝑖(𝑡)(𝑉(𝑡) − 𝐸𝑖)𝑖    (1.2) 
where Ei is the ionic reversal potential of ion i and gi(t) is the channel conductance, 
which is dependent on the dynamics of gating variables. The Hodgkin-Huxley (HH) 
model of the squid giant axon, for example, was the first continuous model to describe 
the three principle ion-channels underlying subthreshold and action potential 
dynamics (Hodgkin and Huxley, 1952a, b, c; Hodgkin et al., 1952). Hodgkin and 
Huxley found that the generation of action potentials was the coordinated result of 
leak conductances, due to passive ion channels, sodium conductance and potassium 
conductance (figure 1.4b). The ionic current from equation (1.1) is then given as 
𝐼𝑖𝑜𝑛 = 𝑔𝐿(𝑉 − 𝐸𝐿) + ?̅?𝑁𝑎𝑚
3ℎ(𝑉 − 𝐸𝑁𝑎) + ?̅?𝐾𝑛
4(𝑉 − 𝐸𝐾)  (1.3) 
Figure 1.4 The simple neuron model as an RC circuit. (a) The neuron membrane acts as a capacitor (C) while 
embedded ion channels act as a resistor (R) with a battery (E) to signify their reversal potentials. The summed 
effects of the ion channels can be represented as a single resistor or can be separated into multiple resistors 
connected in parallel. The latter signifies the Hodgkin-Huxley model and is illustrated in (b). 
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where the gating variables m, h and n are responsible for the activation and 
deactivation of sodium channels and the activation of potassium channels, 
respectively; 𝑔𝐿 is the leak conductance,  ?̅?𝑁𝑎 and ?̅?𝐾 the maximal sodium and 
potassium conductance; and EL, ENa, and EK are their respective reversal potentials. 
The HH model is regarded as one of the most important models in modern 
neuroscience and has been developed in many ways to vary the amount of 
physiological detail (Wang and Buzsaki, 1996; Pospischil et al., 2008). 
Integrate-and-fire (IF) neuron models are simplified forms of the continuous model 
that focus on accurate prediction of spike times rather than detailing the properties of 
the action potential. The leaky integrate-and-fire (LIF) model, which has been used 
extensively to study the activity of single cells (Burkitt, 2006a, b), describes the neuron 
as a capacitor, equation (1.1), with the leak conductance from equation (1.3) to 
illustrate the passive membrane response: 
𝐶
𝑑𝑉
𝑑𝑡
=  𝑔𝐿(𝐸𝐿 − 𝑉) + 𝐼𝑖𝑛   (1.4) 
The IF models focus on the subthreshold activity of a neuron and register a spike when 
the membrane potential reaches a pre-defined threshold value, after which the value is 
reset (Fourcaud-Trocme et al., 2003). This can be extended to better describe spike 
dynamics by introducing a non-linear forcing function, F(V), to produce non-linear IF 
(NIF) models in the form: 
𝑑𝑉
𝑑𝑡
= 𝐹(𝑉) +
𝐼𝑖𝑛(𝑡)
𝐶
    (1.5) 
The exponential IF (EIF), is a NIF model in which the non-linear forcing function 
includes an exponential component for describing the fast activation of voltage-gated 
sodium channels needed for the sharp rise in membrane potential at spike onset 
(Fourcaud-Trocme et al., 2003). The forcing function is given as 
𝐹(𝑉) =  
1
𝜏𝑚
(𝐸𝑚 − 𝑉 + ∆𝑇𝑒𝑥𝑝 (
𝑉−𝑉𝑇
∆𝑇
))  (1.6) 
with the four parameters being: the membrane time constant (τm), the resting potential 
(Em), the spike-onset sharpness (ΔT) and the spike-initiation threshold (VT). The EIF 
model has been experimentally verified in a variety of cell types including thick-tufted 
layer 5 pyramidal neurons (Badel et al., 2008). Furthermore, previous work by Badel 
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et al. (2008) introduced post-spike dynamics in which the parameters of equation (1.6) 
become shifted and then relax back over time to pre-spike conditions with either a 
single (τm and VT) or double (Em) exponential fit; yielding the refractory EIF (rEIF) 
model. The EIF and rEIF models provide an efficient method for accurately extracting 
several neuronal parameters from experimental data. As such, they will be used in this 
thesis for the novel purpose of investigating cortical electrophysiology under 
pathological conditions relating to PD.  
1.5 Risk factors in Parkinson’s disease 
1.5.1 Parkinson’s disease epidemiology 
The biggest risk factor for many neurodegenerative disorders is age (Hindle, 2010; 
Niccoli and Partridge, 2012). PD is well recognised as an age-related disease (Morgan 
and Finch, 1988; Eriksen et al., 2009) with a high prevalence in the elderly; the 
average age of onset being ~60 years (Samii et al., 2004). However, juvenile-onset 
(initial symptoms presenting before 21 yrs) and young-onset PD (between 21-39 yrs) 
do occur (Muthane et al., 1994). Young-onset PD comprises 5-10 % of all patients 
(Golbe, 1991). 
PD is currently the second most common neurodegenerative disorder in humans, after 
AD, and is the most common movement disorder; with a prevalence of ~1 % in adults 
over the age of 60 years, rising to as high as ~4 % in those over 80 years (de Lau and 
Breteler, 2006). The incidence of PD is consistently greater in men than in women 
(Mayeux et al., 1992; Lyons et al., 1998; Van Den Eeden et al., 2003; Haaxma et al., 
2007; Shulman, 2007) which has been attributed to oestrogen activity in women 
promoting higher levels of physiological striatal dopamine (Haaxma et al., 2007). 
People of all ethnicities can be affected by idiopathic PD  (Van Den Eeden et al., 
2003). 
A variety of occupational and environmental risk factors have been associated with 
the development of PD. The chronic exposure to pesticides and herbicides used in 
agriculture has been shown to correlate with higher risk of PD development in farmers 
(Lai et al., 2002). The precise mechanism of toxicity varies depending on product 
although many are believed to induce mitochondrial dysfunciton. The insecticide 
rotenone, for example, is a non-competitive inhibitor of complex 1 (Li et al., 2003) 
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that induces progressive, PD-like motor dysfunction in animal models (Sherer et al., 
2003). 
Increased risk of PD is connected to long-term exposure to metals such as manganese, 
copper, mercury, lead, iron, zinc and aluminium (Lai et al., 2002). This was originally 
observed when a high prevalence of PD mortality was found among workers in heavy 
metal industries (Rybicki et al., 1993). Iron and copper have been shown to bind to 
several PD-associated proteins such as alpha-Synuclein (Bush, 2000; Binolfi et al., 
2006; Brown, 2010b) and DJ-1 (Bjorkblom et al., 2013). In addition, the SNc 
extracellularly accumulates high levels of heavy metal ions during PD (Dexter et al., 
1991). A loss of heavy metal ion homeostasis, typically seen in patients with PD 
(Dexter et al., 1989; Gorell et al., 1999), is therefore a likely contributor to the specific 
denervation of the nigrostriatal pathway (Brown, 2010b). 
Curiously, from an epidemiological perspective, there is strong, consistent evidence 
that cigarette smoking is connected to a lower risk of PD (Checkoway et al., 2002; 
Hernan et al., 2002). In support of this, nicotine has been shown to have potential 
neuroprotective properties for PD (Quik et al., 2012). There is also evidence for 
caffeine consumption lowering the risk of PD (Checkoway et al., 2002; Ross et al., 
2008a), as well as the intake of alcohol (Hernan et al., 2003), vitamin C (Zhang et al., 
2002), vitamin E (Morens et al., 1996) and unsaturated fatty acids (de Lau et al., 2005). 
However, the inconsistency of these findings makes their association less certain (de 
Lau and Breteler, 2006). 
1.5.2 Molecular mechanisms of idiopathic Parkinson’s disease 
Several molecular mechanisms have been proposed to play a role in PD pathology: 
protein aggregation, oxidative stress, mitochondrial dysfunction, protein degredation 
pathway dysruption, membrane permeabilisation and synaptotoxicity to name a few. 
Many of these mechanisms are directly connected to one another or develop in tandem 
and are also found in other neurodegenerative disorders. However, the precise 
underlying mechanism of toxicity is still unknown. 
Protein aggregation and inclusion body formation is a shared pathological trait for 
many neurodegenerative diseases (figure 1.5a) (Ross and Poirier, 2004). The 
subsequent identification of the molecular content of these inclusions was a vital step 
in differentiating these diseases from one another (figure 1.5b). Despite their 
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differences in protein composition, the amyloid fibrils that make up inclusion  bodies 
are generally filamentous with a cross-β structure; in which the β-sheets align almost 
perpendicular to the long axis of the fibril (figure 1.5c). The conversion of disease 
proteins from their native, often unfolded, structure into an aggregating subunit is an 
important and complex mechanism underpinning the development of pathology. 
Following investigations into the aggregation process, there is increasing evidence that 
several intermediate species, oligomeric and protofibrilar, exist prior to the completed 
Figure 1.5 Protein aggregation in neurodegenerative diseases. (a) Proteinaceous inclusions are detected by 
histochemical staining in many neurodegenerative diseases. (b) Identifying the main protein component in these 
aggregates helps to distinguish between the diseases. (c) Protein aggregation is the result of misfolding and 
assimilating into long fibrils that are rich in β-sheet structure (Soto, 2003). 
a b 
c 
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fibrillar state. Although Lewy Bodies are still regarded as a clinical hallmark for 
neurodegenerative diseases, the timing of Lewy Body formation throughout the brain 
poorly correlates with the onset of symptoms (Terry et al., 1991). Oligomeric 
intermediates are now believed to be the most neurotoxic element in protein 
aggregation (Kayed et al., 2003; Outeiro et al., 2008; Brown, 2010b; Winner et al., 
2011) although their precise mechanim of toxicity is still under investigation (see later 
sections on alpha-Synuclein aggregation). Conversely, fibrils are more inert and may 
be neuroprotective as oligomers are removed from the cell (Conway et al., 2000a). 
The oxidation of cytosolic dopamine has been shown to contribute to PD through the 
production of free radicals (Greenamyre and Hastings, 2004). The oxidative stress 
from dopamine may help to explain why the dopaminergic nigrostriatal pathway is 
specifically affected in PD. However, the lack of destruction of dopamine-containing 
neurons in the nearby ventral tegmental area suggests that dopamine stress cannot be 
solely responsible for the specialised susceptability of the SNc. Furthermore, the 
administration of L-dopa to patients does not accelerate disease progression (Fahn 
2005). Regardless of the contributions from dopamine, oxidative stress from other 
sources and cellular components appears to be an important factor in PD. The 
mitochondria are regarded as significant contributors to cellular ageing as they are a 
major source of reactive oxygen species; a toxic by-product of their respiratory 
function. It has been well established that oxidative stress resulting from mitochondrial 
dysfunction plays a role in PD (Henchcliffe and Beal, 2008; Vila et al., 2008).  The 
first evidence of this arose following the hospitilisation of drug abusers intravenously 
exposed to self-administered meperidine contaminated with 1-methyl-4-phenyl-
1,2,3,4-tetrahydropyridine (MPTP), an inhibitor of the mitochondrial complex 1 
machinery (Nicklas et al., 1987; Gluck et al., 1994), that resulted in chronic, 
irreversible parkinsonian symptoms almost indistinguishable from PD (Langston et 
al., 1983). The pathology of MPTP, similar to that of rotenone, has since become a 
widely accepted model for PD (Przedborski et al., 2001; Dauer and Przedborski, 
2003) that has been studied in both human and non-human primates (Porras et al., 
2012), as well as a variety of other animals (Hallman et al., 1985; Tieu, 2011).  
Neurotoxin based models, such as MPTP, provide useful means for investigating 
idiopathic PD. However, there is debate surrounding the reliability of MPTP modeling 
(Porras et al., 2012) and whether or not the environment plays a role in PD aetiology 
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(Tanner, 1989; Hardy, 2006). As such, models based on changes in PD-associated 
genes, that give insight into hereditary forms of PD, are of great interest as they may 
hold the key to further understanding the molecular pathways involved in 
neurodegeneration. 
1.5.3 Genetic risk factors in familial Parkinson’s disease 
While the majority of PD cases are idiopathic, an estimated 10 % are hereditary (de 
Lau and Breteler, 2006); displaying clear mendelian inheriance of disease symptoms 
(Hardy et al., 2003). Thus far, twenty one genetic loci have been described in various 
families with inherited PD (table 1.2), although the function of many of them is largely 
unknown (Gasser, 2007). From these PARK loci, at least ten genes have been 
identified, mainly through positional cloning strategies, that contribute to the genetic 
aetiology of familial PD (Saiki et al., 2012). Many of these genes, such as PTEN-
induced kinase 1 (PINK1) (Valente et al., 2004), DJ-1 (Bonifati et al., 2003), and 
parkin (Kitada et al., 1998) are autosomal recessive; with their pathogenicity theorised 
to stem from a loss-of-function mechanism (Gasser, 2007). Autosomal dominant 
genes include leucine-rich-repeat kinase 2 (LRRK2) (Zimprich et al., 2004), and SNCA 
which codes for alpha-Synuclein (αSyn); the first PD-associated gene to ever be 
identified (Polymeropoulos et al., 1997). 
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Gene mutations involved in familial PD 
Gene (loci) Locus Inheritance Clinical features Protein Protein function 
SNCA (PARK1 & 
PARK4) 
4q21 AD Similar to IPD, 
young onset, rapid 
progression 
α - Synuclein Primary component of 
Lewy bodies 
Parkin (PARK2)  6q25·2–27 AR Young onset, slow 
progression, early 
dystonia and 
dyskinesia 
Ubiquitin ligase component of 
ubiquitin proteasome 
system (UPS) 
Omi/HrtA2 
(PARK3 & 
PARK13) 
  
2p13 AD Similar to IPD, 
levodopa-
responsive 
Omi/HtrA2 Nuclearly encoded 
mitochondrial protein. 
UCHL-1 (PARK5)  4p14 AD Similar to IPD UCHL-1 UPS component 
PINK1 (PARK6)  1p35–36 AR Young onset, 
benign course, 
levodopa-
responsive 
PTEN-induced 
kinase 
Protection against 
mitochondrial 
dysfunction 
DJ-1 (PARK7)  1p36 AR Young onset, 
levodopa-
responsive 
DJ-1 Protection against 
oxidative stress 
LRRK2 (PARK8)  12p11·2–
q13·1 
AD Similar to IPD Dardarin Unknown 
ATP13A2 
(PARK9) 
  
1p36 AR Kufor – Rakeb 
syndrome, early 
onset PD with 
spasticity and  
dementia 
P5 – type ATPase Regulates cation 
homeostasis. Localises 
with lysosomes 
PARK10 1p32 Sporadic - Unknown - 
PARK11 2q37.1 AD - Unknown - 
PARK12  Sporadic - Unknown - 
PLA2G6 
(PARK14) 
22q13.1 AR Young onset PD Calcium 
independent 
phospholipase A2 
Generating free fatty 
acids 
FBXO7 
(PARK15) 
22q12.3 AR Juvenile onset (10 
– 19 years old) 
Fbox7  Molecular scaffold; still 
unknown 
PARK16 1q32 Sporadic - Unknown - 
VPS35 
(PARK17) 
16q11.2 AD Similar to IPD Vacuolar protein 
sorting 35 
Endosome – trans – 
Golgi trafficking 
EIF4G1 
(PARK18) 
3q27.1 AD Similar to IPD Translation 
initiation factor 
Translation machinery 
DNAJC6 
(PARK19) 
1p31.3 AR Juvenile onset PD Auxilin Clathrin – mediated 
endocytosis 
SYNJ1 (PARK20) 21q22.11 AR Early onset PD Synaptojanin 1 Clathrin – mediated 
endocytosis 
DNAJC13 
(PARK21) 
3q22.1 AD Similar to IPD HSP40 homolog Vesicle formation and 
trafficking 
Table 1.2 Genetic and clinical characteristic of familial Parkinson’s disease. AD – autosomal dominant, AR – 
autosomal recessive, IPD – idiopathic PD (modified from Saiki et al., (2012)). 
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Regardless of the manner of inheritance, the translated products of the above 
mentioned genes have been shown to either directly or indirectly influence the 
apoptotic state of mitochondria (Vila et al., 2008). In addition, many of these proteins 
have been found to interact with each other and play important roles in several cellular 
functions including synaptic transmission (αSyn), lysosomal degradation pathway 
(αSyn, parkin, PINK1, Omi/HtrA2), axonal transport (LRRK2) and ubiquitin 
proteasome systems (αSyn, parkin, DJ-1, UCH-L1). 
1.6 Alpha-Synuclein 
1.6.1 Native structure 
In humans, the protein alpha-Synuclein (αSyn) is encoded by the single gene SNCA 
which is located on chromosome 4 (4q21) and made up of seven exons (Chen et al., 
1995). This protein was first identified in neurons; localising to both the presynaptic 
nerve terminals and nucleus, and was accordingly named synuclein (Maroteaux et al., 
1988). Since then, αSyn has been found at high concentrations in both the soluble and 
membrane bound fractions of brains, and has been estimated to comprise as much as 
1 % of the total soluble protein content in cytosolic brain fractions (Iwai et al., 1995).  
The 140 amino acid sequence of αSyn can be divided into three distinct regions (figure 
1.5a). The N-terminal (residues 1-60) is a highly conserved domain in all Synuclein 
proteins that is unordered in solution but can form an α-helical conformation in the 
presence of lipids (George, 2002).The N-terminal includes four imperfect 11-subunit 
repeats, each containing a conserved hexameric motif (KTKEGV) that is capable of 
forming amphipathic alpha helixes when bound to lipid membranes (Davidson et al., 
1998; Jo et al., 2000; Bussell and Eliezer, 2003). 
The central region (residues 61-95) contains a 12 amino acid sequence 
(71VTGVTAVAQKTV82) that is necessary and sufficient for fibrillisation (Giasson et 
al., 2001). This stretch of hydrophobic and amyloidogenic amino acids was originally 
identified as a peptide, known as the Non Amyloid-β Component (NAC), that strongly 
associated with the amyloid plaques found in Alzheimer’s disease; (Ueda et al., 1993). 
The precursor (NACP), from which the NAC peptide is derived, was found soon after 
to be the full length αSyn protein (Chen et al., 1995). The NAC represents a key 
structural determinant of αSyn fibrillisation based on the following evidence: 
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 The NAC enables αSyn to undergo a conformational change from random coil to 
β-sheet structure (Serpell et al., 2000) 
 The NAC sequence is resistant to proteolytic digestion and forms the core in αSyn 
filaments (Giasson et al., 2001). 
 The rate of αSyn fibrilisation in vitro decreases with the insertion of charged 
residues into the NAC sequence (Giasson et al., 2001). 
 Synthetic peptides that contain the NAC are able to self polymerise and promote 
fibrillisation of full length αSyn in vitro (Giasson et al., 2001). 
 Human β-Synuclein (βSyn) and γ-Synuclein (γSyn) both lack the 12 residue 
sequence (figure 1.6) and thereby fail to assemble into filaments in vitro or form 
coploymers with αSyn (Biere et al., 2000). 
The NAC region also contains three more KTKEGV repeats that, combined with those 
in the N-terminal region, collectively form a lipid-binding domain (Perrin et al., 2000) 
that consists of two extended α-helices interupted by a short break (Chandra et al., 
2003) (figure 1.6a). This lipid-binding domain is similar to those found in 
apolipoproteins (Clayton and George, 1998) and fatty acid binding proteins (Sharon 
et al., 2001). The conservation of this domain, accounting for over half the sequence 
of each Synuclein protein, suggests that all three Synucleins share lipid binding 
activity as part of their native function. 
In comparison, the C-terminal (residues 96-140) is predominantly unfolded in 
structure (Hoyer et al., 2002) and does not associate with lipid membranes (Eliezer et 
al., 2001). The C-terminal region is rich in acidic amino acids and has greater variation 
between members of the synuclein family than the rest of the primary sequence (figure 
1.7) (Clayton and George, 1999), suggesting the specific funcitons of each Synuclein 
protein is derived from this area.  The C-terminal of αSyn is critical for chaperone – 
like activity (Kim et al., 2000; Souza et al., 2000; Kim et al., 2002) and offers a 
neuroprotective function against oxidative stress factors (Albani et al., 2004). Forms 
of αSyn with a truncated C-terminal (residues 1-120) show enhanced vulnerability to 
oxidative stress (Kanda et al., 2000) and are more prone to fibrilisation that the full-
length protein (Crowther et al., 1998). The C-terminal is believed to play a role in 
regulating αSyn transport into the nucleus where it can bind to histones (Goers et al., 
2003b; Cherny et al., 2004). Importantly, this region is responsible for numerous sites 
of interaction with other proteins (Jensen et al., 1999; Giasson et al., 2003), metal ions 
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(Paik et al., 1999; Rasia et al., 2005; Bisaglia et al., 2009; Brown, 2009) and natural 
ligands (e.g. dopamine and polyamines) (Goers et al., 2003a; Illes-Toth et al., 2013) 
(figure 1.6b). 
 
 
 
Figure 1.6 Schematic representation of alpha-Synuclein (αSyn) primary sequence indicating: (a) structural 
information and (b) putative interaction domains. Depicted from the top down are the three isoforms of αSyn 
(1a-b); the three structural domains (2); seven imperfect repeats (3); predicted (4a) and experimentally determined 
α – helixes (4b); sites of posttranslational modification (methionine – yellow circles, tyrosine – blue circles, 
phosphorylation sites – red circles, ubiquitination – green boxes, SUMOylation – brown box, transglutaminase 
crosslinking sites – pink ovals) and PD-related mutations – red stars (5). The interaction domains responsible for 
binding of several ligands and proteins are indicated in (b). The N-terminal high affinity Cu(II) binding site, 
involving His-50 (Rasia et al., 2005), is indicated in addition to the low affinity C-terminal binding site. The 
numbers on the bars correspond to the residues in αSyn sequence (image adapted from Breydo et al., 2012). 
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1.6.2 Conformational behaviour of native αSyn 
Since its discovery, native αSyn has been widely regarded as an unfolded, monomeric 
species capable of forming α-helixes when bound to membranes (figure 1.8a) 
(Weinreb et al., 1996; Fauvet et al., 2012). The abundance of acidic residues near the 
C-terminal produces a high net charge (pl = 4.7) and low overall hydrophobicity that 
is common for unstructured proteins (Hoyer et al., 2002). Increasing the temperature 
or decreasing the pH of the protein environment can counter these two structural 
parameters and induce partial folding of αSyn (Uversky et al., 2001a) into an 
intermediate state that facilitates aggregation (Li et al., 2001). 
Recent evidence has shown that αSyn also exists physiologically as a helically folded 
tetramer (figure 1.8b) (Bartels et al., 2011; Wang et al., 2011a). This soluble tetramer 
has been purified from both endogenous (Bartels et al., 2011) and recombinant sources 
(Wang et al., 2011a), and forms unassisted by lipid membranes. Unlike other 
oligomeric states that are pathologically-linked to neurodegenerative diseases, the 
tetramer is non-toxic and does not readily aggregate into amyloid fibrils (Wang et al., 
2011a). The insertion of PD-associated point mutations into αSyn destabilises the 
tetrameric structure; providing a potential mechanism for disease initiation (Wang et 
al., 2011a; Dettmer et al., 2015). Similar to other proteins with a tertiary structure, the 
stability of the αSyn tetramer is likely to be dependent on subunit concentration and 
environmental factors (Wang et al., 2011a). It is predicted therefore that the tetramer 
Figure 1.7 ClustalW2 alignment of α, β and γ – Synuclein primary sequence. Under each aligned residue: * 
indicates homology between all three sequences, : indicates 2/3 homology but all residues share similar properties,  
whereas . indicates 2/3 homology with residues showing different properties. Note the preservation of the N-
terminal domain across the whole Synuclein family. The NAC domain is either missing or mutated in β and γ – 
Synuclein respectively and variation in the C-terminal may provide functional specificity. red – small/hydrophobic 
residues, blue – acidic residues, magenta – basic residues, green – hydroxyl/sulphydryl/amine residues  
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formation constitutes a small percentage of the total αSyn content (Bartels et al., 
2011), which occurs predominantly in cell as an unfolded monomer (Fauvet et al., 
2012), and that tetramer disassembly precedes the fibrillisation process. 
1.6.3 Function of native αSyn 
The physiological role of αSyn has been the subject of many investigations and is still 
not entirely understood. Increasing evidence shows that αSyn may function as a 
cellular ferrireductase (Brown, 2013). For this activity, αSyn is able to bind both 
copper and iron simultaneously (Davies et al., 2011a). Similar to the metal ion 
cofactors found in other proteins, the copper bound to the N-terminal of αSyn is likely 
to catalyse the reduction of cellular iron from Fe(III) to Fe(II) (Davies et al., 2011a; 
Davies et al., 2011b). Metal-binding activity has been proposed for numerous proteins 
associated with neurodegenerative disorders including: DJ-1, prion and Aβ (Brown, 
2010a). 
The localisation of αSyn at presynaptic nerve terminals (figure 1.9a-b) (Jakes et al., 
1994; Iwai et al., 1995; Withers et al., 1997) as well as its interaction with SNARE 
complexes (Burre et al., 2010) and the distal reserve pool of synaptic vesicles (Murphy 
et al., 2000; Lee et al., 2008b), suggests that αSyn is important for regulating 
neurotransmitter release, healthy synaptic function and plasticity (figure 1.9c). The 
association between αSyn and vesicles has been demonstrated in vitro while 
investigating the helical structure of the lipid-binding domain (Davidson et al., 1998; 
a b 
Figure 1.8 Physiological structures of αSyn. (a) 3D structure of αSyn bound to membrane (protein database ID: 
2KKW) (Ulmer et al., 2005). (b) Model structure of αSyn helically folded tetramer based on electron microscopy 
reconstruction. (Wang et al., 2011a). 
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Jo et al., 2000). This interaction is implicated in regulating the size of the presynaptic 
vesicular pool in cultured hippocampal neurons (Murphy et al., 2000). Mice lacking 
αSyn show depleted vesicle reserves and impaired vesicle mobilisation at the nerve 
terminals (Cabin et al., 2002). 
  
Figure 1.9 Physiological role of αSyn in regulating vesicle trafficking and neurotransmission. (a) Wide field 
image (magnified in b) of cultured neurons. MAP2 reveals neuronal dendrites (red); αSyn (green) localises 
presynaptically. (c) The functions of αSyn in the presynaptic terminal include vesicle refilling (αSyn; blue), 
interaction with target membrane – associated SNARE (t-SNARE) and vesicle-associated SNARE (v-SNARE) 
proteins. Accumulation of αSyn (αSyn; red) impairs neurotransmitter release, vesicle recycling and vesicle 
trafficking (Lashuel et al., 2013). 
28 
 
Despite its general abundance throughout the brain (Vivacqua et al., 2011), song 
learning in zebra finches requires a reduced expression of Synelfin (the avian 
homologue to αSyn/NACP) in specific areas during the critical stage of development 
(George et al., 1995). In αSyn-knockout mice, however, only mild, inconsistent 
changes in cognitive/learning behaviour are observed (Chen et al., 2002; Kokhan et 
al., 2012). The fact that single, double and even triple Synuclein knockouts (α-, β- 
and γ- Synuclein) remain viable (Chandra et al., 2004; Drolet et al., 2004; Senior et 
al., 2008; Greten-Harrison et al., 2010) suggests that these proteins are not essential 
for healthy synaptic function but may contribute to the regulation of the 
neurotransmitter release mechanism (Lashuel et al., 2013). 
In particular, dopamine-dependent behavioural changes are often seen in αSyn-
knockout mice (Maries et al., 2003; Drolet et al., 2004; Senior et al., 2008); linking 
αSyn to healthy neurotransmission. It has been shown that αSyn is involved in 
regulating dopamine (DA) neurotransmission by interacting with DA vesicles 
(Lotharius and Brundin, 2002a). In addition, αSyn has been shown to have an 
inhibitory effect on the activity of tyrosine hydroxylase (TH), the rate-limiting enzyme 
in DA biosynthesis (Perez et al., 2002), and regulates the insertion of DA transporters 
into the membrane (Lee et al., 2001; Lehmensiek et al., 2002). The ability to rapidly 
sequester DA, a function that is impaired by familial PD mutations in αSyn (Lotharius 
et al., 2002), provides a protective mechanism against the oxidative damage caused 
by dopamine breakdown products (Lotharius and Brundin, 2002b). This may explain 
why specific dopaminergic pathways in the brain are more susceptible than others in 
PD pathology (Xu et al., 2002). 
1.6.4 Pathological αSyn 
Although its native function remains elusive, αSyn has a well established pathological 
role in a number of neurodegenerative disorders, collectively termed 
Synucleinopathies. Since its initial discovery as a non-Aβ component of amyloid 
plaques in Alzheimer’s disease patients (Ueda et al., 1993), a pathological function 
was always suspected for αSyn. Research interest grew rapidly when, a few years later, 
a missense mutation in the SNCA gene was found in familial cases of early-onset PD 
(Polymeropoulos et al., 1997). At the same time it was discovered, through 
immunohistochemistry, that αSyn fibrils form the main component in Lewy bodies 
(Spillantini et al., 1997; Baba et al., 1998). Over the last few decades, the involvment 
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of αSyn aggregation in PD pathogenesis has become increasingly well established. 
The strongest evidence linking the two is summarsied below: 
 In several cases of familial PD, point mutations in αSyn (A53T, A30P, E46K, 
H50Q and G51D) (Polymeropoulos et al., 1997; Kruger et al., 1998; Zarranz et 
al., 2004; Lesage et al., 2013; Proukakis et al., 2013) and gene multiplications 
(Singleton et al., 2003; Chartier-Harlin et al., 2004; Ibanez et al., 2004; Fuchs et 
al., 2007; Ross et al., 2008b) promote the early onset of symptoms (Conway et al., 
1998; Narhi et al., 1999). 
 The main protein component of Lewy bodies was found to be amyloid αSyn fibrils 
(Spillantini et al., 1997; Spillantini et al., 1998). 
 The expression of human αSyn (both WT and mutants) in transgenic mice 
(Masliah et al., 2000; Kirik et al., 2002; Lo Bianco et al., 2002; Chen et al., 2015), 
flies (Feany and Bender, 2000), and nematode worms (Kuwahara et al., 2006) 
resulted in age-dependent dopaminergic neuron loss, motor dysfunctions and 
inclusion body formation comparable to those found in PD. 
 Conversely, αSyn-null mice display resistance to MPTP-induced degeneration of 
DA neurons as the toxin becomes unable to inhibit complex 1 (Dauer et al., 2002).  
 Expression of αSyn in cell cultures led to increased oxidative stress, calcium influx 
and mitochondrial-associated cell death (Hsu et al., 2000; Ko et al., 2000). 
 Animal models that induce Parkinsonism by exposure to pesticides (rotenone, 
paraquat) and neurotoxins (MPTP) aquire Lewy bodies containing αSyn (Betarbet 
et al., 2000; Sherer et al., 2003; Drolet et al., 2004; Feng and Maguire-Zeiss, 
2011). 
1.6.5 Pathology of extracellular αSyn 
Initially, the aggregation of αSyn was believed to be a largely intracellular trait 
(McNaught and Olanow, 2006) with evidence for Lewy Bodies ending up in the 
extracellular space as a result of host cell destruction (Katsuse et al., 2003). However, 
the release and uptake of αSyn aggregates from the extracellular space appears to play 
an important role in disease progression (Lee, 2008; Brown, 2010b). Implications of 
extracellular αSyn arose following the detection of αSyn oligomers in the 
cerebrospinal fluid of PD patients (El-Agnaf et al., 2003; El-Agnaf et al., 2006) and 
soluble protein fractions from the brains of DLB patients (Paleologou et al., 2009). 
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Subsequently, αSyn release has been shown to occur via a calcium-dependent 
exocytosis mechanism (Emmanouilidou et al., 2010). Whilst in the extracellular space, 
αSyn is chaperoned by Hsp70 (Outeiro et al., 2008; Danzer et al., 2011) which plays 
a neuroprotective role against aggregation (Auluck et al., 2002). However, the 
extracellular accumulation of high levels of heavy metal ions in the SNc (Dexter et 
al., 1991) could promote αSyn aggregation through binding to the C-terminal (Bush, 
2000; Binolfi et al., 2006; Brown, 2010b). A loss of heavy metal ion homeostasis, 
typically seen in patients with PD (Dexter et al., 1989; Gorell et al., 1999; de Lau and 
Breteler, 2006), is therefore a likely promoter of extracellular αSyn toxicity. 
The extracellular release of αSyn in neurons is thought to be mediated from 
presynaptic terminals, which become enriched in αSyn aggregates (Schulz-Schaeffer, 
2010), and may impact upon postsynaptic elements. Complementing the release of 
αSyn, all major brain cell types (neurons, astrocytes, and microglia) are also capable 
of clearing extracellular αSyn (Lee et al., 2008a) and that, once internalised, αSyn can 
be retrogradely transported from the axon to the cell soma (Danzer et al., 2011). The 
transmission of αSyn in this manner has been recorded directly from neuron to neuron 
(Desplats et al., 2009) and from neuron to astroglia (Lee et al., 2010) emphasising the 
likelihood of synaptically-released extracellular αSyn being an important factor in the 
spreading of synucleinopathic diseases. 
The accumulation of αSyn has been associated with a reduction in pre- and post-
synaptic markers (Kramer and Schulz-Schaeffer, 2007) and in the actin-binding 
protein, debrin; involved in the formation and maintenance of dendritic spines 
(Takahashi et al., 2003). Dendritic spine retraction in striatal MSNs is hypothesised 
to underlie late-stage motor complications in PD (Zaja-Milatovic et al., 2005) and 
contribute to executive dysfunction in patients with DLB (Zaja-Milatovic et al., 2006), 
while the dendritic spines of the hippocampus have been shown to regulate long-term 
potentiation (LTP) (Engert and Bonhoeffer, 1999) associated with memory and 
learning. These changes in dendritic spine morphology are accountable as a result of 
increased impairment of neurotransmitter release brought about by the presynaptic 
accumulation of αSyn aggregates (Kramer and Schulz-Schaeffer, 2007). 
Consequently, the disease pathology for many neurodegenerative disorders may stem 
from neurotransmitter deficiencies and synaptic dysfunction instead of being a direct 
result of cell death (Linazasoro, 2007; Nikolaus et al., 2009).  
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1.6.6 Aggregation of αSyn 
The mechanism of αSyn aggregation is a nucleation-dependent process (Wood et al., 
1999); characterised by a slow phase in which the protein unfavourably associates into 
an ordered nucleus, followed by a growth phase in which the nucleus rapidly 
polymerises, and a steady state phase in which the aggregate and monomer are in 
equilibrium (Harper and Lansbury, 1997). This process follows first-order kinetics 
with respect to αSyn concentration (Wood et al., 1999). The aggregation of αSyn into 
fibrils, however, is preceded by oligomeric and protofibrillar intermediate states 
(figure 1.5). Increasing evidence suggests that soluble oligomeric αSyn is more 
neurotoxic and better correlates with PD pathology than the larger insoluble 
aggregates that form later (Haass and Selkoe, 2007; Winner et al., 2011). In cell 
models, toxicity and cell death often precede the appearance of insoluble aggregates 
(Gosavi et al., 2002). Additionally, many familial mutations in αSyn accelerate 
oligomerisation rather than fibrilisation (Conway et al., 2000b). 
1.6.7 Oligomeric αSyn 
Oligomers of αSyn are highly diverse with regard to size, shape, structure, aggregation 
kinetics and toxicity. The secondary structure of αSyn oligomers is varied with some 
describing a predominantly β-sheet structure (Giehm et al., 2011) while others propose 
a greater α-helical content (Apetri et al., 2006). Oligomers have been used to seed 
aggregation indicating that they are on pathway to fibrils (Lee et al., 2002; Danzer et 
al., 2007; Danzer et al., 2009; Hansen et al., 2011). Competing evidence, however, 
shows that some forms of oligomer can impede the aggregation process; suggesting 
that they are off pathway to fibril formation (Hong et al., 2011; Lorenzen et al., 
2014c).  
Soluble oligomers have been reported to be amorphous, globular, tubular, stellate, 
spherical and annular in shape (Lashuel et al., 2002a; Lashuel et al., 2002b; Lowe et 
al., 2004; Pountney et al., 2005; Danzer et al., 2007; Hong et al., 2008; Giehm et al., 
2011). Annular oligomers (figure 1.10) in particular are a commonly seen species and 
their pore-like morphology has been compared with that of the cytolytic, β-barrel pore-
forming bacterial toxin; α-hemolysin (Lashuel et al., 2002b). However, the 
dimensions of ring-like oligomers are also subject to variability with some 
demonstrating external diameters as small as 10-12 nm (Lashuel et al., 2002a), while 
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others report them to be 40-45 nm (Danzer et al., 2007) and even as big as 70-90 nm 
(Lowe et al., 2004). It is unclear whether these different sized ring oligomers are an 
indication of biological/pathological activity, separate stages of oligomer aggregation 
or simply the result of differences in in vitro oligomerisation conditions. Numerous 
physiological factors have already been implicated in having an effect on aggregation 
rate, oligomer morphology and toxicity: molecular crowding (Uversky et al., 2002), 
αSyn concentration (Wang et al., 2011a), divalent metal ions (Binolfi et al., 2006; 
Globular 
Annular (40 – 45 nm) 
30 nm 
Annular (70 – 90 nm) 
Spheroidal Stellate 
100 nm 
Annular (10 – 12 nm) 
10 nm 
Tubular 
10 nm 
Figure 1.10 Variations in the size and shape of oligomeric αSyn formed under different conditions. Annular 
oligomers (10-12 nm) are commonly formed under incubation with shaking conditions, although tubular oligomers 
have also been characterised  (Lashuel et al., 2002b). Spheroidal oligomers, with α-helical structure, were seen by 
atomic force microscopy (AFM) after long incubation under slow aggregation conditions (Apetri et al., 2006). 
Incubation of αSyn with copper produced large stellate oligomers (Wright et al., 2009) while baicalein – stabilised 
oligomers were more globular (Hong et al., 2008). Annular oligomers with larger diameters were formed from 
incubation with iron (40-45 nm) (Danzer et al., 2007) and with calcium/cobalt (70-90 nm) (Pountney et al., 2005). 
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Brown, 2009, 2010b), dopamine (Cappai et al., 2005), environmental pH and salt 
concentrations (Hoyer et al., 2002). Variability in the molecular properties of αSyn 
oligomers between in vitro studies is therefore likely to be, in part, the result of 
differences in oligomerisation conditions. 
1.6.8 Mechanism of toxicity 
The permeabilisation of lipid bilayers was one of the first proposed mechanisms 
through which αSyn oligomers exert their toxicity (Volles et al., 2001). Indeed, 
permeabilisation of artificial vesicles filled with cations or fluorescent dyes has 
become a frequent in vitro model for measuring oligomer toxicity (Butterfield and 
Lashuel, 2010). If such a wide variety of oligomeric species exists physiologically for 
αSyn, then variation in oligomer toxicity is equally plausible. Rod-shaped oligomers 
containing dopamine, for example, are unable to bind or permeabilise membranes 
(Cappai et al., 2005; Pham and Cappai, 2013) but may be involved in loss-of-function 
of the SNARE complex (Choi et al., 2013). Copper binding to αSyn forms soluble 
stellate oligomers but also reduces membrane association (Wright et al., 2009; Wang 
et al., 2010). The flavonoid epigallocatechin gallate (EGCG) has been shown to 
redirect αSyn aggregation and remodel fibrils into disordered, non-toxic oligomers 
(Bieschke et al., 2010; Lorenzen et al., 2014b). The membrane permeabilising activity 
of αSyn oligomers has been proposed to be dependent on the exposure of the 
hydrophobic core. Oligomers that have a less compact hydrophobic core and greater 
structural flexibility are able to insert into membranes and permeabilise vesicles. Non-
toxic oligomers on the other hand are more constrained and do not as readily associate 
with membranes (Campioni et al., 2010). 
Increasing evidence proposes that oligomers are able to permeabilise membranes 
through the formation of a pore complex (Butterfield and Lashuel, 2010). This concept 
is largely attributed to annular oligomers that are able to span membranes (Zhang et 
al., 2013) and produce discrete stepwise changes in membrane conductance reflecting 
the electrophysiology of a single channel opening and closing (Kim et al., 2009; Feng 
et al., 2010; Schmidt et al., 2012; Tosatto et al., 2012; Mironov, 2015). The 
conformational antibody A11 that specifically targets annular oligomers (Kayed et al., 
2003) is able to block channel activity and inhibit membrane permeabilisation 
(Yoshiike et al., 2007). The A11 antibody is also capable of binding Aβ oligomers 
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(Kayed et al., 2003) and α-hemolysin (Yoshiike et al., 2007); supporting the idea of a 
shared mechanism of pathology. 
Counter to the theory of pore-forming oligomers, however, is the finding that 
membrane permeabilisation can be induced by a heterogeneous range of αSyn 
oligomers and is highly sensitive to the charge and content of the bilayer (van Rooijen 
et al., 2009a). This does not support the insertion of a stable pore complex but rather 
the transient association of αSyn with the membrane. Membrane ‘thinning’, in which 
the hydrophobic barrier is destabilised but not perforated by αSyn, is an alternative 
theory for describing the membrane permeabilisation mechanism of oligomers (Stockl 
et al., 2013; Lorenzen et al., 2014b).  
The preferential binding to lipid membranes with high lipid-protein ratio (Auluck et 
al., 2010) suggests that αSyn interacts more efficiently with lipid raft-like domains 
(Fortin et al., 2004). In addition to localisation at synapses, intracellular lipid-rafts, 
such as those present along mitochondria-associated endoplasmic reticulum 
membranes (MAM), present vital subcellular targets for αSyn that may be linked to 
toxicity (Guardia-Laguarta et al., 2014). As described earlier, mitochondrial 
dysfunction plays a central role in PD pathology. The connection between αSyn and 
mitochondria is poorly understood (Nakamura, 2013), although interactions with 
complex 1 have been proposed (Devi et al., 2008; Vila et al., 2008). Oligomer-specific 
alterations to calcium homeostasis (Danzer et al., 2007), as well as the accumulation 
of reactive oxygen species (Junn and Mouradian, 2002), are also likely to play a role 
in mitochondria-linked apoptosis. 
A multitude of other toxicity mechanisms have been proposed for oligomeric αSyn, 
including loss of cytoskeletal integrity (Prots et al., 2013), endoplasmic reticulum 
stress (Thayanidhi et al., 2010), impaired protein degradation systems (Xilouri et al., 
2013), disturbed vesicle-membrane fusion (Choi et al., 2013) and neuroinflammation 
(Beraud et al., 2013). The role of αSyn in these various mechanisms are well reviewed 
by Roberts and Brown (2015) and summarised in figure 1.11. Thus, αSyn oligomer 
toxicity is likely to be the result of many different structural species acting upon many 
different cellular systems. However, there still remains much to be understood with 
regard to oligomers in neurodegenerative diseases. 
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1.7 Thesis outline 
This thesis aims to develop our understanding of how soluble, annular αSyn oligomers 
affect the electrophysiology of neurons in mouse neocortical brain slices. The 
neocortex is an area heavily associated with the non-motor symptoms of PD and other 
neurodegenerative disorders, yet is often overlooked in studies regarding αSyn 
oligomer pathology. Furthermore, research into the electrophysiological properties of 
αSyn oligomers often lack characterisation which is important considering the 
structural and functional heterogeneity described in the previous sections. The 
hypotheses of this thesis are that oligomers will produce changes in specific 
neuronal parameters that are not caused by the monomer. Furthermore, oligomers 
isolated from separate stages of the aggregation pathway will show structural 
differences that alter their impact on neuron electrophysiology. This thesis attempts to 
bridge this gap between structural biology and neurobiology as two well defined 
Figure 1.11 Toxicity mechanisms in relation to properties of αSyn oligomers. Pink circle – properties of αSyn 
oligomers. Yellow circle – molecular effects conferred by toxic oligomers. Green circle – cellular systems disrupted 
by oligomers. Blue box – pathological outcomes of neuron dysfunction. ER – endoplasmic reticulum. UPR – 
unfolded protein response (Roberts and Brown, 2015). 
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populations of soluble αSyn oligomers are injected directly into thick-tufted layer 5 
pyramidal neurons in the neocortex. 
Chapter 2 provides an overview of the methods used to express and purify recombinant 
αSyn. Two point mutations are introduced into the N-terminal region; Y39W provides 
structural information in the form of tryptophan fluorescence and E46K is a disease-
linked mutation that facilitates aggregation.  
Chapter 3 examines the aggregation time course of αSyn and the isolation of 
oligomeric species. In addition to purifying oligomers formed during αSyn 
aggregation, a separate population of oligomers were recovered from the sonication of 
fibrils. A range of analytical tools were applied including circular dichroism and 
fluorescence spectroscopy, transmission electron microscopy, analytical 
ultracentrifugation and Thioflavin-T binding assays to characterise the structural 
differences between these two species of oligomeric αSyn. 
In Chapter 4 monomeric and oligomeric αSyn are introduced directly into thick-tufted 
layer 5 pyramidal neurons using the whole-cell patch clamp technique. Neurons with 
intracellularly injected αSyn remained stable for over half an hour, as determined by 
the series resistance. Additionally, both monomer and oligomer were observed by 
immunofluorescence imaging specifically within recorded neurons. The voltage 
responses to step and naturalistic input currents were used to generate standard and 
dynamic I-V curves respectively. The dynamic I-V curve can be accurately fitted to 
an exponential integrate-and-fire neuron model from which a range of 
electrophysiological parameters can be extracted.  
Chapter 5 examines the time course of changes in electrophysiological parameters, 
derived from standard and dynamic I-V curves, as a result of oligomeric αSyn. Over 
time, neurons injected with oligomer displayed a significantly reduced input resistance 
compared to either control or monomer-injected neurons. Consequentially, the amount 
of current needed for spike initiation was significantly elevated and the firing rate 
markedly slower. 
Finally, a general discussion and conclusion are presented in which the implications 
of these findings, particularly with regard to the cognitive symptoms prevalent 
throughout PD, are assessed. 
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2 Expression and purification of recombinant alpha-
Synuclein 
2.1 Introduction 
While it is possible to extract high yields of endogenous alpha-Synuclein (αSyn) from 
brain tissues and red blood cells (Scherzer et al., 2008; Bartels et al., 2011; Fauvet et 
al., 2012), this process is expensive, inconsistent and technically challenging. 
Recombinant expression of αSyn on the other hand has become a more favourable and 
widely used method as it provides comparably large amounts of protein in a renewable 
manner. Recombinantly expressed αSyn has been used in countless in vitro studies on 
native structure and function, membrane/protein/small molecule interactions, 
aggregation kinetics and mechanism of toxicity. The secondary structure of native 
αSyn purified from human brain tissue, in the unfolded monomeric state, was shown 
to be identical to that of recombinant αSyn (Fauvet et al., 2012). Therefore, 
recombinant αSyn will be used throughout this thesis as an appropriate model for 
native αSyn. 
The dual focus of this thesis is to combine structural characterisation of purified 
oligomeric αSyn (chapter 3) with investigations into their electrophysiological impact 
(chapters 4 & 5) in cortical neurons. To facilitate the aggregation process a point 
mutation linked to a familial form of PD (position 46; glutamate to lysine) will be 
inserted into the recombinant human αSyn construct. The E46K mutation has been 
shown to accelerate aggregation in vitro (Choi et al., 2004), produce amyloid-like 
fibrils faster than the wild type (Greenbaum et al., 2005), and cause juvenile onset of 
disease symptoms (Zarranz et al., 2004). 
The structural changes exhibited by αSyn during aggregation will be investigated 
using circular dichroism spectroscopy and tryptophan fluorescence. Intrinsic 
tryptophan fluorescence is a useful tool for investigating protein structure as the 
emission spectrum of these residues is highly sensitive to the local environment 
(Royer, 2006). Since αSyn does not have any native tryptophan residues, a folding 
sensitive mutation can be strategically introduced through site-directed mutagenesis 
in place of a large aromatic amino acid such as phenylalanine or tyrosine (Smith et al., 
1991). For all investigations, the tyrosine residue at position 39 will be mutated to 
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tryptophan (Y39W). This location was chosen as the N-terminal region is known to 
undergo α-helical folding during lipid binding (Bussell and Eliezer, 2003) and may 
form integral structures in the oligomeric state (Lorenzen et al., 2014c). Three other 
tyrosine residues exist close to the C-terminal end, however the consistently unfolded 
nature of this region (see Introduction) makes them impractical for tryptophan 
insertion. Tryptophan fluorescence has been successfully used to study the native and 
pathological structures of αSyn. Previous investigations have shown that the Y39W 
mutation has no effect on the unfolded monomeric structure, does not interfere with 
protein aggregation or alter the structure of αSyn oligomers (Dusa et al., 2006; van 
Rooijen et al., 2009b). 
This chapter details the methods used for mutagenesis, expression, purification and 
structural characterisation of recombinant αSyn carrying point mutations at Y39W and 
E46K. The fluorescence spectrum of the solvent exposed tryptophan residue as well 
as the secondary structure as determined by circular dichroism illustrate recombinant 
αSynY39W, E46K to be in an unfolded, monomeric state. 
2.2 Materials and methods 
2.2.1 Materials 
IPTG, Tris, PMSF were purchased from Melford (Ipswich, UK) 
Glycerol, NaCl, KH2PO4, K2HPO4, MgSO4, CaCl2, MnCl2, potassium acetate, 
ammonium sulphate, ammonium persulphate, EDTA, 2-mercaptoethanol, were 
purchased from Fisher Scientific (Loughborough, UK). 
Peptone from casein (pancreatically digested) and yeast extract were purchased from 
Merch (Darmstadt, Germany). 
Nitrocellulose membrane filters (0.22 µm diameter) were purchased from Millipore 
(Ireland), 30 % acrylamide solution from Geneflow (Staffordshire, UK), and 
SnakeSkin™ Dialysis Tubing (#68035) was purchased from Thermo Scientific 
(Rockford, IL). All other materials were purchased from Sigma (Poole, UK) unless 
stated otherwise. 
 
 
39 
 
Growth media 
Lysogeny Broth (LB) contained (per litre): 10 g peptone, 5 g yeast extract and 10 g 
NaCl, made up to 1 litre with distilled water and autoclaved. 
Terrific Broth (TB) contained (per litre): 12 g Peptone, 24 g yeast extract, 4 ml 
glycerol, made up with distilled water to 900 ml. After autoclaving, 100 ml of 0.17 M 
KH2PO4 and 0.72 M K2HPO4
 (autoclaved) was added. Ampicillin (100 µg/ml) and 
chloramphenicol (20 µg/ml) were added directly, prior to inoculation with starter 
cultures. 
Competence buffers 
TBF1 contained (in mM): 30 potassium acetate, 10 CaCl2, 50 MnCl2, 100 RbCl, in 15 
% glycerol (pH 5.8). 
TBF2 contained (in mM): 10 MOPS, 75 CaCl2, 10 RbCl, in 15 % glycerol (pH 6.5).  
Both TBF1 and TBF2 were filtered before use and stored at room temperature. 
Purification buffers 
Lysis Buffer: 10 mM Tris (pH 8.0), 1 mM EDTA, 1 mM PMSF 
Buffer A: 10 mM Tris (pH 8.0)  
Buffer B: 10 mM Tris (pH 8.0), 2 M NaCl 
Both buffers A and B were passed through nitrocellulose membrane filters (0.22 µm 
diameter) and degassed either by vacuum pump or sonicating water bath 
Buffer C: 10 mM sodium phosphate buffer (pH 7.40). Dibasic sodium phosphate 
(Na2HPO4) was titrated against monobasic sodium phosphate (NaH2PO4) to achieve 
the desired pH.  
SDS-PAGE solutions 
Resolving Gel: 375 mM Tris (pH 8.8), 15 % acrylamide, 0.1 % SDS, 0.1 % ammonium 
persulphate, 0.004 % TEMED. 
Stacking Gel: 100 mM Tris (pH 6.8), 5 % acrylamide, 0.1 % SDS, 0.1 % ammonium 
persulphate, 0.001 % TEMED. 
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Sample Buffer: 62.5 mM Tris-HCl (pH 6.8), 10 % glycerol (v/v), 2 % SDS, 5 % 2-
mercaptoethanol, 0.0 5% bromophenol blue.  
Running Buffer: 25 mM Tris base, 192 mM glycine, 0.1 % SDS, pH 8.3. 
Staining Solution: 10 % ammonium sulphate, 0.1 % Coomassie G250, 20 % ethanol, 
3 % phosphoric acid. 
Western blotting 
Transfer Buffer: 25 mM Tris, 192 mM glycine, 20 % methanol, topped up to 1 Litre. 
Tris Buffer Saline (TBS): 10 mM Tris, pH 7.5, 150 mM NaCl 
Primary antibody: Mouse anti-αSyn (BD biosciences, Oxford, UK) 
Secondary antibody: Anti-mouse IgG conjugated to alkaline phosphatase (APase) 
(Promega, Southampton, UK). 
Phosphate Buffer Saline (PBS) 
PBS was prepared and sterilised in-house by the University of Warwick Department 
of Biological Sciences media preparation staff; containing: 137 mM NaCl, 2.7 mM 
KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4 
2.2.2 Protein expression 
2.2.2.1 Expression plasmid 
The pGS-21a (6169 bp) plasmid encoding recombinant Human αSynY39W (400 bp), 
flanked by HindIII & NdeI restriction sites, was purchased from GenScript. The pGS-
21a plasmid (Figure 2.1) contains a T7 promoter sequence that is specific to 
bacteriophage T7 RNA polymerase (Studier and Moffatt, 1986) and located upstream 
of a lac repressor binding site. BL21* Rosetta™(DE3) Competent Cells carry a 
chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 
promoter. Consequentially, the addition of IPTG (analogous to allolactose) 
allosterically inhibits the lac repressor enabling both T7 RNA polymerase synthesis 
and the induction of target gene transcription on the pGS-21a plasmid.  
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Figure 2.1 Construct of the pGS-21a plasmid encoding αSynY39W, E46K. The SNCA gene was inserted between 
NdeI and HindIII restriction sites downstream of the T7 promoter. The plasmid also encodes genes for ampicillin 
resistance and the Lac I repressor protein. 
2.2.2.2 Site-directed mutagenesis 
The pGS-21a-αSynY39W plasmid was used as a template for all mutagenesis reactions. 
Site-directed mutagenesis was performed by Antony Wambua (2011) using a 
QuikChange® II Site-Directed Mutagenesis Kit (Stratagene, Amsterdam Zuidoost, the 
Netherlands). The native glutamate residue at position 46 was mutated to lysine using 
the following primers synthesised by Integrated DNA Technologies: 
E46K: 
5’- TGG GTG GGC TCT AAA ACG AAA AAA GGC GTG GTG CAT GGC GTG 
GCG -3’ 
5’- CGC CAC GCC ATG CAC CAC GCC TTT TTT CGT TTT AGA GCC CAC 
CCA -3’ 
The mutagenesis reaction contained 50 ng of template DNA and 300 ng of both the 
forward and reverse primers, with 5 µl of 10x reaction buffer and 1.5 µl of dNTP mix 
(both provided by the QuikChange® II Site-Directed Mutagenesis Kit). The reaction 
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mixture was made up to 50 µl with sterile water after which 1 µl (2.5 units) of 
PfuUltra® high-Fidelity DNA polymerase was added. PCR mutagenesis was carried 
out in a thermal cycler under the following conditions: 
95°C 30 seconds   
    
95°C 0.5 minutes   
X18    
55°C 2 minutes  
   
68°C 8 minutes  
    
72°C 10 minutes   
    
 4°C   
After mutagenesis, a restriction digest assay was performed on 100 ng of the plasmid 
DNA; digested with 1 µl of both HindIII & NdeI (purchased from New England 
BioLabs) in 1 µl of 10x NEbuffer4 (New England BioLabs), topped up to 10 µl with 
sterile water. The plasmid DNA was transformed into competent cells and expressed 
in starter cultures (as described later in Methods). Plasmid extraction and purification 
was performed using a QIAprep® Spin miniprep kit (Qiagen, Dusseldorf, Germany) 
according to the manufacturer’s instructions. 
2.2.2.3 DNA sequencing 
DNA sequencing was carried out by the Warwick Genomics Facility; School of Life 
Sciences; University of Warwick. For each sequencing reaction, 500 ng of plasmid 
DNA was mixed with 5.5 pmol of primer in sterile water to a total volume of 10 µl. 
Plasmids were sequenced in both forward and reverse directions using the T7 promoter 
and terminator primers. 
2.2.2.4 Preparation of competent cells 
A single colony of BL21* Rosetta cells (plated on LB) was picked to inoculate 2.5 ml 
of LB medium; incubated overnight at 37 °C with shaking. This overnight culture was 
made up to 250 ml with LB medium containing 20 mM MgSO4 and incubated as 
previous with aeration until the A600 reached between 0.4-0.6, at which time the cells 
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were pelleted by centrifugation at 4,500 x g for 5 minutes, 4 °C. The cells were 
resuspended in 0.4 volume of ice cold TBF1 and incubated for 5 minutes at 4 °C before 
re-pelleting using the same centrifugation settings as before. The cells were 
resuspended in 1/25th of the original culture volume, in ice cold TFB2 and incubated 
for 15 minutes at 4 °C before dividing into 200 µl aliquots, quick freezing on dry – 
ice, and storage at -80 °C until use.  
2.2.2.5 Transformation of competent cells 
E. coli BL21* Rosetta cells were used for expression of all mutagenised constructs of 
human αSyn. During each transformation: a 200 µl aliquot of competent cells was 
thawed on ice and 10 ng of plasmid DNA was added. The cell + plasmid mix was 
incubated on ice for 30 minutes followed by 45 seconds of heat shock at 42 °C. After 
a further 2 minute incubation on ice, the mix was added to 3 ml of LB medium and 
incubated for 45 minutes at 37 °C with shaking. A 200 µl aliquot of the transformation 
reaction was plated onto LB agar containing 100 µg/ml ampicillin and 20 µg/ml 
chloramphenicol and left at 37 °C overnight.  
2.2.2.6 Expression of recombinant alpha-Synuclein 
From the overnight plates, single colonies of transformed cells were picked and used 
to inoculate starter cultures containing 10 ml LB media with 100 µg/ml ampicillin and 
20 µg/ml chloramphenicol. After 16-24 hours of incubation at 37 °C, with shaking at 
150 rpm, the starter culture was used to inoculate 1 Litre of TB media; incubated at 
same conditions. Expression of αSynY39W, E46K was induced when the cells reached 
OD600 of 0.5-0.8 by adding 1 mM IPTG and incubating for 4 hours as prior to 
induction. Cells were pelleted by centrifugation at 10,000 x g for 15 minutes. 
2.2.3 Protein purification 
2.2.3.1 Cell lysis 
Cell pellets were resuspended on ice in 15 ml lysis buffer and sonicated at 60 % power 
for 3 x 30 second bursts with 30 second intervals in between. Cellular debris was 
removed by centrifugation at 10,000 x g for 30 minutes (4 °C). 
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2.2.3.2 Heat treatment and ammonium sulphate precipitation 
The supernatant was topped up to 100 ml with lysis buffer and incubated in boiling 
water for 10 minutes with continuous stirring. The precipitant formed during the heat 
treatment was removed by centrifugation at 20,000 x g for 20 minutes (4 °C). The 
supernatant was kept on ice and solid ammonium sulphate was added slowly over 20 
minutes with continuous stirring. As the salt saturation increased to 50%, the protein 
content became insoluble and was collected by centrifugation as before. The mass of 
ammonium sulphate needed to bring a solution from 0% to 50% salt saturation was 
calculated as previously described (Wingfield, 2001). The pellet, containing the 
precipitated target protein, was dialysed into buffer A using SnakeSkin™ Dialysis 
Tubing. To ensure complete dialysis, the pellet was resuspended in 5 ml and dialysed 
against 3 x 5 Litres of buffer A (refreshed after 3 hours with the final run overnight) 
at 4 °C with slow stirring. 
2.2.3.3 Ion exchange (IEx) chromatography 
After dialysis, the re-solubilised protein content was loaded onto a 10 ml Source 30Q 
anion exchange column (GE Healthcare, product code: 17-1275-01). The column was 
prepared with at least one column volume (CV) of buffer A before injecting the protein 
sample at a flow rate of 2 ml/min. Protein unable to bind to the column due to incorrect 
charge passed immediately off the column; this was regarded as flow through material. 
A linear salt gradient (Buffer B) from 0-35 % was applied over 15 CV at a flow rate 
of 2 ml/min, with 3 ml fractions collected (Figure 2.4a). From the fractions correlating 
to elution peaks of interest, 20 µl aliquots were removed for analysis by SDS-PAGE. 
Due to a net charge of -9, αSyn typically eluted from the column at 14-17 % buffer B 
(280-340 mM NaCl). Thus, the fractions under the peak corresponding to αSyn 
elution, confirmed by SDS-PAGE (Figure 2.4b), were pooled together and 
concentrated by overnight freeze drying on a Scanvac Coolsafe™ freeze dryer. 
2.2.3.4 Size exclusion chromatography 
The lyophilised protein was resuspended in 4 ml buffer A and loaded onto a HiPrep™ 
26/60 Sephacryl™ S-300 High Resolution gel filtration column (Amersham 
Biosciences, Buckinghamshire, UK) equilibrated with buffer A, flow rate 2 ml/min. 
Fractions (3 ml) were collected across the elution profile and 20 µl aliquots were taken 
for analysis by SDS-PAGE. The fractions containing purified αSyn were pooled 
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together, freeze dried overnight, and resuspended in 5 ml buffer C with dialysis 
(minimum of 3 x 3 hours in 5 L buffer C). The concentration of purified αSyn was 
determined by A280 scan on NanoDrop 1000 (Thermo Scientific). The extinction 
coefficient of αSynY39W, E46K was determined from the primary sequence to be 9530 
cm-1M-1. The αSyn stock solution was divided into 200 μl aliquots, flash frozen and 
stored at -20 °C for future experimentation. 
2.2.4 SDS-PAGE 
Aliquots taken from various purification stages were diluted 1:1 with sample buffer 
and heated at 95 °C for 3 minutes before immediately loading onto a solidified 
stacking gel solution. The protein content of each aliquot was separated out by 
electrophoresis at 170 volts in solidified resolving gel solution. Gels containing protein 
were stained overnight in staining solution and de-stained with repeat washes in 
distilled water. 
2.2.5 Western blot assay 
After running samples on SDS-PAGE, the resolving gel was washed in transfer buffer 
to remove excess SDS. The gel was packed into a Mini Trans-Blot® Cell (Bio-Rad, 
Hertfordshire, UK) in contact with Hybond-ECL™ nitrocellulose membrane paper 
(Amersham Biosciences, Buckinghamshire, UK) and submerged in transfer buffer at 
4 °C with continuous stirring. Electrophoresis was carried out at 100 volts for 1 hour, 
after which the nitrocellulose paper was washed with appropriate antibodies. In cases 
of dot blotting, small aliquots (2 µl) of protein samples were transferred repeatedly 
(20 µl in total) onto nitrocellulose paper, with each additional aliquot being placed 
over the last so as to concentrate the protein into a dot.  
In western bot assays, the nitrocellulose paper was blocked for 1 hour in TBS + 
Tween20 (TBST) containing 2 % dried skimmed milk (Marvel, UK), before staining 
with primary and secondary antibodies. Mouse anti-αSyn antibody (BD biosciences, 
Oxford, UK) 1/1000 in TBST + 2 % milk was used to detect the presence of αSyn, the 
secondary for which was Anti-mouse IgG conjugated to alkaline phosphatase (APase) 
(Promega, Southampton, UK) 1/5000 in TBST+ 2 % milk. Before and after the 
addition of secondary antibodies, the paper was washed thoroughly in TBST to 
remove non-specific binding. A final wash in TBS was carried out to remove Tween20 
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prior to the addition of Western blue™ (Promega), a substrate for APase, that enabled 
visualisation of the target protein.  
2.2.6 Mass spectrometry 
The molecular weight of all αSyn constructs was determined using intact molecular 
mass analysis by means of electrospray ionisation mass spectrometry (ESI-MS), 
carried out on a Q-Tof Ultima Global instrument operated in positive ion mode and 
calibrated over a m/z range of 500-4000 using sodium iodide. Prior to analysis, 
aliquots (200 µl) of αSyn in buffer C were subjected to five desalting steps into 100 
mM ammonium bicarbonate using BioMax Ultrafree-0.5 PBCC Centrifugal filter 
units and diluted to a final concentration of 10 µM in 30 % acetonitrile/1 % formic 
acid. The spectrum was deconvoluted in cases where multiply charged protein species 
were observed. 
2.2.7 Circular dichroism (CD) spectroscopy 
Far-UV CD spectra (190-260 nm) were measured on a JASCO J-815 
spectropolarimeter (JASCO, Essex, UK) using 1 mm path length quartz cuvettes. The 
CD chamber was purged with nitrogen gas and maintained at 20 ± 2 °C by a PFD-
425S/15 Peltier temperature controller. The scanning parameters were set as follows: 
Scanning speed = 100 nm/min, Time constant = 1 second, and bandwidth = 1 nm. 
Spectra were recorded to a resolution of 0.5 nm and an accumulation of 16 – 32 scans 
were averaged per spectrum. The corresponding appropriate buffer backgrounds were 
subtracted from the final spectra. The High Tension (HT) was monitored in parallel to 
the spectra to make sure that the salt content in the samples did not interfere with CD 
analysis. Samples were dialysed in distilled water to prevent the HT from exceeding 
600 V.  
2.2.8 Fluorescence spectroscopy 
Fluorescence spectra were recorded on a Photon Technology International 
spectrofluorometer with a 4mm path length quartz cuvette. The sample was excited at 
295 nm (2 nm bandwidth) and the emission spectra were recorded from 300 to 450 nm 
(2 nm bandwidth) with a resolution of 1 nm and an integration time of 1 second. Each 
spectrum was the average of 4 scans from which the appropriate buffer background 
was subtracted. 
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2.3 Results 
2.3.1 Human αSyn containing point mutations at E46K and Y39W 
To ensure that only the specified mutations of interest were present, the target gene 
was sequenced and aligned with the human wild type (wt) αSyn sequence (Accession 
No. – P37840) using BLASTn and BLASTp online alignment tools (Figure 2.2). Aside 
from the two intended mutations at E46K and Y39W, no other unwanted mutations 
were present throughout the primary sequence, thus providing the construct αSynY39W, 
E46K. 
 
 
Figure 2.2 BLASTn (a) and BLASTp (b) alignment of αSynY39W,E46K template DNA (Query) with Human 
wild-type αSyn (#P37840) (Sbjct). All non-matching bases have no impact on the transcribed protein sequence 
aside from the intended point mutations Y39W and E46K (highlighted). 
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2.3.2 Expression of αSynY39W, E46K 
The expression of αSyn was determined after cell lysis, and monitored throughout 
purification, using SDS-PAGE (figure 2.3). Due to its unfolded nature, αSyn migrated 
slower on an SDS-PAGE than the standard protein markers of similar molecular 
weight. The αSyn band appears closer to 20 kDa on SDS – PAGE despite a Mw of 
~14.4 kDa. 
2.3.3 Ion exchange (IEx) chromatography 
From the IEx chromatogram (figure 2.4a), it is seen that the immediate flow through 
(FT) contained large amounts of protein corresponding to the portion of the total 
protein which was unable to bind to the column, as shown by SDS-PAGE (figure 
2.4b). Unseen in the FT is the αSyn band, determined by anti-αSyn western blot (figure 
2.4c), which has effectively bound to the column. Any αSyn immunoreactivity in the 
FT is likely the result of column saturation or small amounts of protein degradation. 
The discrete elution peak for αSyn displacement was at 280-340 mM NaCl (14-17 % 
buffer B); separate to other bound proteins. 
2.3.4 Size exclusion chromatography 
The size exclusion column was able to further purify αSyn by separating out proteins 
of similar ionic strength according to size. In the elution profile (Figure 2.5a), peaks 
between 50-125 ml were high Mw proteins while peaks after 250 ml were shown by 
SDS-PAGE to be degradation products (Figure 2.5b). The peak containing αSyn 
eluted between 90-110 ml, independently of other components. 
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Figure 2.3 Expression, heat treatment and ammonium sulphate precipitation of αSyn. SDS-PAGE analysis 
of αSyn expression after cell lysis (C). The pellet after heat treatment (H) shows a large amount of cellular protein 
was removed in this step. During ammonium sulphate precipitation, αSyn was collected in the pellet (ASP) while 
the supernatant (ASS) holds very little. The precipitated αSyn was re-solubilised by dialysis and purified by ion 
exchange chromatography. Standard molecular weight markers are shown on left side (M). The bands 
corresponding to αSyn is indicated by the arrows. 
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Figure 2.4 Purification of αSyn by ion exchange (IEx) chromatography. (a) The elution profile (blue) shows 
various bound protein, including αSyn (*), are displaced along the salt gradient (orange, 0-0.7 M). An SDS-PAGE 
(b) and anti-αSyn western blot (c) of the sample loaded onto the IEx column (Load), the immediate flow through 
(FT) prior to the beginning of the salt gradient (pink, 0 ml) and pooled fractions containing αSyn; corresponding 
to peak in (a). 
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Figure 2.5 Purification of αSyn from proteins of similar ionic strength by size exclusion chromatography. 
(a) The elution profile for αSyn on size exclusion chromatography. (b) SDS-PAGE illustrating the protein content 
at various points throughout the elution profile marked by i-iv. 
 
2.3.5 SDS-PAGE and western blot of purified αSynY39W, E46K 
Recombinantly expressed human αSynY39W, E46K was run on SDS – PAGE and western 
blot (figure 2.6) to assess purity. According to SDS-PAGE, αSyn purity was 
consistently higher than 98 % with no other distinct protein bands detected. Western 
blot revealed, in addition to the monomeric protein, some heavier αSyn-positive bands 
that could indicate the formation of dimer, trimer or tetramer. These formations, 
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however, were not abundant enough to be detected on SDS-PAGE suggesting them to 
be uncommon formations.  
2.3.6 Mass spectrometry 
The molecular weight of αSynY39W, E46K was confirmed by electrospray ionisation mass 
spectrometry (ESI-MS) (figure 2.7). Accounting for the two point mutations, 
αSynY39W, E46K has a calculated molecular weight of 14,482 Da which is consistent with 
the experimentally determined value. 
2.3.7 Circular dichroism (CD) spectroscopy 
The secondary structure of purified αSynY39W, E46K was determined by CD 
spectroscopy. The far-UV CD spectrum (figure 2.8) shows a gradual negative trend in 
molar ellipticity between 260 and 220 nm followed by a large negative peak at 195 
nm, consistent with the widely accepted belief that the predominating structure of 
αSyn monomer is unfolded (Eliezer et al., 2001; Fauvet et al., 2012). Previous studies 
on αSyn have concluded that incorporating tryptophan at residue 39 has no impact on 
monomer secondary structure, aggregation kinetics or fibril structure (Dusa et al., 
2006; van Rooijen et al., 2009b). 
2.3.8 Fluorescence spectroscopy  
In an unfolded state, the tryptophan at position 39 is freely available to the 
environment producing a fluorescence maxima at ~350 nm (Pfefferkorn and Lee, 
2010). The fluorescence spectra for αSynY39W, E46K (figure 2.9) illustrates the solvent 
exposed properties of tryptophan-39 in an unfolded protein. 
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Figure 2.7 ESI-mass spectrum of purified human αSyn. The mass spectrum of αSynY39W, E46K. The inset shows 
the deconvoluted spectrum with calculated mass of 14482.2 Da. 
  
Figure 2.6 SDS-PAGE and western blot of purified human αSyn. Purified αSynY39W, E46K as shown by (a) 
SDS-PAGE and (b) anti-αSyn western blot.  
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Figure 2.8 The secondary structure of αSynY39W, E46K. The far-UV CD spectrum of purified αSyn as an unfolded 
monomer. 
 
 
Figure 2.9 Fluorescence properties of αSynY39W, E46K. The tryptophan at position 39 has a fluorescence maxima 
at ~350 nm, indicative of a solvent exposed residue. This is in accordance with monomeric αSyn being unfolded. 
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2.4 Summary 
Recombinant human αSynY39W, E46K has been expressed and purified from BL21* 
Rosetta cells in preparation for future research. Through site-directed mutagenesis two 
point mutations were introduced at Try39Trp and Glu46Lys. The replacement of a 
tyrosine with tryptophan was intended to give intrinsic fluorescence properties within 
the N-terminal region of the protein, thus enabling one to study changes in the local 
environment during the aggregation process. This particular region is of great interest 
as it is believed to play an important physiological role in lipid membrane interaction 
(Davidson et al., 1998) and pathological role in modulating fibril formation (Kessler 
et al., 2003; Greenbaum et al., 2005; Vamvaca et al., 2009). The second mutation, 
glutamate to lysine, is a well characterised disease-associated mutation found in 
familial cases of PD (Choi et al., 2004; Zarranz et al., 2004). The incorporation of a 
mutation linked to early onset PD will promote αSyn aggregation (Greenbaum et al., 
2005) and facilitate the production of toxic oligomers (Fredenburg et al., 2007; 
Winner et al., 2011). 
This αSyn construct was expressed and purified for the purpose of structurally 
characterising oligomers isolated from the aggregation pathway (chapter 3). Isolated 
and characterised αSynY39W, E46K oligomers are to be intracellularly injected into 
pyramidal neurons and electrophysiological recordings taken (chapter 4). Measuring 
the changes in neuronal parameters over time in the presence or absence of αSyn 
oligomer (chapter 5) will provide detailed insight into the mechanism of toxicity and 
potentially link structural elements of αSyn to pathological function. Note; in all future 
chapters the construct αSynY39W, E46K will be referred to only as αSyn, since no other 
constructs are used in this thesis. 
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3 Development of alpha-Synuclein oligomerisation protocols 
and structural characterisation of oligomeric species 
3.1 Introduction 
The association between αSyn and PD came initially from identifying the protein as 
the main component in Lewy bodies. Indeed, the detection of these αSyn-containing 
aggregates in various brain regions remains a clinical hallmark for classifying the 
progression of several neurodegenerative disorders collectively termed 
Synucleinopathies. In some cases of familial PD, point mutations in αSyn (A53T, 
A30P, E46K, H50Q and G51D) (Polymeropoulos et al., 1997; Kruger et al., 1998; 
Zarranz et al., 2004; Lesage et al., 2013; Proukakis et al., 2013) and gene 
multiplications (Fuchs et al., 2007) promote the early onset of symptoms. Increasing 
evidence, however, suggests that soluble αSyn oligomers are more neurotoxic and 
better correlate with PD pathology than the larger insoluble aggregates into which they 
form (Haass and Selkoe, 2007). 
Insoluble fibrils have instead been theorised to provide a neuroprotective function by 
removing smaller toxic aggregates from the cytosol. In support of this, αSyn mutants 
that are able to rapidly form fibrils are less toxic than those that rapidly form oligomers 
(Winner et al., 2011). Fibril fragmentation on the other hand enhances cellular toxicity 
by increasing the fibril load and seeding further aggregation (Xue et al., 2009). 
Fragmentation can occur in vivo as the result of direct mechanical stress, thermal 
motion or the activity of chaperones such as Hsp104, which is known to fragment 
fibril samples (Shorter and Lindquist, 2004). Fibril fragmentation may also release 
soluble oligomeric components, although this concept has yet to be investigated in 
detail.  
There have been many studies on αSyn oligomers, with the oligomerisation protocols 
varying considerably regarding: protein concentration (Volles et al., 2001; Danzer et 
al., 2007), incubation conditions (Lashuel et al., 2002b; Lorenzen et al., 2014c), buffer 
content (Hoyer et al., 2002) and the use of inducers such as metal ions (Binolfi et al., 
2006; Brown, 2009) or dopamine (Cappai et al., 2005). Unsurprisingly, the oligomers 
produced from these different conditions show variability in terms of size, structure 
and toxicity. 
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Annular oligomers in particular have been shown to form membrane inserting pore-
complexes that can induce cell death through various mechanisms including 
membrane permeabilisation (Volles and Lansbury, 2002; Schmidt et al., 2012; Tosatto 
et al., 2012), Ca2+ influx (Danzer et al., 2007), synaptic alterations (Diogenes et al., 
2012; Pacheco et al., 2015) and mitochondrial dysfunction (Guardia-Laguarta et al., 
2014). However, the precise mechanism of toxicity and its relation to oligomer 
structure remains unknown and a vital point for understanding αSyn pathology. 
In this chapter, I examine the time course of αSyn aggregation under varying 
incubation conditions and monitor for the appearance of oligomers using dot blot 
assays. Soluble oligomers, mOligomers, were identified and isolated from the early 
stages of aggregation. As aggregation was allowed to continue for longer, oligomers 
became undetectable and large amyloid fibrils predominated. Fragmentation of these 
fibrils by sonication recovered a mixture of soluble aggregates among which was a 
separate population of soluble oligomers; fOligomers. Secondary structure analysis, 
using CD and fluorescence spectroscopy, suggests that mOligomers have a greater 
helical content than fOligomers. Both oligomeric species were found to be ring-like in 
shape and similar in size, yet had opposing effects on seeding αSyn aggregation. 
3.2 Methods 
3.2.1 Dot blot assay 
Small aliquots (2 µl) of protein were absorbed repeatedly (20 µl in total) onto 
nitrocellulose paper, with each subsequent aliquot being placed over the last so as to 
concentrate the protein into a dot. Once dry, the paper was washed with primary and 
secondary antibodies following the same protocol described previously for western 
blotting (see chapter 2, methods). 
Rabbit polyclonal A11 antibody (Invitrogen, Paisley, UK) 1/1000 in TBST+ 2% milk 
was used to detect the presence of oligomeric αSyn, the secondary for which was anti-
rabbit IgG conjugated to APase (Promega) 1/5000 in TBST+ 2% milk. Rabbit 
polyclonal A11 antibodies specifically target a structural epitope that is present in 
oligomeric αSyn but absent in monomeric or fibrillar αSyn (Kayed et al., 2003; Glabe, 
2004). Bovine Serum Albumin (BSA) was used as a negative control to test for 
background levels of non-specific immunoreactivity. 
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3.2.2 Oligomerisation protocol according to Lashuel et al. (2002) 
In this protocol lyophilised αSyn was resuspended in PBS (pH 7.4) at a final 
concentration of 300μM and incubated on ice for 60 minutes. The protein was further 
stored for four weeks at 4 °C and monitored periodically by A11 dot blot to assay for 
the appearance of oligomers. At four weeks the sample was centrifuged (16,000 x g; 
5 min) and passed through a 0.22 μm nylon filter to remove insoluble components. 
The supernatant was loaded onto a Superdex 200 HR gel filtration column and the 
fractions corresponding to oligomers were collected. 
3.2.3 Oligomerisation protocol according to Winner et al. (2011) 
Monomeric αSyn (300 μM in PBS + 0.01 % sodium azide, pH 7.4) was incubated for 
six days at 37 °C with gentle shaking at 150 rpm. Similar to previous, the aggregation 
reaction was monitored regularly by A11 dot blot to check for the presence of 
oligomer. As an alternative to using centrifugal filters, insoluble aggregates were 
removed by ultracentrifugation at 100,000 x g for 10 minutes and the supernatant 
loaded onto a Superdex 200 gel filtration column to separate soluble oligomers from 
monomer. 
3.2.4 Oligomerisation protocol according to Lorenzen et al. (2014) 
Monomeric αSyn (in PBS + 0.01 % azide, pH 7.4) was prepared at the much higher 
concentration of 12 mg/ml (800-900 μM) and incubated at 37 °C with 900 rpm 
agitation; using an Eppendorf Thermomixer Compact (Fisher Scientific). With 
elevated concentration and shaking speed, aggregation is reported to take place within 
several hours. As such, oligomerisation was monitored every 30 minutes by A11 dot 
blot over a 6 hour period, after which insoluble aggregates were removed by 
ultracentrifugation and soluble oligomers purified by Superdex 200 gel filtration. 
3.2.5 Fibril preparation, sonication and fOligomers 
Fibrilisation was carried out under the same conditions described in Lorenzen et al., 
(2014) with the incubation time extended to overnight. Fibrils were pelleted by 
centrifugation at 16,000 x g for 6 minutes, washed repeatedly in PBS and used for 
spectroscopic analysis and electron microscopy. 
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To determine optimal sonication parameters, resuspended fibrils were kept on ice and 
subjected to probe sonication (VCX 750 sonicator) at either 20, 40, or 60 % power and 
for 5, 30, or 60 seconds (a total of 9 separate conditions). The resulting fibril fragments 
were imaged using TEM and assayed by A11 dot blot for the presence of oligomer. 
The average length of fibril fragments (n = 200 per sonication condition) was 
determined by blind analysis of TEM images using ImageJ Figi software. Insoluble 
fragments were pelleted by ultracentrifugation (100,000 x g for 10 minutes) and the 
supernatant loaded onto Superdex 200 gel filtration column. Oligomers purified from 
sonicated fibrils were found separate to oligomers purified directly from monomers 
and thus were termed fOligomers. 
3.2.6 Ultracentrifugation 
Insoluble aggregates were separated from soluble oligomer and monomer by high-
speed centrifugation. Mixtures of αSyn aggregates produced from any of the 
aforementioned protocols were transferred into a TLA-100.3 fixed angle rotor 
(Beckman Coulter) and placed in a Beckman Optima MAX benchtop ultracentrifuge 
(Beckman Coulter). Samples were ultracentrifuged for 10 minutes at 100,000 x g, at 
4 °C under vacuum. The supernatant was carefully isolated for gel filtration while the 
pellet was repeat washed in PBS and stored at 4 °C until use. 
3.2.7 Superdex 200 high resolution gel filtration 
The supernatant from ultracentrifuged samples was loaded onto a Superdex 200 high 
resolution gel filtration column (Amersham Biosciences, Buckinghamshire, UK) 
equilibrated with PBS at a flow rate 0.5 ml/min. Fractions (0.5 ml) containing αSyn 
monomer or oligomer were collected from separate elution peaks. Oligomeric αSyn 
was concentrated and used within 24 hours of purification. Fractions containing 
monomeric αSyn were recycled into the αSyn stock (see chapter 2 Methods) for further 
use in oligomerisation reactions. 
3.2.8 Concentration and storage of oligomers 
Fractions containing oligomeric αSyn were concentrated using Amicon Ultra – 0.5 ml 
centrifugal filters (Merck Millipore): centrifugal filtration was carried out at 14,000 x 
g for 30 minutes and sample concentrate was recovered by a 1,000 x g spin for 2 
minutes; in accordance with manual instructions. Concentrated αSyn oligomer 
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(between 5-20 μM in PBS, pH 7.4) was stored at 4 °C and used for structural and 
electrophysiological experimentation within 24 hours of purification. 
3.2.9 Thioflavin T (ThT) spectroscopic assay 
Lyophilised αSyn monomer was resuspended in PBS (pH 7.4) + 0.01 % sodium azide 
to a final concentration of 10 mg/ml. A stock solution of Thioflavin T (ThT) was added 
(1/50 dilution) to give a final concentration of 20 μg/ml. The αSyn + ThT sample was 
passed through a syringe filter (pore size 0.25 μm) to remove aggregates and loaded 
into a NUNC™ MicroWell™, optical-bottom, 96-well plate (Thermo Scientific). The 
96-well plate was loaded into a CLARIOstar microplate reader (BMG Labtech) and 
incubated at 37 °C with constant orbital shaking (~700 rpm). Fluorescence 
measurements were taken every 6 minutes over a total of 9 hours using the following 
optical settings: excitation λ = 444 nm, emission λ = 481 nm, excitation/emission 
bandwidth = 10 nm, gain = 1000 and focal height = 3.1 mm. 
In seeding experiments, either mOligomer or fOligomer were added to filtered αSyn 
(final concentration 0.1 mg/ml) immediately prior to the start of recording. All 
experiments were run in three separate wells with 100 μl total volume per well. 
Separate wells used for blanking contained equivalent buffer conditions minus αSyn. 
3.2.10 Analytical Ultracentrifugation (AUC) 
αSyn samples were prepared < 24 hrs in advance and transported on ice to the 
Analytical Ultracentrifugation (AUC) laboratory based at the University of 
Birmingham School of Biosciences. Collaborators; Mrs Rosemary Parslow and Dr 
Sarah Lee, at the Birmingham Biophysical Characterisation Facility, operated a 
ProteomeLab™ XL-I (Beckman Coulter) protein characterisation system. Samples 
were diluted in PBS to give a final concentration of 0.1-0.2 mg/ml; as determined by 
single scan (A280) at 3000 rpm. Sedimentation coefficient was determined from a total 
of 285 scans per sample. AUC was carried out at 20 ± 0.1 °C in sedimentation velocity 
mode. The heterogeneity of oligomer samples was assessed by comparing the peak 
width at 50 % height. 
3.2.11 Transmission Electron Microscopy (TEM) 
Copper EM grids; 400 mesh with formvar carbon support film (Agar Scientific), were 
hydrophilised in a K100x Glow Discharger (Quorum Technologies) set to pass a 20 
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mA current for 30 seconds under vacuum. Protein samples, diluted to 75-100 μg/ml in 
distilled water, were aliquoted (10 μl) onto the prepared grids. Protein was adsorbed 
over 60 seconds after which excess liquid was removed using filter paper and replaced 
by an equal volume of 2 % uranyl acetate for a further 60 seconds. After removing the 
negative stain the grids were stored until use. Images were collected on a JEOL 
JEM2011 CyroTransmission electron microscope with 200 kV acceleration. Large 
fibril structures were imaged under low magnification (15-25 k) while small 
oligomeric structures were imaged at higher magnification (40-120 k) and analysed 
semi – automatically using ImageJ software.  
3.3 Results 
3.3.1 Comparing and optimising protocols for αSyn oligomerisation 
The starting protocol for αSyn oligomerisation was derived from the Lansbury 
research group publication in 2002, in which soluble ring-like oligomers were 
characterised for the first time by single-particle averaging of TEM images (Lashuel 
et al., 2002b). Incubation was carried out over four weeks at 4 °C, during which 
aliquots were taken periodically and assayed by dot blot using an oligomer-specific 
antibody (A11). No oligomers were detected for the first three weeks and while a 
positive blot was seen after four weeks (figure 3.1) the size of the oligomer peak on 
gel filtration was very small (figure 3.2a). The final oligomer yield was 0.1-0.5 % of 
total protein; insufficient amounts for electrophysiological experimentation. In 
addition, the incubation time was inefficiently long to allow for continuous 
experimentation.  
Thus, alternative protocols were sourced to give better yields in a shorter time. 
Providing evidence for oligomer-specific toxicity in vivo, Winner et al. (2011) 
employed an αSyn aggregation protocol that produced annular oligomers comparable 
to those from Lansbury’s group. This protocol was chosen for comparison as both 
starting concentration and buffer were held the same as in Lashuel et al. (2002) (300 
μM in PBS, pH 7.4) with the addition of 0.01 % sodium azide to avoid bacterial 
contamination. Instead of amending the starting conditions, the incubation 
environment was altered to improve oligomer yield and reduce waiting time. 
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Figure 3.2 Separation of αSyn monomer and oligomer by Superdex 200 gel filtration. Oligomerisation was 
carried out according to (a) the Lansbury group protocol; 4 weeks incubation at 4 °C (b) the Winner et al., protocol; 
2 days at 37 °C, 150 rpm or (c) the Lorenzen et al., protocol; 2 hours at 37 °C, 900 rpm.  
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Monomeric αSyn was incubated at 37 °C with gentle shaking (150 rpm) for 6 days. At 
this higher temperature and agitation, αSyn aggregation proceeded more rapidly and 
the reaction mixture turned cloudy with insoluble content; marking the production of 
fibrils. The aggregation of αSyn from unfolded monomer into β-sheet fibrils was 
observed directly by CD spectroscopy of the total reaction mixture (figure 3.3a). 
Similarly, tryptophan fluorescence became progressively blue-shifted over time as the 
exposed amino acid was internalised; indicating protein folding (figure 3.3b). Amidst 
these large aggregates, oligomers were detected by A11 dot blot within days rather 
than weeks (figure 3.1). Soluble oligomers were separated from fibrils by 
ultracentrifugation and from monomers by gel filtration. Only soluble oligomers, not 
monomers or fibrils, remained A11 positive once isolated (figure 3.4). 
The size of the oligomer peak, and thus the oligomer yield from the Winner 
oligomerisation protocol, was consistently higher (5-10 % of total protein) than from 
the Lansbury protocol (figure 3.2b) and were available within 1-2 days; a fraction of 
the original incubation time. When the reaction was allowed to proceed for the full 6 
days incubation, fibrils predominated in the mixture and the amount of oligomer 
detected by dot blot and gel filtration was diminished. In figure 3.5, multiple Winner 
oligomerisation reactions were set up at the same time and under the same conditions. 
After each day of incubation a single reaction was removed, ultracentrifuged and the 
supernatant run on gel filtration. From the time course of gel filtration chromatograms, 
the oligomer peak (~8 ml elution volume) appears within the first day and reaches 
maximum height around day 2, after which it decreases and disappears by day 5/6. As 
one would expect, the monomer peak (~15 ml elution volume) is in continuous decline 
over time as it aggregates together to form oligomers and fibrils. 
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Figure 3.3 CD and fluorescence spectroscopy time course of αSyn oligomerisation according to the Winner 
et al. (2011) protocol. The total reaction mixture was measured each day by (a) circular dichroism, in which the 
transition from unfolded monomer to β-sheet fibrils is observed, and (b) fluorescence spectroscopy which illustrates 
the gradual blue-shift of Trp39 as αSyn aggregates. 
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For many oligomerisation protocols the starting monomer concentration and agitation 
speed are much higher than those used in the Winner protocol (Diogenes et al., 2012; 
Lorenzen et al., 2014c). To investigate oligomerisation under these conditions, 
monomeric αSyn was prepared in the same buffer as before (PBS + 0.01 % sodium 
azide, pH 7.4) but at the higher concentration of 10 mg/ml and incubated at 37 °C with 
900 rpm agitation. From this dynamic incubation, A11-positive oligomers appeared 
within 90 minutes and disappeared after 3-4 hours (figure 3.1). Insoluble aggregates 
formed quickly and after 6 hours only very small amounts monomer or oligomer could 
still be detected in the supernatant. As such, oligomers were typically isolated after 2 
hours incubation. While the amount of oligomer produced was similar to the Winner 
et al., protocol, the overall yield of oligomer appeared much lower due to high starting 
concentration of monomer (~1 % of total protein) (figure 3.2c). However, since the 
incubation time had now decreased to a matter of hours, coupled with the fact that 
unaggregated monomer could be easily purified and recycled, this protocol was used 
consistently for the production of oligomers for structural and electrophysiological 
experimentation. These oligomers, which were produced directly from monomeric 
αSyn, are referred to as mOligomer. 
  
Figure 3.4 Purified mOligomers, but neither monomers nor fibrils, are A11 positive. All three samples were 
assayed with both A11 and anti αSyn antibodies; BSA was negative control. 
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Figure 3.5 Gel filtration time course following the Winner oligomerisation protocol. After 0-6 days incubation, 
the supernatant from ultracentrifugation was loaded onto Superdex 200. The oligomer peak (8 ml elution volume) 
appears after the first day and gradually declines while the monomer peak (15 ml elution volume) starts high and 
rapidly falls as it aggregates together. 
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3.3.2 Recovery of oligomers from fibril sonication 
Fibril fragmentation has been shown to enhance cytotoxicity through the production 
of small fibrillar species that can increase the number of extension sites for new fibril 
growth, and have greater biological availability for interacting with cellular 
membranes (Tanaka et al., 2006; Xue et al., 2010; Wang et al., 2011b). To investigate 
whether soluble oligomers contributed to the mixture of small species produced by 
fragmentation, intact fibrils (figure 3.6a) were subjected to probe sonication at varying 
degrees of power and duration (figure 3.6b). As either parameter was increased, the 
resulting fibril fragments became shorter (figure 3.6c) and A11 immunoreactivity was 
recovered (figure 3.6d). Prolonged sonication (60 seconds) produced weaker A11 
immunoreactivity than shorter durations. Similarly, A11 immunoreactivity was not 
observed after sonication at 20 % power but became clear at higher settings. Based on 
these preliminary findings, in all future experiments fibrils were sonicated at 60 % 
power and for 30 seconds. 
Ultracentrifugation of fibril fragments and subsequent gel filtration of the supernatant 
produced peaks for soluble oligomers and monomer at the same elution volumes as 
seen for mOligomers (figure 3.7a). This separate population of oligomers recovered 
from fibrils, referred to as fOligomers, were similarly found to be A11-positive (figure 
3.7b). 
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Figure 3.6 Fibrils sonicated under various conditions of power and duration produce different size fragments 
and recover A11-immunoreactivity. TEM images of fibrils before (a) and after (b) probe sonication at 20, 40 or 
60 % power and for 5, 30 or 60 seconds duration, were subject to blind analysis to determine the length of 
fragments. As either condition was increased, the average fragment length (c) became shorter and samples 
displayed A11 positive dot blots (d) indicating the presence of oligomers. TEM scale bars = 100 nm. 
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Figure 3.7 Oligomers recovered from sonication of fibrils, fOligomers, are A11 positive. The mixture of 
sonicated fibrils was ultracentrifuged to remove insoluble fragments and the supernatant loaded onto Superdex 200 
gel filtration (a). The fOligomer peak (inset) is similar in size and elution volume to the peak for mOligomers. (b) 
An A11 dot blot of the steps involved in preparing fOligomers from fibrils; S = Sonication step, U = 
Ultracentrifugation and GF = gel filtration. 
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3.3.3 Structural differences between oligomers 
Using CD spectroscopy (see chapter 2; methods), the secondary structure of 
mOligomers and fOligomers were compared to that of monomer and fibrillar αSyn 
(figure 3.8a). The structure of monomeric αSyn was that of a typically unfolded 
protein, with a prominent negative band at <200 nm, while fibrillar αSyn had a 
minimum at 218 nm characteristic of β-sheet. The spectra for mOligomer differed 
from fibrils as the minima is shifted to 212 and the 190 peak was more strongly 
positive. Similar to mOligomers, the spectrum for fOligomer clearly diverges from 
fibrils in wavelength intensity; particularly between 190-210 nm. However, the 
consistent minimum at 218 nm suggests the presence of β-sheet rather than α-helical 
structure.  
Importantly, neither mOligomer nor fOligomer spectra could be reconstructed from 
linear combinations of the monomer and fibril spectra (differences were especially 
prominent between 200-210 nm), indicating that both oligomers exist as their own 
distinct species. 
The secondary structure composition was estimated by DichroWeb analysis (figure 
3.8b) (Whitmore and Wallace, 2004, 2008); comparing spectra to a reference data set 
(Set 7) using the SELCON3 analysis algorithm (Sreerama and Woody, 1993). This 
analysis accurately predicts monomeric αSyn to be mainly unfolded (Fauvet et al., 
2012) but fibrils showed an over estimated percentage of α-helix; amyloid fibrils are 
well known to be β-sheet in structure (Heise et al., 2005; Nelson et al., 2005). The 
predicted composition for fOligomer was very similar to that of fibrils which, despite 
their over-estimation, suggests that they share a similar β-sheet secondary structure. 
In comparison, mOligomers showed a surprisingly high percentage of predicted α-
helix (~ 82 %) that was significantly (two-tailed t-test; p < 0.05) greater than that 
predicted for fOligomers or fibrils. This data suggests that the two oligomer 
populations display secondary structure characteristics that are different from one 
another; mOligomers are predominantly α-helical while fOligomers have more β-
sheet. 
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Figure 3.8 Far UV CD spectra of various αSyn species. The secondary structure of αSyn monomer (green), 
mOligomer (red), fOligomer (yellow) and fibrils (grey) was analysed by far UV CD spectroscopy (a) and their 
percentage structure determined using DichroWeb (b). 
Fluorescence spectroscopy was used to measure the emission spectrum of tryptophan-
39 during aggregation (figure 3.9). The emission wavelength of tryptophan 
fluorescence is dependent on its exposure to the environment; tryptophan residues that 
are buried within proteins display a blue-shift compared to solvent-exposed residues. 
Being structurally unfolded, monomeric αSyn had a freely exposed tryptophan with a 
fluorescence peak of (mean ± SEM) 350 ± 0.32 nm. Upon oligomerisation, the 
external tryptophan became buried resulting in a blue-shift of the emission peak to 335 
± 0.31 nm.  Interestingly, the shifted peaks for purified fibrils and fOligomers were 
339 ± 0.97 and 341 ± 1.10 nm respectively; still notably shifted from the monomer but 
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significantly less than that of the mOligomer (two-tailed t-test; p < 0.005; figure 3.9 
inset); suggesting that fibril fragmentation might recover oligomers with an altered 
structure. 
3.3.4 Transmission electron microscopy 
Transmission electron microscopy (TEM) revealed both species of soluble αSyn 
oligomers to be ring-like in shape similar to those described previously (Lashuel et al., 
2002b) (figure 3.10). Both populations had similar size diameter (n = 1000, mean ± 
std dev: mOligomer = 14.2 ± 2.6 nm; fOligomer = 13.6 ± 2.5 nm) and central cavity 
(mOligomer = 3.8 ± 1.1 nm; fOligomer = 4.3 ± 1.3 nm). 
  
Figure 3.9 Fluorescence spectra of αSyn monomer (green), mOligomer (red), fOligomer (yellow) and fibrils 
(grey). Fluorescence spectroscopy quantifies the Trp39 blue – shift and shows that αSyn aggregates are 
significantly shifted from the monomer by different amounts. Fibrils and fOligomers are shifted by 11 and 9 nm 
respectively, while mOligomers have a larger shift of 15 nm. This suggests mOligomers to have an altered structure 
to fibrils that is not seen in fOligomers. 
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 3.3.5 Oligomers with regard to the aggregation pathway 
Seeding with sonicated fibrils is commonly used to bypass the nucleation stage and 
accelerate amyloid formation (Yagi et al., 2005; Kim et al., 2007; Lorenzen et al., 
2012). To test whether mOligomers and fOligomers were able to accelerate the 
aggregation process in a similar manner to fibril seeds, small amounts (0.1 mg/ml) of 
either species was added to monomer solution (10 mg/ml) containing ThT and 
incubated under fibrillising conditions. Figure 3.11 shows the aggregation growth 
curve produced by ThT fluorescence upon binding to fibrils. Interestingly, the addition 
of fOligomers produced a leftward shift in the curve while adding mOligomers shifted 
the curve right. This parallel shift was the result of either a shortening or lengthening 
of the lag phase (lag phase for fOligomers was ~100 minutes while mOligomers were 
Figure 3.10 TEM images of mOligomers and fOligomers. Both oligomer species are similar in size and have 
distinct ring – like shape. Scale bar = 200 nm, inset = 25 nm. 
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~150 minutes), implying that fOligomers and mOligomers are on and off pathway 
respectively.  
3.3.6 Oligomer size and population heterogeneity 
Analytical ultracentrifugation (AUC) of αSyn monomer (figure 3.12a), mOligomers 
and fOligomers (figure 3.12b) produced peak sedimentation coefficients of 1.2 S, 11.6 
S and 11.3 S respectively. Mass transformation of these peaks gave a predicted 
molecular mass of 8 kDa for monomer and between 250-260 kDa for both oligomer 
species; suggesting that the oligomers are comprised of ~30 monomers. The peak 
width at 50 % height was 0.3 S for monomer, 5.4 S for mOligomer and 5.0 S for 
fOligomer. It is worth noting that the native αSyn tetramer (Bartels et al., 2011) would 
be expected to give a peak at ~5 S, which is observed in the mOligomer sample but 
not the fOligomer; possibly due to sonication. 
 
 
 
Figure 3.11 ThT assay of αSyn aggregation with seeding from either mOligomers or fOligomers. ThT 
experiments were carried out with 10 mg/ml monomer (x) and seeded with 0.1 mg/ml of either mOligomer (○) or 
fOligomer (□). 
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Figure 3.12 AUC experiments to determine oligomer size and heterogeneity. AUC of monomer (a – green) 
and both mOligomers (b – red) and fOligomers (b – yellow) show peak sedimentation coefficients of 1.2 S, 11.6 S 
and 11.3 S respectively. 
 
3.4 Discussion 
There is increasing evidence that soluble oligomers are the most toxic form of αSyn 
aggregates in Parkinson’s disease (Giehm et al., 2011; Winner et al., 2011). The 
transient nature and inherent polydispersity of such species (Uversky, 2010), however, 
limits not only our understanding of their structural properties but of the mechanisms 
through which they act. Since αSyn has been considered a potential target for drug 
treatments (Games et al., 2014), characterisation of the oligomeric species will be of 
great importance for devising new treatments. In this chapter an efficient αSyn 
oligomerisation protocol was developed to produce oligomers of known size, shape 
and structure. In addition to isolating oligomers during the aggregation process, 
referred to as mOligomers, a separate species of oligomer was derived from the 
fragmentation of fibrils by sonication; fOligomers. As such, this chapter presents a 
comparative investigation into these two oligomers with regard to structure and their 
effect on the aggregation pathway. Any differences in the molecular properties of these 
two oligomers could convey differences in their pathological efficacy. 
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3.4.1 Oligomerisation of αSyn is dependent on temperature, agitation speed and 
concentration 
Compared in this chapter are three protocols for αSyn oligomerisation. To begin with 
oligomerisation was carried out at 4 °C following the protocol described by Lashuel 
et al. (2002b) and after one month of incubation oligomers remained at almost 
undetectable levels (figure 3.1). With such a long incubation period and low oligomer 
yields being unsuitable for sustained experimentation, preliminary investigations were 
intended to develop the oligomerisation protocol to give better yields in a shorter time. 
It has been previously found that αSyn folding into an aggregation-prone intermediate 
state is mediated by an increase in incubation temperature (Uversky et al., 2001c; 
Uversky et al., 2001a). As such, many have reported faster oligomerisation rates at 
room temperature (Danzer et al., 2007) and 37 °C (Cappai et al., 2005). Uversky et 
al. (2001c) originally described oligomer formation only at temperatures higher than 
50 °C, although such conditions have not been repeated since. In addition to higher 
temperatures, many modern protocols follow an incubation-with-shaking method with 
the speed of agitation ranging from 150 to over 1400 rpm (Wright et al., 2009; Winner 
et al., 2011; Diogenes et al., 2012; Ariesandi et al., 2013). Implementation of this new 
method (following the protocol from Winner et al. (2011)) had a profound effect on 
both the speed of oligomerisation (figure 3.1) and oligomer yield (figure 3.2). On the 
time scale of days, rather than weeks, αSyn aggregated from monomer to fibrillar 
(figure 3.3) with A11-positive oligomers being detected at intermediate time points 
(figures 3.4 and 3.5). As both the shaking speed and starting monomer concentration 
were increased (following Lorenzen et al. (2014)) oligomerisation was accelerated 
even further and aggregates appeared in a matter of hours. Despite the reduced 
incubation time, oligomer yield was no different for either protocol at 37 °C. As one 
might expect, increasing the temperature, shaking and monomer concentration 
accelerated the overall rate of aggregation without stabilising oligomeric species. In 
comparison, it is possible to improve oligomer stability through cross-linking (Bitan 
et al., 2001; Rosensweig et al., 2012), protein engineering (Sandberg et al., 2010) or 
with heavy metal ions (Danzer et al., 2007; Wright et al., 2009). However these 
methods can have varying effects on oligomer structure and its molecular properties 
(Faendrich, 2012). The mOligomers presented in this work were isolated directly from 
monomers under aggregation conditions with minimised incubation time. 
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3.4.2 Fibril fragmentation recovers soluble, ring-like oligomers 
Fibril fragmentation is a key determinant of physiological impact for amyloid proteins 
(Tanaka et al., 2006; Xue et al., 2010; Wang et al., 2011b). In fact, fragmentation may 
be a more important process than elongation since amyloids with a slow growth rate 
but increased brittleness are less infectious (Wang et al., 2011b) and more cytotoxic 
(Xue et al., 2009). It was observed by Xue et al. (2009) that fibril fragmentation could 
not only generate new seeds that would rapidly increase the fibril load but also create 
small fibrillar species of varying dimensions that may have enhanced pathological 
properties. Still un-investigated, however, is the relation of soluble oligomers to fibril 
fragmentation. 
In this study, fibrils were broken down by probe sonication into fragments and a 
mixture of small fibrillar species, described previously (Xue et al., 2009), was 
observed by TEM (figure 3.6). Novel was the finding that sonicated fibrils gave 
positive results for A11 dot blot; implicating soluble oligomers as a key component of 
the fragment mixture. After ultracentrifugation and gel filtration of the sonicated 
sample, a new species of oligomer, termed fOligomer, was identified separate to 
mOligomers (figure 3.7). Insoluble fibrils were isolated and thoroughly washed prior 
to sonication to ensure that fOligomers were not contaminated by mOligomers during 
purification. In addition, the fibrils were kept at 4 °C throughout sonication and 
ultracentrifugation which, in light of the very slow oligomerisation kinetics observed 
at this temperature, means it is unlikely that fOligomers were the result of re-
aggregating monomers produced by fragmentation. 
3.4.3 Separate species of αSyn oligomer exhibit subtle differences in structure 
Two separate species of αSyn oligomer, fOligomer and mOligomer, were isolated 
from different stages of aggregation. A range of analytical techniques were employed 
to compare the structures of these two oligomers and their role in fibrilisation. 
With regard to secondary structure, the distinct shift in mOligomer CD spectrum 
(minima = 212 nm) suggests that this species has a lower β-sheet content compared to 
fibrils and is predicted by DichroWeb to be predominantly α-helical in structure. The 
shifted spectrum of mOligomers was previously seen by Lorenzen et al (2014) who 
describe a degree of β-sheet structure that is intermediate between unfolded monomer 
and fully structured fibrils, however, the percentage of beta-sheet structure was not 
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quantified. Previous studies using Raman and AFM microscopy on similar αSyn 
oligomers (Apetri et al., 2006) identified a significant amount of α-helical structure 
(47% α-helix and 29% β-sheet) that compliments the CD spectrum and illustrates the 
bias of DichroWeb. The DichroWeb data presented here ascribes a disproportionate 
percentage of α-helical content to fibrils. The over estimation of α-helix structures may 
be the result of DichroWeb bias; in which the geometric parameters for recognising 
helical features are better defined than for β-sheet (Wallace et al., 2003). This can be 
illustrated when analysing a protein of known structural composition such as lysozyme 
C (P00698). Lysozyme C has a native secondary structure composition of ~37 % α-
helix and ~16 % β-sheet (~34 % unordered and ~13 % turn; see UniProtKB – 
LYSC_CHICK). However, according to DichroWeb analysis Lysozyme C is predicted 
to have 81 % α-helix and 0 % β-sheet composition. As such, the true structural 
composition of αSyn oligomers cannot be inferred from these CD spectra alone, but 
instead can be used in comparison to fibrils and to each other to indicate that they may 
have subtle differences.  
A folding-sensitive tryptophan mutation was positioned in the N-terminal region of 
αSyn. The N-terminal is naturally capable of forming α-helixes during the interactions 
of monomers with lipid membranes (van Rooijen et al., 2009b). This region also 
appears to be folded in mOligomers as the fluorescence spectrum from tryptophan-39 
was strongly blue shifted; significantly more so than for fibrils. This suggests that the 
microenvironment in this region may be altered in the oligomeric state and changes 
during aggregation. Indeed, recovering fOligomers from fibrils did not reproduce the 
same level of blue shift or α-helical content as seen for the mOligomer, indicating that 
fOligomers retain elements of the fibril structure that are not present in mOligomers.  
The impact of the two types of oligomer on the process of amyloid fibril formation 
was investigated by adding each species separately to a ThT assay (figure 3.11). It was 
observed that fOligomers accelerate aggregation while mOligomers are inhibitory; 
causing a shortening or lengthening of the lag phase respectively. The close correlation 
between lag phase duration and the first appearance of A11-positive dot blots in the 
aggregation time course (figure 3.1), indicates that mOligomers form in the lag phase 
of the ThT curve and disappear during the exponential elongation phase (Giehm et al., 
2011). Similar to the findings of Lorenzen et al. (2014), the mOligomers did not act as 
seeds for fibril growth. Lorenzen et al. (2014) demonstrated oligomer inhibition to be 
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concentration-dependent with lag phase extension becoming saturated around 0.1 
mg/ml of oligomer seeds. Furthermore, this effect was not the result of monomer 
sequestration by oligomer but rather the inability for oligomers to incorporate into 
fibrils. The mOligomers presented here closely replicate the structural and aggregation 
findings of Lorenzen et al. (2014) and may therefore share these properties as well. 
Sonicated fibrils have been found previously to act as seeds for fibril formation (Kim 
et al., 2007; Lorenzen et al., 2012). Since fOligomers were produced by sonication it 
is possible that this population contains small β-sheet rich fragments, for example 
soluble tubular protofibrils (Lashuel et al., 2002b), which are present along with the 
ring-like oligomers. Indeed, the various soluble fibril fragments within the post-
sonication supernatant would likely be purified together on gel filtration since soluble 
oligomers of different sizes elute close to the exclusion limit (~1300 kDa) and cannot 
be separated on Superdex 200 (Lorenzen et al., 2014c).  
This data, therefore, may suggest that fibril fragmentation produces oligomers that are 
different in structure to those formed prior to fibrils, but could also imply that through 
sonication a mixture of soluble fragments are recovered; some of which (soluble 
protofibrils) have β-sheet secondary structure and can seed aggregation, while others 
(soluble oligomers) have a more helical structure. If this were the case one might 
expect the heterogeneity of the fOligomer population to be greater than the 
mOligomer. According to AUC analysis, however, both oligomer species had similar 
sedimentation peaks and widths at 50 % height (figure 3.12b), suggesting they have 
the same size and heterogeneity. According to the transformation ratio of oligomer 
mass to monomer mass, both mOligomers and fOligomers are predicted from AUC to 
contain ~30 monomers. While this ratio is similar to that found previously, the 
calculated mass (~250 kDa) is much lower than the expected value for an oligomer of 
this size (Lorenzen et al., 2014c). However, since AUC mass transformation of 
monomeric αSyn was equally underestimated (8 kDa), the resulting ratio of monomers 
per oligomer may still be predicted. Were the calculated oligomer mass to be 
compared to the known mass of αSyn (14.482 kDa), then the ratio falls to ~15 
monomers in each oligomer. From the literature, oligomers as small as hexamers, 
pentamers and octamers have been described previously to form annular, pore-like 
structure in membranes (Lashuel et al., 2002b; Tsigelny et al., 2007; Zhang et al., 
2013). Therefore, while this data, consistent with Lorenzen et al. (2014), suggests 
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mOligomers and fOligomers are large 30 monomer structures, smaller annular 
oligomers may form under different conditions. Alternatively, annular oligomers may 
be able to shift between multiple sizes creating stepwise changes in membrane 
conductance (Tosatto et al., 2012). 
Overall, αSyn oligomers were purified from the early stages of aggregation and also 
recovered from fibril fragmentation. Characterisation of these two oligomer 
populations suggests them to be similar in size and ring-like shape. Analysis of their 
secondary structures, however, reveals some subtle differences that may be the cause 
for their varying effects on seeding aggregation. The following chapters will 
investigate the effects of αSyn oligomers on neuron electrophysiology and whether 
differences in oligomer structure equate to differences in toxicity. 
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4 Intracellular injection of monomeric and oligomeric alpha-
Synuclein into thick-tufted layer 5 pyramidal neurons 
4.1 Introduction 
The pathological spread of αSyn aggregates to the higher regions of the brain, 
including the hippocampus and neocortex, occurs commonly in the later stages of PD 
(Braak et al., 2005). The appearance of αSyn-immunoreactive cortical Lewy bodies 
strongly correlates with the onset of cognitive impairment in PD patients (Hurtig et 
al., 2000; Mattila et al., 2000). In other neurodegenerative disorders, such as 
Alzheimer’s disease or dementia with Lewy bodies, cortical Lewy bodies can appear 
without prior loss of motor control; suggesting that they have pathologies distinct from 
that of PD. Loss of neurons in the neocortex results in a variety of neuropsychiatric 
symptoms that are severely detrimental to the patient’s quality of life (Braak et al., 
2005; Poewe, 2008). The neocortex, therefore, presents an important, yet often 
overlooked, target for studying αSyn toxicity. 
The neocortex is responsible for higher cognitive functions including memory, 
sensory feedback, motor control and emotional/social processing. The preserved 
interlayer connectivity of pyramidal neurons denotes a canonical microcircuit that 
forms the basis for signal integration throughout the neocortex (Thomson and Lamy, 
2007). The main subcortical output from the neocortex comes from thick-tufted layer 
5 (TTL5) pyramidal neurons. The varying morphological and physiological properties 
of TTL5 neurons, as well as their subcortical projections, help to derive the functional 
specificity of different cortical regions (Ramaswamy and Markram, 2015). In 
developing our understanding of cortical function and circuitry, TTL5 neurons have 
been extensively studied through patch clamp recordings of both in vitro brain slices 
(Stuart et al., 1993) and in vivo brains of freely moving animals (Murayama et al., 
2007), as well as through in silico models (Hay et al., 2011; Ramaswamy et al., 2012; 
Reimann et al., 2013). 
Neuronal response properties are typically found from measurements of current-
voltage (I-V) relationships constructed from the application of stepwise inputs 
(Hodgkin et al., 1952) or voltage ramps (Swensen and Marder, 2000). Alternatively, 
injecting a continuous waveform into the cell represents a more naturalistic stimuli 
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from which I-V curves can be measured during ongoing firing activity. These dynamic 
I-V curves closely fit to a reduced neuronal model (Exponential Integrate-and-Fire; 
EIF model) that provides a reliable, in-depth description of electrophysiological 
properties (Badel et al., 2008). This efficient method is capable of accurately 
predicting experimental data and has been used previously to assess the heterogeneity 
of neocortical pyramidal cell populations for use in the modelling of neuronal 
networks (Harrison et al., 2015).  
In this chapter, I develop a system for investigating the electrophysiological effects of 
αSyn applied intracellularly into TTL5 pyramidal neurons. Monomeric and oligomeric 
αSyn (purified and structurally characterised as shown in chapters 2 and 3) were 
injected directly into neurons using the whole-cell patch clamping technique. At 
regular intervals, the voltage responses to both step and naturalistic currents were 
recorded and used to construct standard and dynamic I-V curves respectively. 
Deriving an EIF model from the dynamic I-V curves provides a time course of 
neuronal parameters. 
I assess the integrity of this method by showing that αSyn remains stable throughout 
recordings and can be detected specifically inside recorded neurons. Furthermore, I 
demonstrate that the reliability of the reduced neuron model at predicting action 
potential spike times is not affected by the toxicity-induced changes of αSyn; making 
this approach suitable for modelling neurons in a pathological state.  
4.2 Materials and methods 
4.2.1 Materials 
Glycerol, NaCl, KCl, CaCl2, KH2PO4, NaHCO3, Tris and glucose were purchased 
from Fisher Scientific (Loughborough, UK) and the MgCl2 was purchased from Merch 
(Darmstadt, Germany). Compressed gas containing 95 % oxygen and 5 % CO2 was 
supplied by BOC gases (Surrey, UK). All other materials were purchased from Sigma 
(Poole, UK) unless stated otherwise. 
Solutions 
Artificial Cerebrospinal fluid (aCSF) contained (mM): 127 NaCl, 1.9 KCl, 1 MgCl2, 
2 CaCl2, 1.2 KH2PO4, 26 NaHCO3, 1 D-glucose (pH 7.4 when bubbled with 95 % 
O2 and 5 % CO2; 290-300 mOSM). 
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Cutting solution was a high Mg2+, low Ca2+ aCSF solution containing (mM): 127 
NaCl, 1.9 KCl, 8 MgCl2, 0.5 CaCl2, 1.2 KH2PO4, 26 NaHCO3, 1 D-glucose (pH 7.4 
when bubbled with 95 % O2 and 5 % CO2; 290-300 mOSM), used to reduce synaptic 
activity and maintain slice integrity.  
Intracellular solution contained (mM): 135 potassium gluconate, 7 NaCl, 10 HEPES, 
0.5 EGTA, 2 ATP, 0.3 GTP, 10 phosphocreatine (290-300 mOSM, pH 7.2). Aliquots 
of 500 μl were stored at -20 °C until use. Aliquots (2 μl) of Alexa Fluor® 488 
hydrazide, in deionised water, were stored at -20 °C and added to the intracellular 
solution immediately prior to patch clamp recording; to give a final concentration of 
50 μM. 
Patch pipettes 
Borosilicate glass capillary tubes (1.5 mm, 0.86 mm) were purchased from 
HARVARD APPARATUS (Kent, UK). Patch pipettes were prepared using a Model 
P-87 Micropipette puller (Shutter Instrument Co., USA) and fire polished to produce 
a 2 µm wide tip with 4-5 MΩ resistance.  
Immunostaining 
Glass slides and coverslips were purchased from Menzel-Gläser (Braunschweig, 
Germany). Plastic coverslips were purchased from Agar Scientific (Elektron 
technology, Essex UK) and a square hole was cut out of the middle to make a frame. 
VECTASHIELD® mounting media was purchased from Vector Laboratories Ltd. and 
stored at 4 °C until use. 
PFA buffer: 4 % Paraformaldehyde dissolved in distilled water with gentle heating 
(pH 7.4). Aliquots of 10 ml were stored at -20 °C until use. 
Blocking buffer: 0.4 % Triton X-100, and 1 % Bovine Serium Albumin (BSA) in PBS. 
Secondary antibodies: All Alexa Fluor® conjugated IgG secondary antibodies, the 
Alexa Fluor® 488 hydrazide and the 4',6-diamidino-2-phenylindole (DAPI) nuclear 
stain, were purchased from Molecular Probes™ (Invitrogen, Oregon, USA). 
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4.2.2 Electrophysiology 
4.2.2.1 Slice preparation 
All experiments were approved by the local ethic committee. B6CBF1 mice (male, 
postnatal days P28-35) were killed by cervical dislocation and decapitated in 
accordance with the UK Animals (Scientific Procedures) Act 1986. Following rapid 
isolation of the whole brain in cold (2-4 oC) cutting solution, the two hemispheres were 
divided with an incision along the midline and glued onto a petri dish with the sagittal 
plane facing down. The dish was submerged in cold cutting solution and mounted onto 
a Microm HM 650V microslicer (Carl Zeiss, Welwyn Garden City, UK). With the 
dorsal side of each hemisphere facing towards the blade, the dish was tilted forwards 
at an angle of +15 ° so that slicing began in the neocortex and travelled ventrally 
towards the midline. This method provided parasagittal slices of the neocortex (300 
μm thick) containing layer 5 pyramidal neurons with intact apical dendrites. Slices 
were transferred into normal aCSF with continuous bubbling and incubated for 60 
minutes at 34 °C and then stored at room temperature (20-22 °C) for 1-6 hours prior 
to recording. 
4.2.2.2 Intracellular solution with αSyn 
Prior to patch clamp recording, all αSyn protein samples were prepared in filtered PBS 
and added to intracellular solution, with Alexa Fluor® 488, to give a final concentration 
of 500 nM (5 % v/v). In control recordings, an equivalent volume of PBS was added 
to the intracellular solution (5 % v/v). The intracellular solution was passed through a 
Phenex™-RC 4 mm syringe filter (Phenomenex, Cheshire UK) with a pore size of 
0.45 μm, before the addition of αSyn, to remove impurities that would otherwise block 
the flow of solution through the patch pipette tip. 
4.2.2.3 Intracellular recording 
A brain slice was transferred into the recording chamber, submerged in normal aCSF 
and perfused at a continuous flow rate of 3 ml/min. Temperature was regulated at 32 
± 0.5 °C using a heated perfusion tube (ALA Scientific Instruments Inc., NY USA) 
controlled by LinLab software (Scientifica, Bedford UK). Slices were visualised with 
an Olympus BX51W1 microscope with a Hitachi CCD camera (Scientifica) using IR-
DIC optics. 
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The somatosensory region of the neocortex was located from its position relative to 
the hippocampus under low magnification. Single or double whole-cell patch clamp 
recordings were made from thick-tufted layer 5 pyramidal neurons under x630 
magnification using patch pipettes filled with intracellular solution and either αSyn or 
vehicle. As Alexa Fluor® 488 dye quickly diffused intracellularly, neuron morphology 
could be visualised by excitation from a pE-100 light source (CoolLED, Andover UK). 
To ensure a complete morphology, only neurons with somata at least 50 μm below the 
slice surface were recorded from. 
Thick-tufted layer 5 pyramidal neurons were identified by their large size and distinct 
apical dendrite; projecting from layer 5b and bifurcating within layer 2/3. In addition 
to morphology, pyramidal neurons of the neocortex displayed distinct current-voltage 
relationships that facilitate identification (Kasper et al., 1994; Ramaswamy and 
Markram, 2015). Thick-tufted layer 5 neurons exhibit typical burst-firing action 
potentials and large inward-rectifying currents. Neurons that did not adhere to the 
aforementioned morphological and electrophysiological features were considered to 
be either interneurons or thin tufted layer 5 pyramidal neurons and were discarded 
from analysis. 
The voltage responses from current clamped neurons were recorded using an Axon 
Multiclamp™ 700B amplifiers (Molecular Devices, USA) and digitised at 20 kHz 
using Axon Digidata® 1440a (Molecular Devices). Data acquisition was carried out 
using Clampex and analysed using Clampfit; both applications of the pCLAMP™ 
software (version 10, Molecular Devices). 
4.2.2.4 Stimulation protocols 
To extract electrophysiological properties over time, both step and dynamic currents 
were injected at 8 minute intervals (5 minutes recovery time followed by 3 minutes 
recording) over a 32 minute period and the respective voltage responses used for 
analysis by standard and dynamic I-V methods. 
4.2.2.4.1 Standard I-V method 
The standard I-V relationship was produced by the injection of 1 second duration 
square current sweeps (step currents); starting between -600 and -400 pA (to give a 
membrane potential of ~ -100 mV), and incrementing by 100-200 pA until a regular 
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firing pattern (6-12 Hz) was induced. A plot of step current against average voltage 
response around the resting potential generates the standard I-V curve. The step 
current needed to generate action potentials was used as an indication of the gain factor 
required for noisy current injection (see Dynamic I-V section below).  
4.2.2.4.2 Dynamic I-V method 
In contrast to standard I-V, in which the input current is stepwise, the dynamic I-V 
curve is generated from the neuronal response to a continuously injected waveform 
(noisy current) that reflects ongoing synaptic activity (Badel et al., 2008). The 
dynamic I-V curve, defined by the average transmembrane current as a function of 
voltage, is able to parameterise single-variable integrate-and-fire models (exponential 
integrate-and-fire, EIF (Fourcaud-Trocme et al., 2003), and refractory exponential 
integrate-and-fire, rEIF (Badel et al., 2008)). The complete method has been described 
previously (Badel et al., 2008) and a brief account is given below. 
Injected noisy current traces were constructed from the summed numerical output of 
two Ornstein-Uhlenbeck processes (Uhlenbeck and Ornstein, 1930) with time 
constants τfast = 3 ms and τslow = 10 ms. These stochastic waveforms, with time 
correlation, are representative of the background post-synaptic activity resulting from 
activation of AMPA and GABAA receptor channels. Two sets of variances were 
applied to the waveform (low; σfast = σslow = 0.18 and high; σfast = 0.36, σslow = 0.25), 
both with a DC bias of 0.06 (relative units), to give two different current traces (LowV-
06 and HighV-06). Each trace had a duration of 40 seconds and was preceded and 
followed by 5 seconds of zero current (null stimulus). The traces were multiplied by a 
gain factor (300-800 pA) when injected to give a desired firing frequency of 5-15 Hz. 
Between recovery intervals both LowV-06 and HighV-06 noisy currents (and step 
current sweeps) were injected consecutively into the recorded neuron in the presence 
of intracellularly applied αSyn constructs or vehicle. When investigating the pre-spike 
parameters using the EIF model, the dynamic I-V curve was constructed solely from 
the pre-spike voltage response (subthreshold and run up to spike) with all data falling 
in a 200 ms window after each spike being excluded from analysis. Pre-spike 
parameters were collected from both low and high variance traces and averaged. For 
the post-spike parameters, the previously excluded refractory data (200 ms after each 
spike) was used to construct dynamic I-V curves to fit the rEIF model. Since the 
88 
 
refractory parameters require a high firing frequency, only the voltage responses to 
HighV-06 noisy current were used for post-spike investigations. 
4.2.2.5 Electrode filter 
With only one electrode being used for both injecting current and measuring voltage, 
the recorded traces (Vrec) become the sum of the true membrane voltage (V) and the 
voltage across the electrode (Vel). The latter, assumed to be a linearly filtered version 
of the input I(t), can be written as a convolution integral of the current with unknown 
electrode filter f(s). 
𝑉𝑟𝑒𝑐(𝑡) = 𝑉(𝑡) + 𝑉𝑒𝑙(𝑡) = 𝑉(𝑡) +  ∫ 𝑓(𝑠)𝐼(𝑡 − 𝑠)𝑑𝑠
∞
0
            (4.1) 
The combined electrode and membrane filter is then determined using a variance 
minimisation procedure following Badel et al. (2008). This combined filter is made 
from the sum of two exponentials; one with a fast time constant (0.2-0.5 ms) that is 
due to the electrode and one with a slow time constant (~15 ms) that is due to the 
membrane. The exponential with the slower decay is subtracted from the combined 
filter to yield the electrode filter. Using this electrode filter, the component of the 
voltage due to the electrode can be calculated and subtracted from Vrec to obtain V. 
4.2.2.6 Data analysis for Dynamic I-V  
It is well established that the electrical properties of a neuron can be represented by an 
equivalent RC circuit (Piwkowska et al., 2009) in which the capacitor represents the 
charge storing ability of the phospholipid bilayer and the single resistor in parallel is 
equivalent to the combined transmembrane current passing through various ion 
channels embedded in the membrane. Thus, any current injected into the neuron (Iinj) 
can be equated to the sum of current passing through the capacitor (ICap) and current 
passing through the resistor (Iion), as shown in equation (4.2). 
 𝐼𝑖𝑛𝑗(𝑡) = 𝐼𝐶𝑎𝑝 + 𝐼𝑖𝑜𝑛(𝑉, 𝑡) +  𝐼𝑛𝑜𝑖𝑠𝑒            (4.2) 
Additional sources of high frequency variability gives the term Inoise which also 
accounts for weak background synaptic activity. The passing of current through the 
capacitor (ICap) can be represented as the resulting change in potential difference 
across the membrane multiplied by the cell capacitance; equation (4.3).  
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𝐼𝑖𝑛𝑗(𝑡) = 𝐶
𝑑𝑉
𝑑𝑡
+ 𝐼𝑖𝑜𝑛(𝑉, 𝑡) +  𝐼𝑛𝑜𝑖𝑠𝑒            (4.3) 
The injected current (Iinj) is known beforehand (noisy current traces), the derivative 
dV/dt can be calculated from recorded voltage response, and the capacitance can be 
calculated using a standard optimisation procedure based on the variance of the 
voltage (V) (Badel et al., 2008). Therefore, the ionic transmembrane current (Iion) can 
be calculated as shown below: 
𝐼𝑖𝑜𝑛(𝑉, 𝑡) + 𝐼𝑛𝑜𝑖𝑠𝑒 = 𝐼𝑖𝑛𝑗(𝑡) − 𝐶
𝑑𝑉
𝑑𝑡
            (4.4) 
A scatter plot of the transmembrane current against voltage illustrates the dynamic 
relationship between the two (figure 4.8c), with the majority of variability coming 
from intrinsic noise (Inoise) (Badel et al., 2008). The average transmembrane current in 
1 mV bins removes the time dependence of Iion (V,t) and defines the dynamic I-V 
curve (Idyn). 
𝐼𝑑𝑦𝑛(𝑉) = 𝑀𝑒𝑎𝑛[𝐼𝑖𝑜𝑛(𝑉, 𝑡)]             (4.5) 
The exponential integrate-and-fire model, from the class of single-variable neuron 
models, follows the general structure 
𝑑𝑉
𝑑𝑡
= 𝐹(𝑉) +
𝐼𝑖𝑛𝑗(𝑡)
𝐶
                  (4.6) 
Where the forcing function F(V) for the EIF model is given below (equation 4.7) and 
is equivalent to the inverse of the dynamic I-V over capacitance (equation 4.8; found 
by merging equations 4.5 and 4.6) 
𝐹(𝑉) =  
1
𝜏𝑚
(𝐸𝑚 − 𝑉 + ∆𝑇𝑒𝑥𝑝 (
𝑉−𝑉𝑇
∆𝑇
))  = −
𝐼𝑑𝑦𝑛(𝑉)
𝐶
             (4.7) 
𝐹(𝑉) =
−𝐼𝑑𝑦𝑛(𝑉)
𝐶
                  (4.8) 
The EIF model has four parameters: membrane time constant (τm), resting potential 
(Em), spike-initiation threshold (VT) and spike-onset sharpness (ΔT), which describes 
the voltage range over which an action potential initiates. The refractory properties 
were generated by making Em, 1/τm and VT dependent on the time since the last spike; 
thus constituting the rEIF model. A dynamic I-V curve was constructed from post-
spike data in each of the following time windows: 5-10, 10-20, 20-30, 30-50, 50-100, 
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100-200 ms. The rEIF parameters relax back to the EIF parameters over time with 
either a single exponential (1/τm and VT) or double exponential (Em) relaxation (figure 
4.9).  
The pre and post-spike parameters calculated from the EIF and rEIF models were used 
to simulate a voltage response to the same noisy current inputs. The accuracy of these 
parameters was then tested by comparing the simulated response to the experimentally 
recorded voltage trace. The number of matching spikes, aligning to within ± 5 ms, was 
typically 60-90 %. Percentage spike match was compared across all time points for 
neurons filled with αSyn and vehicle. 
4.2.3 Immunofluorescence 
4.2.3.1 Immunostaining 
After patch clamp recording, the patch electrode was carefully removed from the 
recorded cell and the integrity of the cell assessed. If the cell was still intact, then the 
slice was fixed immediately in PFA buffer for at least 1 hr at 4 °C, after which the 
slice was washed repeatedly with PBS (3 x 10 minutes). Slices were incubated for 1hr 
at room temperature in blocking buffer before being resuspended in either anti-αSyn 
or A11 antibodies (see western blot methods), 1/100 dilution in blocking buffer, for 1 
hr at room temperature followed by overnight incubation at 4 °C. The primary 
antibodies were aspirated and the slices washed thoroughly in PBS (5 x 10 minutes) 
prior to the addition of secondary antibodies (1/100 in blocking buffer): Alexa Fluor® 
568 goat anti-mouse IgG (H + L) for anti-αSyn staining or Alexa Fluor® 647 chicken 
anti-rabbit IgG (H + L) for A11 staining (molecular probes, #A11004 & #A21443 
respectively). 
Slices were incubated in secondary antibodies for 4 hours at room temperature and 
washed into PBS afterwards. For the purposes of background nuclear staining, slices 
were stained with DAPI (1 μg/ml in blocking buffer) for 4-8 minutes followed by 
repeated washes (5 x 4 minutes) with PBS. 
Each slice was mounted onto a glass slide and excess liquid removed with filter paper. 
The slice was framed by a plastic coverslip and preserved with a drop of 
VECTASHIELD® mounting medium (Vector laboratories Ltd). A glass coverslip was 
placed on top and sealed down. Slices were stored at 4 °C before imaging on confocal 
microscopy. 
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4.2.3.2 Conjugation of Dylight-594 to αSyn 
In addition to the immunostaining of fixed brain slices, monomeric αSyn was directly 
labelled with Dylight-594 to provide a quicker, more effective means of detecting 
αSyn intracellularly with confocal microscopy. The abundance of primary amine side 
chains in αSyn provide multiple covalent binding sites for N-hydroxysuccinimide 
(NHS) activated Dylight-594 esters. The protein was tagged using a Dylight labelling 
kit (Thermo Scientific) following the given instructions. In brief; monomeric αSyn 
stock was diluted to 1 mg/ml in PBS + 0.05 M Borate buffer (500 μl total volume) and 
added to 65 μg of lyophilised Dylight-594 NHS ester. The mixture was protected from 
light and left to stand for 4 hours at room temperature. Unbound ester was removed 
using the purification resin and microcentrifuge spin columns provided in the kit. The 
dye/protein ratio was calculated as described in the kit; by comparing the protein 
absorbance (A280) to the absorbance at maximum excitation for Dylight-594 (A595). 
Monomeric αSyn was found to be labelled at a ratio of 2.57 moles of dye per mole of 
protein. Labelled αSyn was aliquoted, flash frozen and stored at -20 °C until use. 
Attempts to label oligomeric αSyn directly were unsuccessful due to low protein 
concentrations. Labelled monomer did not readily aggregate into labelled oligomers 
and was not incorporated into aggregates when incubated in the presence of unlabelled 
αSyn (as determined by A595 absorbance). 
4.2.3.3 Confocal microscopy 
For all confocal experiments, the pinhole setting was 70 μm and scan speed was 400 
Hz. Fluorescence antibodies were excited using multiple lasers in sequential scan 
mode; the gain and offset for each laser was held constant across all experiments. 
Control slices, incubated with secondary antibodies only, were imaged at the same 
confocal settings as those for recorded cells.  
A drop of immersion oil was added on top of a mounted slice before positioning in an 
inverted microscope attached to a Leica SP5 confocal head (Leica Microsystems, 
Germany). Patched cells were located with an HCX PL APO lambda blue 40.0 x 1.25 
OIL UV objective using epifluorescence from an EL6000 external light source. All 
images, z-stacks and tile scans were recorded and analysed in Leica acquisition 
software (LAS AF lite). Single images were the accumulative average of 3 frame scans 
and the optimal step size (0.5-0.13 μm) for z-stacks was determined by the software 
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depending on the objective being used. Neuron morphology was observed under 400 
x magnification while studies of intracellular αSyn accumulation were recorded at 630 
x and 1000 x magnification (HCX PL APO 62 x 1.40 OIL and HCX PL APO CS 100.0 
x 1.40 OIL objectives respectively). All tile scans and z-stacks are presented as 
maximal projections. 
4.3 Results 
4.3.1 Preparation of oligomeric and monomeric αSyn in intracellular solution 
Preliminary investigation showed that oligomeric αSyn preparations remained 
immunoreactive to the A11 antibody after several hours when diluted in intracellular 
solution and after being passaged out of the tip of patch pipettes (figure 4.1a). To 
prevent impurities from interfering with the formation of a tight seal in patch clamp 
recordings, the intracellular solution was passed through a standard filter (pore size 
0.45 μm). However, A11 immunoreactivity was lost after passing the oligomer-
containing intracellular solution through the filter; although samples still remained 
positive for anti-αSyn antibodies. It was thus deduced that oligomers, but not 
monomers, were removed by filtration. To prevent this from happening, the 
intracellular solution was filtered prior to the addition of oligomeric αSyn. However 
filtering the intracellular solution containing monomer ensured that any larger αSyn 
aggregates were removed during these experiments. A dilution series of αSyn 
oligomers (figure 4.1b) showed that the lower limit for A11 antibody detection was 
~250 nM. The detection of monomer by anti-αSyn was more sensitive and remained 
positive at concentrations as low as 100 nM. Therefore, the concentration of αSyn 
species added to the intracellular solution for whole-cell patch clamp recordings was 
500 nM; enough to allow diffusion into recorded cells and for immunofluorescence 
staining. 
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4.3.2 Introduction of αSyn into neurons via whole-cell patch clamp technique 
To investigate the effects of αSyn species on neuronal electrophysiological properties, 
monomeric and oligomeric species were introduced into thick-tufted layer 5 (TTL5) 
pyramidal cells via the patch pipette during whole-cell patch clamp recordings. 
Including αSyn in the patch pipette, particularly without prior filtering, increased the 
risk of blockage at the tip of the electrode. The build-up of an αSyn aggregates in the 
electrode would increase the series resistance and thus worsen the voltage error during 
recordings. Therefore, the series resistance was carefully monitored at each time point 
(figure 4.2) and recordings were rejected if it exceeded 15.0 MΩ. In the data set (15 
control recordings, 14 with monomer, 16 with mOligomer and 12 with fOligomer) 
there was no significant difference in the series resistance at time zero (breakthrough 
into whole cell, in MΩ: control 12.2 ± 0.28, monomer 12.1 ± 0.18, mOligomer 11.81 
Figure 4.1 Oligomeric αSyn remains A11 positive after being added to intracellular solution but cannot pass 
through the filter. (a) Oligomers were tested with A11 (top) and anti-αSyn antibodies (bottom). Oligomers were 
stable in intracellular solution and passed out of the tip of the patch pipette, but were removed by the filter. Filtered 
αSyn remained positive for anti-αSyn indicating that monomers were able to pass through the filter. As such 
oligomers, but not monomers, were not filtered prior to patch clamping experiments. (b) Dilution series of αSyn 
oligomer and monomer to examine the strength of antibody immunoreactivity. Dot blots of oligomer become 
undetectable after ~0.25 μM while monomer remains positive at concenrations as low as 100 μM.. 
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± 0.20, fOligomer 12.0 ± 0.18) and after 32 minutes of recording (in MΩ: control 13.1 
± 0.23, monomer 12.6 ± 0.19, mOligomer 12.38 ± 0.19, fOligomer 12.3 ± 0.14). 
In addition to αSyn, the intracellular solution in the patch pipette contained 
fluorescence dye (Alexa Fluor® 488) that rapidly diffused into cells so their 
morphology could be visualised (figure 4.3a). In the rare event of the pipette becoming 
blocked (fewer than 1 in 10 pipettes were blocked), the dye would also reveal this 
disruption (figure 4.3b) and the recordings would be disregarded. 
  
Figure 4.2 The series resistance of neurons was monitored over time to ensure that αSyn was not blocking 
the patch pipette. The series resistance did not significantly change throughout the duration of recordings for any 
of the experimental conditions. The cut-off point for series resistance was 15 MΩ; above which recordings were 
rejected. 
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4.3.3 Identification of thick-tufted layer 5 (TTL5) pyramidal neurons 
TTL5 pyramidal neurons are the largest of all the cortical cells and can be identified 
by their distinct morphology (Larkman, 1991; Kasper et al., 1994) (figure 4.4). TTL5 
neurons characteristically display a long apical dendrite, which ascends to layer 1 
bifurcating along the way, and thin basal dendrites that project outward from the base 
of the soma in all directions (Markram, 1997; Ramaswamy et al., 2012). Slender-
tufted pyramidal neurons are also found in layer 5 and are similar in size. However, 
their lack of bursting activity and reduced IH current means that they could be 
distinguished from TTL5 pyramidal neurons (Kasper et al., 1994).  
 
  
Figure 4.3 During whole-cell patch clamp recordings Alexa Fluor® 488 dye diffuses into the neuron so that its 
morphology can be visualised. The dye provides a way of monitoring blockages in the pipette tip. In the majority 
of experiments no blockage was seen (a), however, in a small number of cases a blocked tip (b) was revealed by 
the dye and the experiments were disregarded. Scale bars = 20 μm. 
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Figure 4.4 Thick-tufted layer 5 pyramidal neurons were identified by their size, distinct morphology and 
position within the neocortex. Neurons were visualised by fluorescence at 488 nm, both during whole-cell patch 
clamp recordings (left) and afterwards with confocal microscopy (right). NOTE; the two images presented here are 
separate examples of TTL5 pyramidal neurons. Green = Alexa Fluor® 488, blue = DAPI. Scale bars = 50 μm. 
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4.3.4 Endogenous expression of αSyn in the neocortex 
In order to determine the effects of αSyn injected intracellularly into TTL5 neurons, it 
is necessary to show that protein in the patch pipette is able to diffuse into recorded 
cells. However, it was first important to examine the background expression of native 
αSyn so that it may be distinguished from the recombinant αSyn injected during 
recordings. Endogenous expression of αSyn in the CNS has been previously studied 
at a subcellular level (Vivacqua et al., 2011). Here we investigated the varying 
expression levels of native αSyn in brain slices using an anti-αSyn antibody (figure 
4.5), with particular focus on the layers of the neocortex (figure 4.6). 
Similar to previous findings, αSyn was abundant in the hippocampus and striatum 
(Vivacqua et al., 2011). For the majority of the cortical layers (1, 2/3 and 5) αSyn was 
not observed in the somata; thus creating a void pattern around the DAPI stained nuclei 
(figure 4.6). Some layer 4 neurons, however, showed distinctly strong levels of αSyn 
in both the nucleus and cytosol. Some neurons in layer 6 were also positive for 
intracellular αSyn though not as notably. Immunofluorescence staining also shows 
αSyn in other areas separate to the soma that may highlight its presynaptic localisation. 
Although this cannot be certain without additional markers, similar patterns of 
Figure 4.5 Endogenous expression of αSyn throughout the neocortex, hippocampus and striatum. A 
parasagittal section of mouse brain immunostained with anti-αSyn antibodies (red). N – neocortex, H – 
hippocampus, S – striatum. Scale bar = 1mm. 
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immunofluorescence have been seen for αSyn localised to synaptic terminals 
(Vivacqua et al., 2011). The finding that layer 5 pyramidal neurons have little 
endogenous αSyn in their soma and dendrites means that recombinant αSyn monomer 
and oligomer, applied intracellularly via the patch pipette, can easily be identified. 
 
Figure 4.6 Endogenous expression of αSyn in the mouse somatosensory neocortex; magnified from figure 
4.5. The layers of pyramidal neurons are labelled on each side. Layers 4 and 6 in particular show some expression 
of native αSyn within cell bodies while layers 1, 2/3 and 5 appear void of αSyn. Scale bar = 200 μm. 
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4.3.5 Detection of intracellularly injected αSyn species 
Following whole cell patch clamp recording and slice fixation, αSyn species could be 
detected inside TTL5 pyramidal neurons. This was achieved by immunofluorescence 
staining with either A11 or anti-αSyn antibodies for cells filled with oligomer (figure 
4.7a) or monomer (figure 4.7b) respectively. Oligomer was mainly detected in the 
soma of cells while monomer was detected in both the soma and going up the apical 
dendrite. Neither monomer nor oligomer were detected in the dendritic tufts, even after 
Figure 4.7 Immunofluorescence staining of neurons filled with αSyn species. During whole-cell patch clamp 
recordings, both oligomeric (a) and monomeric (b, right) αSyn diffused into the recorded neurons and was detected 
by immunofluorescence staining (red = A11 or anti-αSyn). In neurons injected with vehicle (b, left), 
immunostaining with anti-αSyn produced a void pattern indicating low native expression levels of αSyn in the 
soma. (c) Injecting conjugated αSyn-Dylight594 directly demonstrated αSyn diffusion into the recorded neuron 
and can be visualised in real time (d). Scale bars = 50 μm. 
100 
 
two hours of recording. Since only low background levels of αSyn were seen inside 
TTL5 neurons, it was possible to distinguish between vehicle filled neurons (figure 
4.7b, left) and neurons filled with recombinant monomer (figure 4.7b, right). To 
further demonstrate protein diffusion out of the patch pipette and into the cell, αSyn 
monomer was conjugated to Dylight-594™ (figure 4.7c). With fluorescence labelling, 
αSyn could even be recorded live rapidly passing from the pipette into the cell (figure 
4.7d). 
4.3.6 Deriving electrophysiological parameters from neurons using the dynamic I-V 
method 
A pair of naturalistic noisy currents with low and high variance (see methods) were 
injected, in series, into neurons at 8 minute (start-to-start) intervals following the 
injection of typical step current protocols (for standard I-V measurements). The 
voltage responses to these noisy currents were recorded using a single electrode setup 
with compensation to remove the electrode filter. To demonstrate the accuracy of the 
de-filtering process (see methods) a preliminary dual recording experiment was 
carried out in which both electrodes were attached to the soma of the same neuron; 
current was injected from one pipette and the voltage measured from both 
simultaneously. The differences in recorded voltage between the injecting electrode 
and the control electrode were removed by the filtering process (figure 4.8a) which is 
able to effectively separate the electrode voltage from the true membrane voltage. The 
dynamic I-V curve (Idyn) is equivalent to the average transmembrane current (Iion) 
(figure 4.8b), calculated from the difference between injected current (Iinj) and 
capacitive current (CdV/dt), at a given voltage (figure 4.8c) (see methods and Badel 
et al. (2008)). The forcing function for an exponential integrate-and-fire (EIF) model; 
𝑑𝑉
𝑑𝑡
= 𝐹(𝑉) +
𝐼𝑖𝑛𝑗(𝑡)
𝐶
           
equates to the inverse of Idyn over capacitance (figure 4.8d), thus providing a rapid and 
accurate protocol for extracting neuron parameters. The refractory properties of 
neurons were found by modelling the post-spike data in subdivided time windows 
(figure 4.9a), giving EIF parameters that exponentially relax back to the pre-spike 
parameters (figure 4.9b). 
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Figure 4.8 Generating the dynamic I-V curve and extracting parameters. (a) The optimal linear filter of the 
combined electrode and neuron. The sum of two exponentials (green dashed line) is fitted to the combined filter 
(blue). Removing the slower of the two exponentials, associated with the membrane response, provides the pure 
electrode filter (red dashed line). Inset: a control electrode (electrode 2, green) illustrates both the necessity and 
accuracy of defiltering when compared to the current – passing electrode (electrode 1; before (red) and after (blue) 
defiltering). (b) Neurons were stimulated with naturalistic current (Iinj (t), top) and the voltage response was 
recorded (V (t), middle). The ionic transmembrane current (Iion (t), bottom) is calculated from the difference 
between stimulated current and capacitance current. (c) A scatter plot of Iion (t) against V (t) (grey), with data 200ms 
after each spike excluded. The average Iion in 1 mV bins constitutes the dynamic I-V curve Idyn (red). (d) Thus, the 
experimentally derived data (blue points = inverse of Idyn over capacitance) can be closely fitted to a computational 
neuron model (red = EIF model fit) from which electrophysiological parameters can be extracted; the roles of these 
various parameters are shown (E = resting membrane potential, τ = time constant, VT = spike – initiation threshold 
and ΔT = spike – onset sharpness) 
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Figure 4.9 Measuring the refractory properties of neurons. (a) Dynamic I-V curves, generated from post – 
spike data in different time windows, show how neuron properties are shifted after firing but relax back over time 
to the pre-spike/subthreshold curve (black). (b) The relaxation of post-spike parameters over time: dots indicate 
parameters measured from EIF model fits in (a), red lines show relaxation with either a single (1/τ and VT) or 
double (E) exponential. The spike-onset sharpness (ΔT) did not consistently change during the post-spike time. 
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Figures 4.8 and 4.9 illustrate the dynamic I-V method in which experimental 
measurements may be used to parameterise EIF and rEIF neuron models. To assess 
the accuracy of this method parameters, extracted over time from neurons filled with 
either control or αSyn species, were used to simulate voltage responses in silico which 
were compared to the original experimentally recorded voltage traces (figure 4.10a-
d). Both simulated and recorded voltage traces were produced from the same noisy 
current input. The percentage of matching spikes between recorded and simulated 
traces (± 5 ms), were above 70 % for all experimental conditions (vehicle, monomer, 
mOligomer and fOligomer) and did not significantly change over time (after 32 
minutes, the percentage of correctly identified spikes was: control 79.1 ± 2.9 %, 
monomer 77.0 ± 3.6 %, mOligomer 72.4 ± 3.7 % and fOligomer 75.7 ± 5.5 %) (figure 
4.10e). This degree of spike matching is similar to previously reported values for layer 
5 pyramidal cells (Badel et al., 2008). Thus, the accuracy of parameter extraction is 
not compromised by perfusion of cells with either monomeric or oligomeric αSyn. 
Note that the spike matching will never be 100 %, due to spontaneous synaptic activity 
in experimental recordings which is absent in the simulations. 
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Figure 4.10 Percentage spike matching between recorded and simulated voltage responses in control and 
αSyn filled neurons. For control (a, blue), monomer (b, green), mOligomer (c, red) and fOligomer (d, yellow) 
filled neurons there is a consistently good fit of EIF model (line) to the F(V) derived from DIV curve (points). 
Next to each plot is a comparison of rEIF model simulation (black) to the experimentally recorded voltage 
(coloured); showing accurate spike prediction. Model fitting in this way means the reliability of the extracted 
parameters can be assessed. The percentage spike matches between experimentally recorded and rEIF simulated 
voltage traces (e) remain greater than 70% for all time points and for all αSyn populations, showing the dynamic 
IV method to be a consistently accurate approach to measuring neuronal changes in the presence of αSyn. 
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4.3.7 Standard I-V curves 
Prior to injecting the noisy current at each time point, a short sequence of incrementing 
step currents were injected into neurons; the subthreshold response to which (figure 
4.11a) was used to produce standard I-V curves (figure 4.11b). The standard I-V curve 
provides an alternative method for characterising neuron electrophysiology and can 
be constructed from the voltage response either before the sag due to inward rectifying 
current (IH) or during the steady state that follows (Vsag or Vsteady respectively). The 
gradient of the standard I-V curve around the resting potential equates to the neuron’s 
input resistance.  
     
Figure 4.11 Generating the standard I-V curve. (a) Step currents (top) were injected into neurons and the 
subsequent voltage responses recorded (bottom). The standard I-V curve (b) was calculated from either the 
maximum voltage change during the initial sag (VSag; circles) and during steady state (VSteady; triangles). The values 
of VSag and Vsteady were the average voltage between the indicated dashed lines. The gradient of the standard I-V 
curve at 0 pA equates to the input resistance of the cell.  
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4.4 Discussion 
The aim of the work outlined in this chapter was to develop a system whereby 
monomeric and oligomeric αSyn species could be injected into TTL5 pyramidal 
neurons and their electrophysiological properties monitored over time. To achieve 
this, I used the whole-cell patch clamp recording method in which αSyn was present 
in the intracellular recording solution. This novel approach allowed αSyn to pass via 
the pipette tip into the recorded cell and at the same time enabled electrophysiological 
measurements to be made using standard and dynamic I-V curves.  
Oligomeric αSyn remained A11-positive after being diluted in intracellular solution. 
While figure 4.1 demonstrates that oligomers are indeed present after several hours, 
their dynamic nature could mean that a small fraction might have separated back into 
monomer. Therefore, the true concentration of oligomeric αSyn in the intracellular 
solution may be lower than the desired concentration of 500 nM. However, many 
studies have previously investigated αSyn toxicity and pore-like membrane 
permeabilisation activity using concentrations equivalent to or lower than 500 nM 
(Huels et al., 2011; Diogenes et al., 2012; Martin et al., 2012; Tosatto et al., 2012; 
Mironov, 2015). Diogenes et al. (2012) demonstrated impaired LTP action of αSyn 
oligomers in hippocampal neurons using concentrations lower than 100 nM. Similarly, 
amyloid-β peptides were shown to inhibit hippocampal LTP in a concentration 
dependent manner; reaching a maximal effect after 200 nM (Ripoli et al., 2014). A 
dilution series of A11 immunoreactivity (figure 4.1b) shows that concentrations lower 
than ~250 nM are too weak to be detected. Therefore, while the exact oligomer 
concentration in intracellular solution may change, the difference is likely to be small 
and far above the minimum concentration used in other studies to elicit toxic effects. 
The stability of the series resistance of recordings over time (figure 4.2) and the 
continuous passage of Alexa Fluor® 488 dye (figure 4.3) into the recorded cell 
confirms that the pipettes did not become blocked at any point during experiments. 
The diffusion of αSyn out of the patch pipette and into the soma was confirmed by 
immunofluorescence staining. To identify injected αSyn it was first important to 
assess the levels of endogenous αSyn in the neocortex (figures 4.5 & 4.6). Endogenous 
αSyn is expressed in a wide range of neuronal cell types including dopaminergic, 
noradrenergic and cortical neurons, as well as non-neuronal cell types such as 
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endothelial cells and platelets (Hashimoto et al., 1997; Abeliovich et al., 2000; Li et 
al., 2002; Tamo et al., 2002; Baltic et al., 2004). Interestingly, αSyn appeared to be 
differentially expressed in the various cortical layers, with some showing clear somatic 
expression (layers 4 and 6) while others were distinctly void of αSyn in their soma 
(layers 1, 2/3 and 5). The visualisation of endogenous αSyn is dependent on the choice 
of antibody. Monoclonal 2E3 antibodies, for example, detect αSyn in nerve cell fibers 
while 3D5 antibodies preferentially detect within nuclei (Alim et al., 2004; Yu et al., 
2007). Both these antibodies, however, have found that αSyn strongly associates with 
synaptic terminals in all the cortical layers (Vivacqua et al., 2011). Nuclear localisation 
in the neocortex has been found to be absent from layers 1-3 and becomes increasingly 
abundant in layers 4-6 (Vivacqua et al., 2011). The immunofluorescence presented 
here did not co-localise with DAPI suggesting cytoplasmic detection rather than 
specifically within the nucleus. In addition, immunofluorescence within each layer 
was not constant for every cell throughout the cortex, suggesting intra-layer variability 
that may highlight functional or area specificity. Pipette-to-soma diffusion was 
observed directly and in real time using conjugated αSyn-Dylight 594 (figure 4.7c-d). 
Attempts to incorporate labelled αSyn into oligomers were unsuccessful. Instead, A11 
antibodies with conformational specificity (Kayed et al., 2003) were used to detect 
oligomeric αSyn inside recorded neurons. 
TTL5 pyramidal neurons were identified by their morphological and 
electrophysiological properties. While the morphology of TTL5 pyramidal neurons 
are easily distinguishable from neurons in the other cortical layers, increasing evidence 
shows morphological variation within layer 5 that can be distinguished by differences 
in their subcortical projections (Kasper et al., 1994; Hattox and Nelson, 2007; Oswald 
et al., 2013). However, the intrinsic morphological diversity of TTL5 neurons has also 
been shown in silico to have no effect on average synaptic properties and may provide 
a mechanism for robust microcircuit behaviour (Ramaswamy et al., 2012). The precise 
morphology-physiology relationship of layer 5 pyramidal neurons is still not fully 
understood and is beyond the scope of this thesis. Therefore, the TTL5 pyramidal 
neurons described in this thesis were examined as a collective since it was not possible 
to determine the subcortical projection for each neuron. In addition to ensure that 
recordings were made consistently from the same region of the neocortex, only those 
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with distinct burst firing and IH currents were selected; thus eliminating slender-tufted 
neurons from the analysis.  
To examine the electrophysiological properties of TTL5 pyramidal neurons, both 
standard and dynamic I-V curves were constructed from the voltage responses to step 
and naturalistic currents respectively. As shown in this chapter, and previously in the 
literature (Badel et al., 2008), dynamic I-V curves fit closely to the EIF model which 
can extract subthreshold parameters, show post-spike refractory properties and 
accurately predict spike times. Integrate-and-fire models have both a long history and 
a wide range of applications (Burkitt, 2006a). They are especially important for 
developing our understanding of neural network dynamics and temporal responses 
(Burkitt, 2006b). While the literature focuses on modelling the physiological 
properties of neurons, my work attempts to utilise these models to capture the 
pathological activity of αSyn. As shown by the consistently accurate spike predictions 
(figure 4.10), the effects of αSyn species can be captured within the parameters of 
these quantitative models. A thorough analysis of the impact of αSyn on a wide range 
of parameters over time is presented in chapter 5. These findings should promote the 
use of pathology modelling to further elucidate the electrophysiological changes 
underpinning neurodegenerative disorders. 
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5 Oligomeric alpha-Synuclein alters the electrophysiological 
properties of thick-tufted layer 5 pyramidal neurons in the 
neocortex 
5.1 Introduction 
The association between αSyn and cell death has been well established from 
expression models in yeast (Outeiro and Lindquist, 2003), flies (Park and Lee, 2006), 
nematode worms (Kuwahara et al., 2006) and rodents (Winner et al., 2011). However, 
many of the symptoms of neurodegenerative diseases present themselves not 
necessarily as the direct result of cell death but rather through progressive neuronal 
dysfunction or network compensation (Linazasoro, 2007; Nikolaus et al., 2009; 
Appel-Cresswell et al., 2010). Therefore, while it is important to develop our 
understanding of oligomer toxicity at the molecular level, investigating changes in 
neuronal function and electrophysiological properties may reveal how oligomer 
toxicity translates into pathological symptoms. 
In the hippocampus, for example, αSyn oligomers have been shown to impede long 
term potentiation and modulate synaptic transmission; forming the basis for impaired 
memory and learning observed in disease patients (Diogenes et al., 2012; Martin et 
al., 2012). In contrast to the hippocampus, however, much less is known about the 
toxicity of αSyn on pyramidal neurons in the neocortex; despite these regions being 
similarly afflicted neurodegenerative disorders. 
Numerous theories exist surrounding the toxicity mechanisms through which αSyn 
oligomers act. Variations in toxicity can often be attributed to the structural and 
biophysical heterogeneity of the oligomers used (Roberts and Brown, 2015). Soluble, 
annular oligomers of αSyn have been shown to form membrane-inserting pore 
complexes that allow the passage of cations in a non-selective manner (Schmidt et al., 
2012). Stepwise changes in membrane conductance have been observed after 
incubating αSyn with either planar bilayers (Kim et al., 2009; Schmidt et al., 2012; 
Tosatto et al., 2012), or cell cultures (Feng et al., 2010; Mironov, 2015). This action 
of αSyn oligomers has been compared to leak channels in neuronal membranes that 
promote excitability through distortions in ion homeostasis. While some have 
observed kinetic and pathological differences between oligomers applied to the 
110 
 
extracellular side of the membrane compared to insertion from the intracellular side 
(Schmidt et al., 2012; Mironov, 2015), others have shown that internalisation and 
intracellular accumulation are vital for effecting changes in neuronal behaviour (Ripoli 
et al., 2014). 
Thus far, in chapter 3 two oligomeric species of αSyn were isolated from separate 
points along the aggregation pathway and structurally characterised. In chapter 4, 
using whole-cell patch clamping technique, monomeric and oligomeric αSyn was 
injected into TTL5 pyramidal neurons in the neocortex of mice. In this chapter, I use 
standard and dynamic I-V curves to examine the changes in electrophysiological 
parameters of neurons over time in the presence of αSyn oligomers. By employing an 
efficient method for neuronal model identification, described in chapter 4 (Badel et 
al., 2008), I offer an in depth analysis of toxicity-induced changes in neuronal 
parameters to give insight into the mechanism through which oligomers act. Over 
time, neurons injected with these two oligomeric species displayed a similar reduction 
in input resistance compared to either control or monomer-injected neurons. 
Consequentially, the amount of current needed for spike initiation was significantly 
elevated and the firing rate markedly slower. These effects on neuron excitability 
could account for many of the cognitive symptoms prevalent throughout PD. 
5.2 Methods of analysis 
Using either the standard or dynamic I-V methods described in chapter 4, parameters 
were extracted from neurons with different treatments of αSyn and over a range of 
time points. Individual treatments were compared across different time points using 
repeated measures Analysis of Variance (ANOVA). At set time points, different αSyn 
treatments were analysed using two-tailed t tests with Bonferoni Correction for 
multiple comparisons. With the exception of threshold voltage, resting potential and 
spike amplitude, the parameters did not follow a normal distribution and, unless stated 
otherwise, are presented here as the mean value with bootstrap 95 % confidence 
intervals (made from 2000 bootstrap samples). 
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5.3 Results 
Alpha Synuclein monomers and oligomers were injected into TTL5 pyramidal cells 
via the patch pipette (all at 0.5 μM). In control recordings, an equivalent volume of 
the buffer in which monomer and oligomer were dissolved (PBS 5 % V/V) was added 
to the intracellular solution. To monitor the changes in neuron parameters over time, 
both stepwise and naturalistic currents were injected in series at 8 minute (start-to-
start) intervals, over a total period of 32 minutes. The resulting voltage responses were 
recorded, filtered and analysed by the standard and dynamic I-V methods outlined in 
chapter 4. 
5.3.1 Impact of alpha-Synuclein on neuron parameters: marked reduction in input 
resistance 
Dynamic I-V curves were generated for each αSyn treatment and at each time point 
(figure 5.1a). A number of parameters were extracted from the subthreshold and pre-
spike data: membrane capacitance (C), membrane time constant (τ), input resistance 
(Rin = τ/C), resting membrane potential (E), spike threshold (VT) and spike onset 
sharpness (ΔT) (figure 5.1b). 
In control cells (n = 18), the subthreshold parameters remained stable for the duration 
of experiments: values were not significantly different when measured at 8 minutes 
versus those measured at 32 minutes following whole cell breakthrough (p > 0.05 for 
all parameters). Since control parameters were unaltered after 32 minutes, I 
investigated whether parameters had changed at this point for neurons perfused with 
αSyn. A comparison of the effects of monomer (n=20) after 32 minutes showed no 
significant change (p > 0.05) in any of the parameters compared to control. There 
were, however, significant changes in parameters for both mOligomer (n = 19) and 
fOligomer (n = 13) filled neurons. After 32 minutes, there was a significant (p < 0.005) 
decrease in the input resistance (Rin) of recorded cells: from (mean ± std dev) 89.0 ± 
22.3 MΩ in control cells to 55.1 ± 16.0 MΩ and 59.7 ± 18.6 MΩ in cells perfused with 
mOligomers and fOligomers respectively, a reduction of ~ 40 % (figure 5.1b). As 
expected, the membrane time constant was also significantly reduced (p < 0.005) from 
16.1 ± 4.6 ms (control) to 11.8 ± 2.9 ms (mOligomer) and 13.1 ± 3.3 ms (fOligomer), 
a reduction of ~ 36 %. The membrane capacitance had significantly increased by ~20 
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% in oligomer perfused cells: from 183 ± 39.8 pF (control) to 219 ± 40.3 pF 
(mOligomer, p < 0.005) and 228 ± 56.1 pF (fOligomer, p < 0.05). 
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To investigate the time course for changes in input resistance, membrane time constant 
and capacitance, I compared neuron parameters at earlier time points (8, 16 and 24 
minutes) and found that oligomer perfused neurons remained significantly different 
from control. This suggests that the effects of the oligomers on these parameters 
occurred rapidly, within the first few minutes and then stabilised for the duration of 
the recordings. There was no significant difference between the effects of mOligomers 
and fOligomers on either input resistance, membrane time constant, or capacitance (p 
> 0.05). 
The resting membrane potential and spike onset sharpness were unaffected by αSyn 
at any of the time points. The spike-threshold voltage, however, was significantly 
reduced in mOligomer filled neurons (mean ± standard deviation, 32 min, -56.0 ± 3.6 
mV) compared to control (-52.6 ± 5.4 mV, P = 0.003), but not in fOligomer filled 
neurons (-54.91 ± 1.8 mV, P = 0.841). 
Figure 5.1 Time course of subthreshold parameters for TTL5 neurons filled with control (blue), αSyn 
monomer (green), mOligomer (red) or fOligomer (yellow). (a) The inverted dynamic I-V curves for each αSyn 
treatment and at each time point demonstrate the oligomer specific changes in parameters. Both oligomers have an 
increased slope (reduced input resistance) and the mOligomer is shifted left, giving a lower threshold voltage. (b) 
Quantification of subthreshold parameters: scatterplots show mean values (darker points) amongst all data (pale 
points) with error bars (95 % bootstrap confidence intervals). * p < 0.05, ** p < 0.01, *** p < 0.005. 
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The differential effects of mOligomers and fOligomers on subthreshold parameters are 
illustrated by their respectively shifted dynamic I-V curves from the control (figure 
5.1a). In comparison the monomer dynamic I-V curves, and thereby monomer 
subthreshold parameters, align closely to those of the control. The qualities of the 
dynamic I-V curve in relation to each parameter are outline in chapter 4, figure 4.8d. 
The change in time constant with oligomers, for example, is seen as a steeper gradient 
for the linear portion of the dynamic I-V curve. Similarly, the change in VT is conveyed 
by the leftward shift of the mOligomer curve that is not seen for the fOligomer (figure 
5.1a). Although no significant change in resting membrane potential was found for 
either oligomer, their shifted curves both intersect with the control at approximately -
80 mV, suggesting that αSyn oligomers have a reversal potential close to this voltage.  
The effects of αSyn on the post-spike relaxation properties of TTL5 neurons were 
examined for each time point (figure 5.2). The post-spike dynamics of the membrane 
time constant, normalised to the pre-spike baseline, were unaffected by either 
monomer or oligomer. Similarly, changes in resting potential and threshold voltage 
showed no differences in their post-spike increase or exponential relaxation. 
Figure 5.2 Time course of post spike parameters, normalised to baseline, for TTL5 neurons filled with control 
(blue), αSyn monomer (green), mOligomer (red) or fOligomer (yellow). Parameters show an immediate post-
spike increase followed by either a single (1/τ & VT) or double (E) exponential decay, but are unaltered by either 
monomeric or oligomeric αSyn. 
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Table 5.1 Extracted parameter values for neurons filled with αSyn monomer, f and mOligomers and vehicle. 
Values are means (μ) and standard deviations (σ) at 8 and 32 minutes after break through to whole-cell patch clamp 
recording. (*p<0.05; **p<0.005; versus control parameters at corresponding time points.) 
To corroborate the findings from the dynamic I-V method, the input resistance was 
measured from the gradient, around rest, of the standard I-V curve either before or 
after the effects of the sag due to IH activation had occurred (figure 5.3a-b). After 32 
minutes, the input resistance was (mean ± SEM) 69.1 ± 3.8 MΩ in control compared 
to 45.4 ± 1.8 MΩ in mOligomer and 45.8 ± 3.4 MΩ in fOligomer. Thus a similar 
reduction in input resistance was observed to that measured by the dynamic I–V 
(~35% reduction, P < 0.005, figure 5.3c). Since the standard I-V curve could be 
generated from a much shorter stimulus than the dynamic I-V, this method was used 
to measure the input resistance at time zero. As shown in figure 5.3d-e, the input 
resistance was not significantly different between control cells (52.1 ± 6.3 MΩ) and 
mOligomer perfused cells (49.6 ± 5.4 MΩ) at time zero (P = 0.78) but became different 
after 16 minutes (VSteady: control Rin 58.7 ± 3.2 MΩ versus mOligomer Rin 44.2 ± 2.6 
MΩ; P = 0.001) suggesting that the changes in input resistance do occur within a short 
period of recording. 
In a small number of cells, the concentration of mOligomer in the intracellular solution 
was increased from 0.5 to 1.5 μM (n = 4) to see if the effects on parameters were 
concentration dependent. While a similar drop in input resistance was observed for 
mOligomer at this higher concentration (figure 5.3f), the change was not significantly 
greater than that observed with a lower concentration; suggesting that these effects are 
at a maximum. Conversely, increasing the monomer concentration from 0.5 to 1.5 μM 
(n = 7) did not significantly affect the input resistance compared to control cells. 
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Figure 5.3 The oligomer induced fall in input resistance is observed in standard IV curves constructed from 
step currents. (a) Typical voltage responses of neurons filled with either vehicle (control) or mOligomer (input 
step currents were -400 & 100 pA). (b) The standard IV curve was generated from both the maximum voltage 
response during the initial sag (open points) and during the steady state (filled points). The shallower gradient at 0 
mV for the mOligomer IV curve (squares) compared to control (circles) illustrates the reduction input resistance. 
(c) The standard IV input resistance at 32 minutes for control, monomer, mOligomer and fOligomer. (d-e) The 
standard IV curve was used to measure the input resistance immediately after whole-cell break through. At this 
early time point, the input resistance is the same for control and mOligomer but becomes significantly different 
over time. (f) The reduction in input resistance was still seen with higher concentrations of mOligomer (1.5 μM) 
but not with higher concentrations of monomer. This reduction was not significantly greater than that produced by 
lower concentrations of oligomer suggesting the effects are maximal. * p < 0.05, ** p < 0.01, *** p < 0.005. 
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5.3.2 Oligomeric αSyn impacts neuron excitability  
With a reduction in input resistance the voltage response to a given current stimulus 
decreases, which would have a detrimental effect on neuron excitability. It would be 
predicted that a larger current is required to reach the action potential firing threshold 
for neurons perfused with oligomer compared to control cells. As seen from figure 
5.4a, the potential difference between resting and threshold (VT – E) is unaffected by 
αSyn treatments, despite the changes in VT described earlier. Instead, changes in 
neuron excitability stem from a significant increase in the current required to trigger 
an action potential (Ispike) (figure 5.4b: over 60 % increase with either mOligomer or 
fOligomer compared to control; p < 0.005). 
It would also be expected that the firing rate of oligomer perfused cells would be lower 
than control cells for a given current input. This was not directly observed in most 
recordings as the gain factor for the injected noisy currents was continually altered in 
order to maintain the firing rate. A higher gain factor, compared to control, was often 
required for oligomer filled cells to produce a 5-15 Hz firing rate. In a subset of 
recordings, however, the gain was set at the same level (400 pA) for both control cells 
and interleaved oligomer perfused cells to allow the firing rate to be fairly compared 
(figure 5.4c). After 32 minutes, the average firing rate was (mean ± SEM) 9.4 ± 0.54 
Hz (n=5) in control neurons compared to 5.6 ± 1.14 Hz in mOligomer filled neurons 
(n=5), illustrating a significant (p < 0.005) decline in firing rate (figure 5.4d).  
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Figure 5.4 Oligomer perfused neurons have reduced excitability. (a) For a fixed current stimulus (-400 & 100 
pA) a neuron with smaller input resistance (mOligomer) will produce a smaller voltage response. (b) Scatterplots 
of the voltage between resting and threshold (VT - E) for control, monomer and oligomer perfused cells at different 
time points. (c) Scatterplots of spike initiation current (ISpike), the amount of current needed for a resting neuron to 
reach threshold, show how oligomer-filled neurons require a much larger stimulus than control neurons in order to 
produce a similar voltage change. (d) Example voltage responses to a noisy current stimulus (gain = 400 pA) for a 
cell filled with vehicle (PBS, control) and a cell filled with mOligomer. (e) Bar chart plotting the mean firing rate 
for neurons perfused with mOligomer or vehicle against the time from whole-cell break through. * p < 0.05, ** p 
< 0.01, *** p < 0.005. 
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Furthermore, when parameters were simulated using the rEIF model, the linear 
increase in firing rate with input current gain factor (from 400 to 1000 pA in steps of 
100) was significantly reduced (as determined by Analysis of Covariance) for both 
fOligomer (p < 0.05) and mOligomer (p << 0.005) filled neurons compared to either 
control or monomer (figure 5.5). Interestingly, the simulated firing rate for mOligomer 
was reduced after 8 minutes while the fOligomer only had an effect after 32 minutes. 
This later reduction was also significantly weaker than the mOligomer (the gradients 
of the linear regressions were significantly, p < 0.005, different from one another).  
Figure 5.5 The linear relation between rEIF model firing rate and input current gain factor is reduced in 
oligomer, but not monomer, filled neurons. (a-d) The linear regressions at each time point were subject to 
Analysis of Covariance; those marked with * had significantly different intercept and slope than either control or 
monomer. This indicates that, for the mOligomer at all time points (p << 0.005) and fOligomer at 32 minutes (p < 
0.05), both the overall firing rate (intercept) and the change in firing rate with increasing gain (slope) were 
significantly different.  
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5.3.3 Oligomeric αSyn impacts action potential duration 
I investigated whether αSyn oligomers had any effect on the action potential by 
measuring a number of parameters that define the action potential waveform (figure 
5.6a). There was no significant difference in action potential amplitude. However, 
action potential duration (Adur) was significantly reduced by both mOligomer (8 
minutes, p < 0.005) and fOligomer (p < 0.005) but not by monomer (p = 0.606) (figure 
5.6b). This decrease in duration was not associated with an increase in the maximal 
rate of rise (Arise) of the action potential but was instead associated with a faster rate 
of repolarisation.  
Figure 5.6 Action potential parameters were taken from responses to naturalistic current. (a) The average 
spike (blue) was generated from isolated spikes with an ISI greater than 200 ms (grey, overlaid). The spike initiation 
threshold (blue cross) was calculated using the peak second-derivative method (Sekerli et al., 2004), shown in 
green. (b) The action potential amplitude, maximum rate of rise and duration were measured at each time point. 
The AP duration was significantly shorter for oligomers than for either control or monomer. * p < 0.05, ** p < 
0.01, *** p < 0.005. 
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5.4 Discussion 
This chapter offers an in-depth analysis of the findings from the experimental methods 
outlined in chapter 4. After injecting αSyn monomer and oligomer species into TTL5 
pyramidal neurons, parameters were extracted at regular intervals using both standard 
and dynamic I-V methods. The intracellular recording solution contained an ATP 
regenerating system (phosphocreatine) as well as 2 mM ATP. Such a system is 
important as it prevents the ‘rundown’ of many voltage gated and ligand gated ion 
channels during whole-cell dialysis (Chen et al., 1990; Rosenmund and Westbrook, 
1993). Thus the αSyn induced changes in electrophysiological properties were 
independent of a fall in ATP production due to the disruption of mitochondrial 
homeostasis. 
Table 5.2 summarises the trends in parameters for neurons injected with monomer, 
mOligomer or fOligomer. Neurons filled with either species of oligomeric αSyn 
showed a markedly reduced input resistance (Rin), as calculated by both standard and 
dynamic I-V curves (figures 5.1 and 5.3 respectively), that was not seen for either 
monomer-filled or control neurons. The Rin values for control neurons (table 5.1) were 
similar to those determined elsewhere for TTL5 pyramidal neurons in mice (Dani and 
Nelson, 2009; Oswald et al., 2013). The Rin of a neuron is a measure of how open 
Table 5.2 Summary of the trends in neuron parameters. Changes in the electrophysiological properties of 
neurons injected with monomer, mOligomer or fOligomer. Relative to the average value of control neurons after 
30 minutes, parameters had either increased (↑), decreased (↓) or stayed the same (–). 
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channels are in the membrane. Increasing evidence shows αSyn oligomers form pore 
complexes that are able to permeabilise lipid membranes both in vitro (Volles and 
Lansbury, 2002; Kim et al., 2009; Schmidt et al., 2012) and in cell cultures (Feng et 
al., 2010; Tosatto et al., 2012; Mironov, 2015). By retracing the parameter’s time 
course, it is clear that the oligomer-specific reduction in Rin appeared within the first 
8 minutes of recording; the time zero values for Rin were not significantly different 
from control. Such rapid effects have been seen previously, with reports that αSyn 
pore formation can occur within as little time as 5 minutes (Mironov, 2015). In 
complementation of the reduced Rin, many have reported increases in membrane 
conductance caused by the formation of leaky, non-selective cation channels by αSyn 
(Feng et al., 2010; Schmidt et al., 2012; Tosatto et al., 2012). Others have shown cross 
– talk between αSyn and potassium channels (Mironov, 2015) which is supported by 
the -80 mV reversal potential observed here. It is possible therefore that with the 
intracellular application of αSyn, the Rin decreases as oligomers either directly insert 
into the membrane or activate channels already embedded. Sodium-potassium pumps 
(N+/K+-ATPase), responsible for maintaining the polarity of the membrane, would 
counter the effects oligomer channels and prevent rapid depolarisation. Over extended 
periods of time, however, the elevated activity of ion pumps could increase the energy 
demand on a cell and ultimately become unsustainable. Neurons with naturally high 
metabolic rates, such as dopaminergic neurons in the SNc, could be at greater risk of 
this and struggle to balance ionic concentrations across the membrane. 
As one might expect, based on Ohm’s law (V = IR), a fall in Rin means that for the 
same amount of input current the voltage response will be weaker. Inversely, the 
amount of current needed to push a PD-afflicted neuron up to firing threshold (ISpike) 
will be greater than that of a healthy neuron (figure 5.4a-c). Thus, these results indicate 
that αSyn oligomers, but not monomers, have an inhibitory effect on neuron 
excitability and consequentially have a markedly reduced firing rate (figure 5.4d-e). 
Furthermore, these findings suggest that over the time period of the experiments (up 
to 120 minutes for some recordings) the introduced monomer does not oligomerise in 
the cell. This remained true when the concentration of monomer was markedly 
increased.  
Despite their structural differences, the two oligomers (mOligomers and fOligomers) 
produced similar changes in the electrophysiological properties of TTL5 neurons. As 
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such, the specificity of αSyn to produce these effects is uncertain and may instead be 
due to the ring-like shape of the oligomer which has been described for other disease-
associated proteins. In addition, an important control test would be to inject an 
oligomer made from randomised sequence, or to use a different protein such as amylin, 
to make sure that changes were specific to the disease protein of interest. Amylin has 
been used previously as a control to test whether membrane protein binding was a 
general property of amyloid fibrils or specific to amyloid-β (Lorenzo et al., 2000). 
Previous studies on the effects amyloid-β oligomers on field EPSPs and LTP in 
hippocampal brain slices have used amylin oligomers for their control (Kimura et al., 
2012; Ripoli et al., 2014).  
Since both oligomeric species of αSyn are ring-like in shape and of similar size, they 
may also share the pathological mechanism of forming pore-complexes in membranes. 
Subtle differences between oligomer species, however, in the shape of the dynamic I-
V curve and in neuron excitability suggest that the mOligomer has a greater and faster 
effect than the fOligomer. The membrane permeabilising activity of oligomers is 
dependent on the structural flexibility of their hydrophobic core (Campioni et al., 
2010). Differences in tryptophan-39 fluorescence and CD spectra (chapter 3) may 
indicate differences in core rigidity between mOligomers and fOligomers that impact 
their ability to interact with membranes. 
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6 General Discussion 
In this thesis, the aim was to combine in-depth structural characterisation of αSyn 
oligomers with detailed insight into their time-dependent effects on a wide range of 
electrophysiological parameters. This work was carried out to investigate two 
hypotheses. Firstly, that αSyn oligomers, but not monomers, produce changes 
in specific neuronal parameters. Secondly, that oligomers isolated from separate 
stages of the aggregation pathway display structural differences that alter their impact 
on neuron electrophysiology. 
In chapter 3, recombinantly expressed human αSynY39W, E46K was shown to form 
soluble, annular oligomers, referred to as mOligomers, under in vitro conditions during 
the early stages of aggregation. Insoluble, amyloid fibrils became the predominant 
structure in later stages of aggregation. When these fibrils were subjected to 
sonication, however, the resulting mixture of solubilised fragments were shown to 
include a separate species of A11-positive oligomer; fOligomers. In chapter 4, both 
monomeric and oligomeric αSyn were injected into TTL5 pyramidal neurons using 
the whole-cell patch clamp technique. Standard and dynamic I-V curves were 
generated at regular intervals to provide a time course of electrophysiological changes; 
presented in chapter 5. Neurons filled with either species of oligomer showed a 
reduced input resistance compared to either control or monomer-filled neurons. This 
translated into a reduction in neuron firing rate as a greater amount of input current 
was required for oligomer-filled neurons to reach their threshold voltage. 
These effects could lead to circuit changes in the neocortex which might produce many 
of the cognitive symptoms experienced by patients suffering from PD and other related 
neurodegenerative disorders. The actions of oligomers specifically within TTL5 
pyramidal neurons are likely to have major implications for the dynamics of network 
activity in the neocortex, signalling to subcortical areas and a number of physiological 
processes. Furthermore, the use of whole-cell patch clamp recordings and the 
extraction of parameters from dynamic I-V curves by EIF modelling presents a valid 
and reliable tool for studying the neuronal effects of disease-linked proteins such as 
αSyn. 
The work presented in this thesis seeks to add electrophysiological context to current 
theories on oligomer toxicity and provides the groundwork for further investigations 
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into the influence of αSyn on the activity and functional properties of neurons. My 
findings support the first hypothesis that ring oligomers produce changes in neuronal 
electrophysiology. This supports previous work, both in vitro and in cell cultures, 
showing that ring oligomers may permeabilise membranes leading to an increase in 
conductance (decrease in resistance). The two species of ring oligomer investigated in 
this thesis showed differences in their secondary structure that may reflect their 
separate positions in the aggregation pathway. However, the electrophysiological 
impact of the oligomers was unaffected by their structural differences, thus nullifying 
the second hypothesis. This suggests that the conserved ring shape of the two species, 
resulting from the assembly of central hydrophobic regions into a pore complex, is 
enough to produce neuronal changes regardless of subtle differences in structure in the 
terminal regions. Since the general ring shape is not exclusive to αSyn, it is possible 
that oligomers formed from other proteins may also impact electrophysiology in a 
similar way. 
6.1 The native structure of αSyn 
Until recently, the native structure of αSyn was almost unanimously accepted as that 
of an unfolded monomer. However, recent findings of a physiologically occurring, 
helically folded αSyn tetramer have cast debate on the subject (Bartels et al., 2011; 
Wang et al., 2011a; Fauvet et al., 2012). This tetrameric structure has been extracted 
from brain tissues and red blood cells (Bartels et al., 2011), but has also been 
characterised from recombinantly expressed αSyn (Wang et al., 2011a). The αSyn 
protein used throughout this thesis was found to exist predominantly as an unfolded 
monomer prior to aggregation experiments. Despite this, there are certain elements of 
my work that could support the theory of a physiological tetramer. Firstly, the 
detection of αSyn on western blots (figure 2.6, page 53) frequently produced small 
bands at higher molecular weights than the monomer. These bands were not strong 
enough to be detected by normal SDS-PAGE and did not appear on gel filtration 
chromatography, suggesting that they were only present in very low amounts. 
Secondly, analytical ultracentrifugation (AUC) of αSyn samples (figure 3.12, page 76) 
revealed a small peak with a sedimentation coefficient corresponding to a tetramer. 
Interestingly, this tetramer peak was observed in the mOligomer sample but not for 
the fOligomer; suggesting that sonication may remove it from the mixture. 
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The study of αSyn tetramer requires cross-linking and native gel electrophoresis 
(Bartels et al., 2011; Wang et al., 2011a) which were not carried out in this work. 
Therefore, it is uncertain whether the minor findings on western blot and AUC are 
linked to the physiological tetramer without further experimentation. Heat treatment 
of αSyn, a commonly used step in purification, has also been suggested to degrade the 
tetramer (Bartels et al., 2011) making it less likely to be present in the protein stock. 
6.2 Structure of αSyn oligomers 
The aggregation of αSyn into fibrils is a well-established feature of PD that has been 
extensively studied over the last few decades. Intermediate aggregates, formed prior 
to fibrils, include protofibrils and soluble oligomers, the latter of which represents a 
more pathologically active species compared to the relatively inert fibrils. The 
transient nature and inherent polydispersity of αSyn oligomers means that a variety of 
sizes, shapes and structures have been proposed; with many of the differences 
potentially stemming from the choice of oligomerisation protocol (Uversky, 2010). In 
addition to structural heterogeneity, the toxicity mechanism through which αSyn 
oligomers act is the subject of numerous theories and ongoing debate (Roberts and 
Brown, 2015). 
The mOligomers characterised in this thesis are structurally similar to the soluble, 
annular oligomers shown previously to permeabilise vesicle membranes (Volles et al., 
2001; Lashuel et al., 2002b) and impede fibril formation (Lorenzen et al., 2014c). The 
fOligomers characterised in this thesis represent a potentially novel oligomeric species 
recovered from the fragmentation of αSyn fibrils. 
Other species of annular oligomer, with varying diameters, have been formed by αSyn 
in the presence of different metal ions. Iron-induced oligomers, for example, were 
found to be 40-45 nm in diameter (Danzer et al., 2007), whereas calcium produced 
annular oligomers 70-90 nm (Lowe et al., 2004; Pountney et al., 2005) and cobalt 
oligomers were 22-30 nm (Pountney et al., 2005). There is also evidence for αSyn 
interactions with copper, lead, aluminium, magnesium, manganese, zinc and nickel 
ions (Breydo et al., 2012), although the oligomers formed from such treatments are 
not necessarily annular in shape. The ability of αSyn to interact with such as array of 
metal ions is likely to be the result of low-affinity binding. The abundance of negative 
side chains in the exposed C-terminal allow metals to interact and neutralise the 
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Coulombic charge-charge repulsion; resulting in partial folding of αSyn (Uversky et 
al., 2001b). Higher-affinity copper binding sites have also been located in both the N- 
and C-terminals (Binolfi et al., 2008; Brown, 2009, 2010b). The increased amount of 
folding as a result of metal ion binding at either terminal region leads to the production 
of oligomers with varying properties and sizes. 
Annular αSyn oligomers have been previously compared to the bacterial toxin; α-
hemolysin (Lashuel et al., 2002b) that forms a cytolytic β-barrel structure. The central 
hydrophobic region of αSyn is vital in fibril formation (Giasson et al., 2001) and is 
likely to be involved in the formation of the hydrophobic core in ring-like oligomers 
(van Rooijen et al., 2009a). As the hydrophobic regions of αSyn monomers align to 
form a β-sheet-rich oligomeric structure, the N- and C-terminal regions are more 
exposed for membrane, protein and small molecule interactions. Indeed, the 
membrane binding activity of the N-terminal region remains functional in the 
oligomeric state (Lorenzen et al., 2014a), suggesting that this region is not hindered 
by αSyn oligomerisation. Therefore, it is possible for αSyn to form a wide range of 
annular oligomers that, although they share the same ring-like shape and hydrophobic 
core, are structurally diversified by the conformations and interactions in their 
terminals. 
With this in mind, a comparison of mOligomers and fOligomers showed that both are 
similar in regard to size and shape, but differ in secondary structure characteristics. 
The structural differences reported in this thesis are likely to be located in the N-
terminal region. This is because analysis of CD spectra for the two oligomers showed 
differences in α-helical content which is a structural feature exclusive to the N-
terminal region. Furthermore, the fluorescence spectrum of the tryptophan-39 residue, 
located in the N-terminal, had a greater blue-shift in the mOligomer than the 
fOligomer. This suggests that the microenvironment surrounding this tryptophan is 
different within these two species.  
The fact that the two oligomer species were isolated from different stages of the 
aggregation pathway is likely to be an important factor in understanding these 
conformational differences. The similarities between fOligomers and fibrils indicates 
that fOligomers may retain elements of the fibril structure that are not present in 
mOligomers. Alternatively, the fragmentation of fibrils might produce a mixture of 
128 
 
soluble fragments that could interfere with the specific structural characterisation of 
fOligomers. Nevertheless, the finding that annular fOligomers can be recovered from 
fibril fragmentation, could indicate that oligomers are able to directly insert into, and 
dissociate from, fibrillar structures. 
6.3 Toxicity of αSyn oligomers 
Lewy bodies were originally believed to be the most pathologically relevant form of 
αSyn as they predominated inside apoptotic neurons throughout the brain 
(Wakabayashi et al., 2007). As a result, cell death was considered to play a principle 
role in the development of PD. However, attempts to correlate Lewy body density, in 
either cortical or brain stem neurons, with clinical symptoms have been unsuccessful. 
Many studies fail to correlate Lewy body density with neuron loss, the onset of 
symptoms, disease duration, disease severity or cognitive decline (Gomez-Isla et al., 
1999; Gomez-Tortosa et al., 1999; Gomez-Tortosa et al., 2000; Weisman et al., 2007; 
Jellinger, 2008; Schulz-Schaeffer, 2015). Instead, recent evidence has shown that 
neurodegeneration and cellular dysfunction precede Lewy pathology (Milber et al., 
2012) and are caused by small oligomeric forms of αSyn (Lashuel et al., 2013). 
If the death of neurons is a secondary event in the pathology of PD (Schulz-Schaeffer, 
2015) then the toxic action of oligomers must impact upon neuron function, i.e. 
synaptic activity and electrophysiology, in some manner. The physiological 
association of αSyn with synapses has made them the focus of current research in 
pathology (Kramer and Schulz-Schaeffer, 2007; Schulz-Schaeffer, 2010). Oligomeric 
αSyn has been shown to modulate synaptic transmission and LTP by affecting 
glutamate receptors in the postsynaptic terminal (Huels et al., 2011; Diogenes et al., 
2012; Martin et al., 2012), as well as disrupt vesicle binding and neurotransmitter 
release in the presynaptic terminal (Volles et al., 2001; Giehm et al., 2011; Choi et al., 
2013; Spinelli et al., 2014). Previous electrophysiological investigations have led to 
the theory that αSyn oligomers are able to permeabilise membranes through the 
formation of a pore complex (Butterfield and Lashuel, 2010). This concept is largely 
attributed to annular oligomers that are able to span membranes (Zhang et al., 2013) 
and produce discrete stepwise changes in membrane conductance reflecting the 
electrophysiology of a single channel opening and closing (Kim et al., 2009; Feng et 
al., 2010; Schmidt et al., 2012; Tosatto et al., 2012; Mironov, 2015). Such pathological 
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activities would result in cellular dysfunction prior to death and are easily associated 
with disease symptoms; such as reduced LTP and memory loss. 
Depending on the conditions for aggregation, oligomers have been characterised in a 
wide range of shapes and sizes, which alters their structural and functional properties. 
This heterogeneity only increases the complexity of the proposed mechanisms of 
oligomer toxicity (Lashuel et al., 2013; Roberts and Brown, 2015). Other proposed 
mechanisms for the toxicity of αSyn oligomers include loss of cytoskeletal integrity 
(Prots et al., 2013), endoplasmic reticulum stress (Thayanidhi et al., 2010), impaired 
protein degradation systems (Xilouri et al., 2013) and mitochondrial dysfunction (Devi 
et al., 2008). It is unclear whether many of these reported mechanisms produce an 
effect on neuron electrophysiology, or how these processes might interact with one 
another. Some toxicity mechanisms may not have a direct effect on electrophysiology 
but instead lead to changes in neuron structure that affect normal cell function. For 
example, changes to the cytoskeletal system with αSyn aggregation has been linked to 
dendritic spine retraction; reducing neuron connectivity (Takahashi et al., 2003; Zaja-
Milatovic et al., 2005). Protein degradation pathways, on the other hand, can be 
directly linked to synaptic activity as they are important for the turnover of glutamate 
receptors and their impairment by αSyn will affect neurotransmission (Tai and 
Schuman, 2008). Mitochondrial dysfunction is known to play a central role in PD 
pathology and may be associated with electrophysiology as the oligomer pore complex 
can create an influx of calcium ions (Danzer et al., 2007; Cali et al., 2012) that leads 
to mitochondria-associated apoptosis (Vila et al., 2008). Furthermore, the preferential 
insertion of αSyn into lipid-raft domains reveals subcellular targets that are linked to 
mitochondrial homeostasis (Guardia-Laguarta et al., 2014).  
The membrane permeabilising activity of oligomers has been proposed to be 
dependent on the compactness of their hydrophobic core (Campioni et al., 2010). 
Despite their structural differences, the diameter of the central cavity was found to be 
similar for mOligomers and fOligomers which may indicate that they have a shared 
degree of permeabilising activity. This is reflected in the electrophysiological findings 
which showed that, while oligomers did alter the response properties of neurons, 
neither oligomer had a greater impact on neuronal electrophysiology than the other. In 
comparison, monomeric αSyn did not elicit a change in electrophysiological properties 
on the time scale of these experiments (some as long as two hours). Furthermore, 
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neurons filled with monomer were negative for A11 immunostaining; suggesting that 
the monomer did not noticeably oligomerise during the experiments. The fact that 
monomeric αSyn had no effect indicates that neuronal changes were not simply the 
result of the αSyn protein but rather the presence of a toxic, ring-like oligomeric 
structure. This oligomeric structure is not exclusive to αSyn and has also been reported 
for amyloid-β (Lashuel et al., 2002a; Kayed et al., 2003; Haass and Selkoe, 2007; 
Faendrich, 2012). Therefore, the electrophysiological changes seen for αSyn 
oligomers may provide insight into the shared pathological mechanisms through 
which other proteins act (Kayed et al., 2003; Yoshiike et al., 2007). 
6.4 Endogenous αSyn in the neocortex 
The differential expression of endogenous αSyn in the layers of the neocortex has been 
reported previously (Vivacqua et al., 2011) and was also observed in this work by 
immunostaining (figure 4.6, page 98). Interestingly, the high expression of αSyn in 
the somata of layer 4 neurons could indicate an important physiological role in the 
maintenance of the neocortical microcircuitry. Layer 4 neurons receive the strongest 
thalamic input of all cortical layers and send important excitatory signals to layer 2/3; 
which then relay an integrated signal to layer 5 (Feldmeyer et al., 2002; Kampa et al., 
2006). If specific neuron loss was to occur in layer 4 rather than in layer 5, then the 
pathology of αSyn in the neocortex might take place further upstream in the 
microcircuit. However, the resulting decrease in signal integration may still have 
downstream effects on the subcortical output from layer 5. 
The purpose of differential expression of αSyn throughout the brain remains an 
unknown component for understanding its physiological function. With regard to 
neurodegenerative disease, elevated expression of αSyn has been reported in neurons 
under chronic oxidative stress (Quilty et al., 2006) and could therefore represent an 
indicator for neuron vulnerability. Neuron morphology and physiology are also 
believed to play an important role in the predisposition of specific cell types to 
neurodegeneration. Susceptible cells share two common properties. Firstly, they are 
projection neurons with disproportionally long and thin axons relative to the size of 
their somata (Braak et al., 2003a). In contrast, local circuit neurons and projection 
neurons with short axons (such as the pyramidal neurons in layers 2 and 4) are more 
resistant (Braak et al., 2004). Secondly, the long axon projections are typically 
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unmyelinated or poorly myelinated (Braak et al., 2003b). Myelination potentially 
offers a neuroprotective function as the sheath thickness is directly proportional to 
axonal conduction speed. As a result, less energy is required for the transmission of 
impulses in neurons with myelinated axons (Nieuwenhuys, 1998). The long projecting 
axons of TTL5 pyramidal neurons are unmyelinated in their primary collaterals and 
become progressively myelinated at the higher order axon branches (Shu et al., 2007; 
Ramaswamy and Markram, 2015). These morphological properties, which are also 
found in DA neurons in the SNc, may put TTL5 pyramidal neurons at greater risk than 
other cortical layers in neurodegenerative diseases. 
6.5 The pathological significance of oligomer-specific changes in electrophysiological 
properties 
Increasing evidence points towards αSyn oligomers as being the most neurotoxic 
species. Therefore, it is possible that the significantly altered parameters observed for 
neurons perfused with oligomer, compared to neurons filled with vehicle (PBS) or 
monomer, may be the result oligomer toxicity. This allows one to theorise on the 
underlying mechanisms that would produce such electrophysiological changes and 
how they might affect physiological activity in a way that could elicit pathological 
symptoms. 
Throughout the lifespan of rodents, for example, the input resistance of TTL5 
neocortical neurons naturally decreases during maturation of the neocortex (Zhu, 
2000). This reduction is believed to be the result of increasing expression of ion 
channels that are open close to the resting membrane potential, such as IH and other 
potassium conductances (Zhu, 2000). As such, the insertion of αSyn oligomers into 
the membrane, forming pore complexes with reversal potentials close to -80 mV, or 
their activation of pre-existing potassium channels (Mironov, 2015) may add to the 
physiological age of the neocortex. This could explain the age dependence of many 
neurodegenerative disorders (Niccoli and Partridge, 2012) and why patients with 
familial mutations in αSyn experience early onset of symptoms (Conway et al., 
2000b). 
A reduction in input resistance was accompanied by a change in excitation parameters 
that resulted in a lower firing rate for neurons filled with oligomer. In the microcircuit 
of the neocortex, TTL5 pyramidal neurons integrate signals from all neocortical layers 
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and are the primary output pathway for passing information to subcortical areas 
(Romand et al., 2011; Ramaswamy and Markram, 2015). The loss of excitation 
specifically in these neurons would have a devastating impact on healthy cognitive 
function (Winkler et al., 1995), emotional behaviour (Hariri et al., 2000; Black et al., 
2004), semantic memory (Hodges and Patterson, 1995) and sleep regulation (Steriade 
et al., 2001). Disruption of all these processes, and many more, have all been 
characterised as secondary, non-motor symptoms for PD and other neurodegenerative 
disorders (Chaudhuri et al., 2006). 
6.6 Sleep regulation and αSyn 
Sleep disturbances in PD have a reported prevalence ranging from 40 to 90 % (Suzuki 
et al., 2011). The appearance of REM sleep behavioural disorder in early, 
presymptomatic stages of PD results from degeneration of the brainstem regulatory 
centres involved in sleep/wakefulness (Boeve, 2010). However, other sleep disorders, 
involving slow-wave sleep, are commonly the result of impairments in thalamocortical 
activity (Diederich and McIntyre, 2012). Slow-wave sleep duration naturally declines 
with age (Doerr et al., 2010) and is notably decreased in patients with PD (Diederich 
et al., 2009); promoting symptoms of parasomnia. The onset of slow-wave sleep is 
characterised by low-frequency oscillations in neocortical neurons; rhythmically 
alternating between hyperpolarised (silent) and depolarised (active) phases (Steriade 
et al., 1993; Contreras et al., 1996). These consistent fluctuations in membrane 
potential are accompanied by changes in input resistance; which effectively doubles 
during the hyperpolarising phase compared to the depolarising phase of slow-wave 
sleep (Steriade et al., 2001). Furthermore, the input resistance of cortical neurons was 
found to be lowest during REM sleep and became highest in the waking state (Steriade 
et al., 2001). Therefore, a pathological reduction in input resistance, as a result of αSyn 
oligomers, could potentially disrupt the pattern of slow-wave sleep and impede 
transitions between sleep and awake states. 
6.7 Memory impairment and αSyn 
At the end of oscillatory periods during slow-wave sleep, cortical neurons exhibit 
short-term, self-sustained activity that is believed to play an important role in 
declarative memory consolidation (Steriade and Timofeev, 2003). The switching 
between silent and active states is mediated by an increase in firing rate in layer 5 
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neurons (Timofeev et al., 2001; Chauvette et al., 2010). This physiological function 
may be affected by αSyn oligomer as neurons that are less able to regulate their firing 
rate might struggle to integrate memory during slow-wave sleep. 
In addition to the neocortex, the hippocampus plays a principle role in the formation 
of memory and lesions in this area are implicated in neurodegenerative diseases as the 
source of amnesia and dementia (Zolamorgan et al., 1986; Small et al., 2011). The 
hippocampus, therefore, has become the subject of many investigations into the 
electrophysiological effects of αSyn oligomers. Increasing evidence shows that 
synaptic transmission in hippocampal neurons is modulated by αSyn oligomers, which 
leads to a reduction in long-term potentiation (LTP) (Diogenes et al., 2012; Martin et 
al., 2012). Both basal synaptic transmission and miniature synaptic currents were 
found to be enhanced by αSyn oligomers through a mechanism involving NMDA and 
AMPA receptor activation (Huels et al., 2011; Diogenes et al., 2012). The activation 
of glutamatergic receptors by oligomeric αSyn is predicted to promote excitotoxicity 
by the accumulation of intracellular calcium in the postsynaptic terminal (Danzer et 
al., 2007; Huels et al., 2011). Positive synaptic regulation through glutamatergic 
receptors has also been demonstrated for physiological levels of amyloid-β (Puzzo et 
al., 2008; Abramov et al., 2009), although at abnormally high levels of amyloid-β 
synaptic transmission is markedly depressed along with LTP (Palop and Mucke, 2010; 
Ripoli et al., 2014). 
Overall, this suggests that pathological forms of αSyn (and amyloid-β) promote 
synaptic transmission and receptor activation but in doing so may weaken the effects 
of LTP. It is possible that the reduced input resistance observed for neurons filled with 
oligomers is the result of pre-existing or newly inserted ion channels opening in the 
membrane. However, which ion channels are involved and their effects on firing 
activity may be dependent on cell type and location in the brain. For example, cross-
talk between αSyn and ATP-sensitive potassium channels has been reported 
previously in hippocampal cell cultures (Mironov, 2015). On the other hand, the 
impairment of A-Type potassium channels by αSyn has led to an enhanced firing rate 
in dopaminergic SNc neurons (Subramaniam et al., 2014).  
While previous research shows that αSyn increases neuronal activity in the 
hippocampus and SNc, my findings suggest that neocortical neurons become less 
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active. It is possible, therefore, that the findings of oligomer toxicity in one brain 
region may not necessarily hold true for other regions. It is likely that αSyn has a 
varying effect in different brain regions; with the increased susceptibility of certain 
neurons contributing to the disease pathology.  
6.8 Mitochondrial dysfunction and αSyn 
The permeabilisation of membranes by annular oligomers has been associated with an 
influx of intracellular calcium (Volles and Lansbury, 2002; Demuro et al., 2005; 
Furukawa et al., 2006; Danzer et al., 2007; Emmanouilidou et al., 2010) that leads 
not only to post-synaptic dysfunction and excitotoxicity (Danzer et al., 2007; Huels et 
al., 2011) but would also contribute to mitochondrial-mediated cell death (Henchcliffe 
and Beal, 2008; Vila et al., 2008; Nakamura, 2013; Chen et al., 2015). The 
pathological insertion of oligomers into lipid-raft domains within mitochondrial-
associated ER membranes (MAM) has been linked to mitochondrial dysfunction 
(Guardia-Laguarta et al., 2014). Furthermore, the accumulation of αSyn within 
mitochondria and its interaction with complex 1 activity leads to increased reactive 
oxygen species (ROS) production and mitophagy (Devi et al., 2008; Chinta et al., 
2010). 
It is uncertain whether the toxicity effects of αSyn on mitochondria would present 
themselves through distinct electrophysiological changes. Nevertheless, the ATP 
regenerating system used for my whole-cell patch clamp recordings means that the 
changes in neuron parameters seen with intracellular oligomers were independent of a 
fall in ATP concentration.  
6.9 Potential treatments of αSyn oligomers 
There are newly emerging theories on treatment methods for αSyn that aim to disrupt 
the formation of annular oligomers and may also counter their neurotoxic effects. 
Several ligands that are known to bind to αSyn have been shown to form stable, non-
toxic oligomers that are off pathway to fibril formation. The flavonoid baicalein, for 
example, inhibits oligomerisation of αSyn and amyloid-β and has also been shown to 
disaggregate existing fibrils (Zhu et al., 2004; Jiang et al., 2010; Lu et al., 2011). The 
αSyn oligomers formed from baicalein are a compact globular species that do not 
permeabilise membranes as readily as annular oligomers (Hong et al., 2008). 
Epigallocatechin gallate (EGCG), which has a structure similar to baicalein, is also 
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known to inhibit and disaggregate αSyn oligomers (Bieschke et al., 2010; Caruana et 
al., 2011). EGCG binds to the C-terminal region of αSyn where it reduces membrane 
binding affinity (Lorenzen et al., 2014b). These ligands present a possible treatment 
method for PD as they are able to prevent the formation of toxic, ring-like oligomers. 
Another treatment method involves antibodies that have a structural epitope that is 
able to recognise oligomeric, but not monomeric or fibrillar, species. The A11 
antibody used throughout this thesis has been shown previously to effectively target 
αSyn oligomers in membranes and inhibit their permeabilising activity (Schmidt et al., 
2012). The use of A11 antibodies might be able to reverse the electrophysiological 
effects of αSyn by blocking the conductance channels formed by pore-complex 
insertion. Animals that have been immunised with other antibodies, which target the 
C-terminal of αSyn, have shown attenuated neurodegeneration in PD-like models 
(Masliah et al., 2011; Games et al., 2013; Games et al., 2014) and are currently in 
phase 1 clinical trials (PRX002 – Prothena/Roche). 
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7 Conclusions and future research 
7.1 Conclusions 
Protein aggregation is a shared pathological trait for many neurodegenerative diseases. 
In synucleinopathies such as Parkinson’s disease, multiple system atrophy and 
dementia with Lewy bodies, the accumulation of αSyn in specific regions of the brain 
remains a clinical hallmark for the stages of pathology. The molecular mechanism(s) 
through which αSyn aggregates and exerts its toxicity remains unknown. Increasing 
evidence, however, supports the hypothesis that oligomeric αSyn species, that are 
formed prior to the appearance of large amyloid fibrils, play a central role in the 
pathogenesis of disease. Fibrillar αSyn, the main component of Lewy bodies, is 
thought to play a neuroprotective role by removing potentially toxic soluble 
aggregates from the cytosol. The fragmentation of fibrils is believed to present an 
additional stage of the protein aggregation pathway in which smaller aggregates are 
released back into the cytosol where they enhance toxicity and act as seeds for new 
fibril formation.  
In this thesis, I examined the occurrence of soluble oligomers during the in vitro 
aggregation of αSyn. In addition to purifying mOligomers formed during the early 
stages of aggregation, I found that fOligomers were a key component in the solubilised 
mixture recovered from fibril fragmentation. Despite their isolation from separate 
points on the aggregation pathway, the two oligomeric species were similar in size and 
shape, although structural analysis suggested that fOligomers may retain elements of 
the fibril structure that are not present in mOligomers. 
A leading hypothesis for αSyn oligomer toxicity is through the formation of a pore 
complex in lipid membranes. This activity has been mainly ascribed to ring-like 
oligomers, similar to those presented in this work, that are able to produce changes in 
membrane conductance similar to leak channels. Therefore, understanding the 
electrophysiological impact of αSyn oligomers could not only further our 
understanding of their toxicity mechanism, but also reveal their impact upon the 
functional output of neurons and how this in turn translates into the pathological 
symptoms of disease. To this endeavour, I investigated the effects of αSyn oligomers 
on TTL5 pyramidal neurons. I used dynamic I-V curves and reliable mathematical 
models to examine the changes in neuronal parameters over time. My findings are 
137 
 
consistent with the theory of oligomer insertion or channel opening in the membrane. 
The fact that monomeric αSyn did not alter neuronal properties supports the mounting 
evidence that αSyn toxicity stems from a gain-of-function mechanism in the oligomer. 
However, it is uncertain whether the changes in neuronal properties are specific to the 
αSyn protein or to the annular structure of the oligomers. The characterisation of 
annular oligomers produced by other disease-linked proteins highlights the possibility 
that the electrophysiological changes observed for αSyn may apply to other proteins 
and indeed have relevance in other neurodegenerative diseases.  
Overall, this thesis sought to better our understanding of the electrophysiological 
impact of structurally characterised αSyn oligomers in the neocortex. By acting on the 
input resistance and excitability of neurons, we see how oligomers exhibit their 
pathology on healthy cortical activity and may theorise how these effects give way to 
the plethora of non-motor symptoms associated with neurodegenerative diseases. 
7.2 Future research 
Investigating the toxicity-induced changes in electrophysiology for cortical neurons 
provides insight into the pathology surrounding cognitive impairments in PD. 
However, the underlying cause of motor dysfunction in PD is the specific loss of 
dopamine (DA) containing neurons in the substantia nigra pars compacta (SNc) region 
of the basal ganglia. The selective vulnerability of these neurons is believed to be the 
result of their combined morphological and physiological traits. In addition to their 
long, unmyelinated axonal projections, that are orders of magnitude larger than other 
neuronal types (Pissadaki and Bolam, 2013), their perpetual DA metabolism produces 
an abnormal build-up of free radicals that puts greater strain on their energy costs 
(Jenner et al., 1992; Bolam and Pissadaki, 2012; Hwang, 2013). Furthermore, the 
expression of αSyn in disease models has been shown to cause specific 
neurodegeneration in DA neurons of the SNc (Winner et al., 2011). A useful extension 
of my research would be to characterise the electrophysiological impact of αSyn in 
these neurons to further elucidate their inherent susceptibility to degeneration. 
Preliminary work to this effect as already been carried out by myself with successful 
identification of and recording from DA neurons in the SNc (figure 7.1a). However, 
the prominent IH current displayed by these neurons (figure 7.1b) is currently 
unaccounted for in the EIF models (figure 7.1c) which results in a poor prediction of 
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spike times (figure 7.1d). Therefore, a first step would be to develop the EIF model to 
account for the physiological properties of SNc neurons.  
The structural characterisation of oligomeric αSyn species, shown in chapter 3, 
involved spectroscopy analysis of their size and secondary structure and imaging 
under transmission electron microscopy. To gain further insight into the structure of 
αSyn oligomers would require more powerful analytical tools such as nuclear 
magnetic resonance (NMR), atomic force microscopy (AFM), cryo-electron 
microscopy or X-ray crystallography. However, many of these techniques require 
highly purified and homogenous protein samples which may present a difficulty due 
to the range of oligomer sizes produced during aggregation. Heavy metal ions and 
cross-linking agents have been previously used to stabilise the oligomeric structure 
(Dettmer et al., 2013), although such structures are likely to have altered properties 
from those formed in the absence of inducers (Pountney et al., 2005). Low resolution 
Figure 7.1 Dopaminergic neurons in the substantia nigra pars compacta (SNc) region show prominent IH 
current that is unaccounted for in the EIF model. (a) Recorded neurons in the SNc were labelled with Alexa 
Fluor® 488 (green) and confirmed to be dopaminergic by staining for tyrosine hydroxylase (red); nuclei were 
stained with DAPI (blue) (scale bar = 100 μm). (b) The typical voltage response of DA SNc neurons to step currents 
(-300 to 100 pA in steps of 100 pA). Note the prominent IH current with hyperpolarising step current and continuous 
firing pattern at rest. (c) The EIF fit (red line) to an inverted dynamic I-V curve (blue points) taken from the voltage 
response to naturalistic currents. The accentuated curvature of the dynamic I-V (as a result of IH current) means 
that these neurons cannot be reliably parameterised by the EIF model. (d) Simulation of EIF parameters (green) 
does not accurately replicate the firing pattern from experimentally recorded DA SNc neurons (blue).  
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3D models of annular αSyn oligomers have been generated based on single angle X-
ray scattering (Giehm et al., 2011) and NMR paramagnetic relaxation enhancement 
(Bertoncini et al., 2005). It is possible therefore that these methods may be used in the 
future to provide more detail on the differences between mOligomers and fOligomers. 
Both species of αSyn oligomer described in this thesis produced similar effects on 
neuronal parameters. The fact that monomeric αSyn did not produce the same effects 
as the oligomers indicates that unfolded and un-aggregated αSyn was not inherently 
toxic over this time course. However, these findings alone cannot confirm whether 
toxicity is a specific function of the αSyn protein or if it is derived from the generic 
ring-like conformation of the oligomer. Similar ring-like oligomers have been found 
for the amyloid-β peptide which suggests a shared mechanism for aggregation 
(Lashuel et al., 2002a; Kayed et al., 2003). Amylin, a protein that differs from 
amyloid-β and αSyn in its primary sequence but shares the ability to oligomerise 
(Lorenzo et al., 2000), has been used previously as a control to demonstrate the 
specific toxicity of amyloid-β oligomers (Kimura et al., 2012; Ripoli et al., 2014). In 
addition, investigating whether the non-toxic αSyn oligomers induced by flavonoids 
are able to reverse the electrophysiological changes would strengthen the theory of 
oligomer toxicity. Thus, comparing the electrophysiological impact of other proteins 
that are able to form toxic or non-toxic oligomers would be important for conclusively 
assigning toxicity to αSyn but may also demonstrate a shared pathology for disease-
associated proteins.  
The methods detailed in chapter 4 provide a way for toxic αSyn oligomers to be 
directly injected into neurons for studying their intracellular effects. However, 
increasing evidence shows extracellular αSyn to have an important role in toxicity and 
the spreading of pathology (Lee, 2008). Previous investigations have applied 
extracellular αSyn oligomers to brain slices and recorded changes in neuronal 
properties and synaptic transmission (Huels et al., 2011; Diogenes et al., 2012; Martin 
et al., 2012). Importantly, the membrane interacting and permeabilising properties of 
αSyn have been found to be different when inserting from the extracellular side 
compared to the intracellular side (Mironov, 2015). Extracellular oligomers were not 
used in this thesis as the amounts need for continuous circulation in aCSF were greater 
than those available from purification of mOligomers or fOligomers. However, the 
pre-incubation of brain slices or cell cultures in solutions containing oligomers, 
140 
 
followed by patch clamp recordings, could present a plausible approach as the amount 
of oligomer required would be more reasonable. 
The elevated expression of αSyn found in layer 4 pyramidal neurons, compare to layer 
5, may highlight the differences in their functional role within the neocortical 
microcircuit and could indicate differences in their susceptibility to disease. 
Investigating the electrophysiological effects of αSyn in layer 4 could provide an 
interesting contrast to layer 5 and may help us understand the role of endogenous αSyn 
in the neocortex. The electrophysiological impact of oligomers may be accentuated in 
cells expressing higher levels of endogenous αSyn and monomer-injected cells may 
also reveal a delayed onset of changes as they might be more likely to oligomerise 
intracellularly. 
The work presented in this thesis shows that the electrophysiological impact of αSyn 
oligomers can be accurately captured within the parameters of EIF models. As such 
the altered electrophysiological properties of TTL5 neurons may be applied to 
previously established network models (Harrison et al., 2015) to investigate how αSyn 
toxicity may impact upon the dynamic connections within the neocortical 
microcircuit. The development of pathological models based on experimental data 
presents a useful, ethically viable approach to furthering our understanding of 
neurodegenerative diseases. 
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